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1. BURKHOLDERIA CEPACIA COMPLEX 
1.1. Background   
The Burkholderia cepacia complex or Bcc is a complex of 20 closely related opportunistic, Gram-negative 
bacterial species.[1] An overview of all currently described Bcc species is shown in Table 1. Thus far, the 
diversity of the Bcc is not completely mapped and additional Bcc species will likely be described in the 
future. Bcc species most frequently occur in association with a variety of hosts (including humans, 
animals, plants and fu ngi) in which they may cause severe infections. Bcc members possess 
bioremediation and pesticidal properties when occurring in soil, water, plants or fungi.[2, 3] In 1950, 
these obligate aerobic, non-spore-forming bacilli were first identified by Walter Burkholder as the 
causative agent of onion rot.[4, 5] They were then referred to as Pseudomonas cepacia, until their 
transfer to the genus Burkholderia in 1992 on the basis of 16S rRNA sequences and DNA-DNA homology 
analyses.[6, 7] In 1997, Vandamme and colleagues proposed a subdivision of Burkholderia cepacia in five 
genomovars (I – V), referring to phenotypically similar but genotypically different species.[8] In the next 
20 years, numerous new Bcc species and genomovars have been identified. More accurate identification 
and novel insights into the natural diversity of this group of organisms will likely reveal many more.[7, 9] 
Table 1. Overview of Burkholderia cepacia complex species and their isolation sources.[1, 10-12] 
Species Genomovar Natural habitat  Clinical habitat 
B. ambifaria VII Soil, rhizosphere CF, non-CF 
B. anthina VIII Soil, rhizosphere, water, plant CF, hospital materials 
B. arboris  Soil, rhizosphere, water CF, non-CF, industrial equipment 
B. cenocepacia  III Soil, rhizosphere, water, plant, animal CF, non-CF, industrial equipment 
B. cepacia I Soil, rhizosphere, water, plant CF, non-CF, medical solutions 
B. contaminans  Sheep, plant CF, non-CF, hospital materials 
B. diffusa  Soil, water CF, non-CF, hospital materials 
B. dolosa VI Maize, rhizosphere CF 
B. latens   / CF 
B. lata  Soil, rhizosphere, water, flower CF, non-CF, industrial equipment 
B. metallica   / CF 
B. multivorans II Soil, rhizosphere, water, plant CF, non-CF, CGD 
B. pyrrocinia IX Soil, rhizosphere, water, plant CF, non-CF 
B. pseudomultivorans  Rhizosphere CF & non-CF sputum 
B. seminalis  Soil, rhizosphere, rice CF, non-CF, nosocomial infection 
B. stabilis IV Plant, rhizosphere CF, non-CF, hospital materials 
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B. stagnalis  Soil CF sputum, non-CF tracheal aspirate 
B. territorii  Water  / 
B. ubonensis  Soil non-CF, nosocomial infection 
B. vietnamiensis V Soil, rhizosphere, water, plant, animal CF, non-CF, industrial equipment 
  CF; Cystic Fibrosis. CGD; Chronic granulomatous disease 
 
1.2. Infections with Bcc bacteria 
Members of the Bcc are well-known as rare but potentially life-threatening opportunistic pathogens in 
immunocompromised patients, such as subjects with cystic fibrosis (CF) or chronic granulomatous 
disease (CGD). Burkholderia multivorans and Burkholderia cenocepacia are currently the most frequently 
encountered Bcc species in CF patients and patients with CGD.[7]  
CF is an autosomal, recessive disease causing a rapid decrease in lung function and low life expectancy, 
and is most common among Caucasian people.[13] Mutations in the gene that encodes CFTR (Cystic 
Fibrosis Transmembrane Conductance Regulator) are the main cause of the development of CF.[13, 14] 
CFTR mainly functions as a chloride channel but has also many regulatory roles including regulation of 
ATP transport, sodium transport and intracellular transport of vesicles.[15] Mutations of the CFTR gene 
disrupt the function of CFTR thereby leading to clinical defects in the lungs, pancreas and gastrointestinal 
tract and to a lesser extent in sweat glands, reproductive tracts and submucosal glands.[16] The most 
common mutation is a single deletion of phenylalanine at position 508 in NBD1 (ΔF508).[13, 17] 
Impaired chloride transport leads to the production of a sticky, dehydrated mucus in the respiratory 
tract, causing a decrease in mucociliary and alveolar clearing. Consequently, colonization of the lungs by 
bacterial pathogens is facilitated, leading to airway infections.[18, 19] In young children (<10 years old) 
with CF, the bacterial pathogens most frequently recovered from the airways are Pseudomonas 
aeruginosa, Staphylococcus aureus and Haemophilus influenzae. Stenotrophomonas maltophilia, 
Achromobacter xylosoxidans, Aspergillus fumigatus, nontuberculous mycobacteria and species belonging 
to the Bcc are also present in CF lungs but are found less frequently.[20] Although Bcc species are less 
commonly found in CF airways (prevalence in the USA is approximately 3%), their impact on 
pathogenesis and prognosis can be considerable.[7] Acute bacterial infections lead to increased cough 
and sputum production, weight loss, fever and pulmonary exacerbations, requiring antibacterial 
chemotherapy. Eventually, CF patients can suffer from chronic respiratory infections which are the main 
cause of the decline in lung function and ultimate mortality.[6, 21] Furthermore, an acute infection 
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known as ‘cepacia syndrome’ characterized by necrotizing pneumonia, bacteremia and sepsis can cause 
a rapid clinical deterioration leading to an early death.[6]  
CGD is a hereditary immune disease where autosomal, recessive mutations on the X-chromosome lead 
to defects in polymorphonuclear leukocytes, causing difficulty in forming reactive oxygen species 
(ROS).[22, 23] Due to this defective oxidative killing, these immune cells are not able to kill certain 
ingested bacteria.[7] The most commonly isolated microorganisms from CGD patients are S. aureus, 
Escherichia coli, Aspergillus species, Klebsiella species and Bcc species.[24] Bcc infections leading to 
sepsis and pneumonia are the second most common cause of death in CGD patients.[24] 
Therapeutic options for treatment of Bcc infections are limited because of their innate resistance to a 
variety of antibiotics. This is further discussed in 1.3.3. Therefore, elucidation of novel targets for anti-
Bcc chemotherapy is indispensable to conquer infections with Bcc bacteria. For this dissertation we 
focused on two strategies to overcome Bcc infections, including the nonmevalonate pathway for 
isoprenoid biosynthesis as an antibacterial target and combination therapy of β-lactam antibiotics with 
β-lactamase inhibitors which are further discussed in Chapter I.2 and I.3, respectively. 
 
1.3. Virulence factors 
1.3.1. Quorum sensing 
Bcc bacteria possess a comprehensive, density-dependent, cell-to-cell communication system, also 
known as quorum sensing (QS).[25] QS systems are triggered when a bacterial population reaches a 
critical density, enabling bacterial cells to release signal molecules which are able to modify gene 
expression in adjacent bacterial cells. Bacteria use QS systems to regulate certain processes including 
biofilm formation, antibiotic resistance, virulence, secretion systems and stress response.[26, 27] 
The first QS system in Bcc was discovered in B. cenocepacia K56-2 and designated as CepIR.[7] CepIR 
consists of two components: CepI which is an acyl homoserine lactone (AHL) synthase and CepR which 
detects AHLs and regulates transcription. In 2005, CciIR was discovered as a second AHL-controlled QS 
system in B. cenocepacia strains belonging to the epidemic ET12 lineage. CciIR is encoded in the genomic 
region surrounding the B. cenocepacia epidemic strain marker (BCESM).[28] CepR primarily functions as 
a positive regulator while CciR globally induces negative gene regulation. Both AHL-based QS systems 
were found to reciprocally regulate the expression of multiple genes. Homologous systems have been 
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described in all Bcc species, but most QS systems in Bcc are controlled by CepR.[27] In 2008, another QS 
system was described in B. cenocepacia which employs cis-2-dodecenoic acid (also known as the 
Burkholderia diffusible signal factor or BDSF) as a signal molecule.[29]    
 
1.3.2. Biofilm formation 
Biofilm formation is thought to be an important factor for chronic Bcc infections in the lungs, 
nevertheless, the exact mechanisms of biofilm formation remain to be determined.[30] Bcc bacteria are 
assumed to form biofilms on both biotic (e.g. epithelial cells) and abiotic surfaces (e.g. synthetic heart 
valves).[31-33] The process of biofilm formation starts with bacteria approaching closely to a surface, 
simultaneously decreasing their motility and associating with the surface and/or microorganisms already 
attached to the surface (Figure 1 [33]). This first reversible step involves intercellular signalling and is 
mediated by flagella and/or pili on the bacterial cell surface.[33] In the second step, the transient 
attachment stabilizes and bacteria start to form microcolonies. Consequently, bacteria start to divide 
and produce an extracellular matrix generally consisting of extracellular polymeric substances composed 
of exopolysaccharides (EPS), extracellular DNA, proteins and lipids.[32] Biofilms are provided with 
nutrients and signalling molecules by a network of open water channels, which separate bacterial 
Figure 1. Schematic overview of biofilm formation. Step 1 involves the approach of bacterial cells to a surface, 
decrease in cellular motility and attachment to the surface. In step 2 the cells start to form microcolonies, in step 3 
and 4 bacteria start to divide, produce an extracellular matrix and form a three-dimensional biofilm structure. In step 
5, bacterial cells can become motile again and spread to other locations.[33] 
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microcolonies. Mature biofilms may adopt a flat and undifferentiated form or can adopt a more 
differentiated (sometimes mushroom-shaped) form, depending on the environmental conditions and 
available nutrients. In the fifth and last step, sessile bacterial cells can be released from a microcolony, 
become motile again and disperse to other locations.[34] Dispersal of biofilms enables bacteria to spread 
to other organs or even through the whole body, where they can lead to several threatening clinical 
implications.[32] 
Bacterial biofilms can move in numerous ways on their trajectory to infect new tissues. They can move 
cooperatively, by detaching in clumps, or by rolling across the attached surface.[35] The ability of Bcc 
bacteria to form biofilms in vitro and in vivo contributes to reduced antimicrobial susceptibility, 
treatment failure and persistent infection.[36, 37]  
 
1.3.3. Antimicrobial uptake mechanisms and resistance 
The uptake of antibiotics in Gram-negative bacterial cells is significantly slowed by the presence of an 
outer membrane consisting of lipopolysaccharides (LPS) and phospholipids, which functions as a 
permeability barrier. Nonspecific porins and specific uptake channels are the most important factors 
accounting for active uptake of antimicrobial compounds through the membrane.[38, 39] Passive 
diffusion of hydrophobic compounds is slower due to the high rigidity of the LPS-containing bilayers and 
narrow porins limit penetration of large hydrophilic drugs.[40] There is an urgent need for quantitative 
methods to measure and image the localisation of antibiotics and to understand penetration in bacteria 
cells. Several research groups are currently focusing on different methods to address this query; label-
free 3D imaging of antibiotics in bacteria, real-time quantitative measurement of drug-uptake in bacteria 
and biofilms and traceable quantification of vertical concentration profiles of antibacterial agents in 
bacteria.[41-43] 
Members of the Bcc show a high level of intrinsic resistance towards a variety of antibiotics including 
aminoglycosides, polymyxins, first and second generation cephalosporins, carboxypenicillins and other β-
lactam antibiotics. Bcc species are also able to develop in vivo resistance towards almost any class of 
antibiotics currently available.[7, 44, 45] Various mechanisms are responsible for this multidrug-
resistance in Bcc bacteria, including reduced membrane permeability, modified target sites (e.g. 
penicillin binding proteins (PBPs)), drug elimination by efflux pumps (EPs), and/or production of 
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antibiotic-modifying and inactivating enzymes (e.g. β-lactamases and aminoglycoside-inactivating 
enzymes) (schematically depicted in Figure 2).[45-47] Antimicrobial resistance mechanisms can be 
divided into two stages: a first and fast response with changes in membrane organization and 
permeability and a second and slower response in which genetic changes are responsible for the 
acquisition of long-term antibiotic resistance.[39, 48, 49] 
 
Figure 2. Schematic overview of antimicrobial resistance mechanisms in Bcc species.  
1.3.3.1. Reorganization of the cell membrane 
The permeability of bacterial cells can be changed due to a reorganization of different compounds of the 
cell membrane including decrease of porin content, alterations in composition of LPS and/or 
overexpression of EPs.[48]  
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Porins are multimers of identical subunits creating a pore, and are found in Gram-negative bacteria and 
mycobacteria. Porins form channels of sufficient size to enable passive diffusion through the outer 
membrane and serve as the main entrance into the periplasm for antibiotics (including β-lactams and 
fluoroquinolones) and a variety of small hydrophilic molecules.[48] Mutations in the genes encoding 
porins or decreased porin content can cause resistance against several antibacterial agents, as passive 
diffusion through the outer membrane becomes difficult or impossible.[50] 
LPS consist of a core polysaccharide, a lipid A compound, and an O-antigen, shown in Figure 3 [7]). LPS 
form a lipophilic layer in the outer membrane of Gram-negative bacteria and thereby contribute to the 
protection and structural integrity of the bacterial cells.[51] LPS do not only form a simple barrier; they 
play an essential role in the response of bacteria to their environment.[52] The properties of LPS from 
Bcc species are different from those of other Gram-negative bacteria as they are less negatively charged 
due to a lower content of phosphate and/or  3-
deoxy-D-manno-oct-2-ulosonic acid (KDO) 
residues on their core oligosaccharide.[53] This 
characteristic confers resistance to 
aminoglycosides due to an inability of these 
antibiotics to bind to Bcc LPS.[7, 54] 
Additionally, 4-deoxyarabinose groups are 
attached to the lipid A backbone, further 
reducing the negative charge of the LPS and 
decreasing the cellular uptake of cationic 
antibiotics such as polymyxin B and colistin.[7] 
LPS from Bcc species are more endotoxic than P. 
aeruginosa LPS, and lead to a pronounced 
cytokine production, including tumor necrosis 
factor (TNF) and interleukin-8 (IL-8), that leads 
to inflammatory reactions.[7, 55]  
Transport of antibiotic molecules out of the cell 
by overexpression of EPs is one of the most 
commonly encountered resistance mechanisms in clinical isolates.[56, 57] These cellular pumps play an 
Figure 3.  LPS from the outer membrane of Burkholderia cepacia 
complex bacteria.[7] 
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important role in the physiology and homeostasis of the cell as they are responsible for the extrusion of 
both endogenous and exogenous toxic compounds.[48] EPs also play a significant role in QS signalling 
systems and biofilm formation in some bacteria.[58, 59] Five different transporter families have been 
identified: major facilitator superfamily (MF), multidrug and toxic efflux (MATE), resistance-nodulation-
division (RND), small multidrug resistance (SMR) and ATP-binding cassette (ABC). All transporters 
systems, except for the ABC family, use the proton motive force (PMF) to drive the export of substrates. 
The ABC transporters use ATP hydrolysis as an energy source for export.[60]  
 
1.3.3.2. Genetic acquisition of antimicrobial resistance 
Susceptible bacteria can acquire resistance through mutations in their DNA (that may be promoted by 
activation of certain “mutator genes”) and/or by horizontal gene transfer between organisms.[48, 61] 
Mutations can occur in genes involved in normal physiological processes and cellular structures, for 
example in the gene encoding dihydrofolate reductase (dhfr) which is essential for amino acid synthesis 
and can be inhibited by trimethoprim.  A point mutation in dhfr is responsible for trimethoprim-resistant 
strains of Bcc and other Gram-negative bacteria (E. coli and H. influenzae).[62] 
Horizontal gene transfer between bacterial species can happen through transformation, transduction or 
conjugation of transferable resistance genes. Transformation involves direct uptake and incorporation of 
DNA (mostly carried on plasmids, transposons or integrons) by competent bacterial cells.[63] 
Transduction comprises transfer of DNA via bacteriophages from one bacterium to another and 
conjugation involves transfer of DNA between bacterial cells in direct cell-to-cell contact.[64] Plasmid-
mediated transfer of genes encoding AmpC β-lactamases is an example of horizontal gene transfer and 
has been described in E. coli, Klebsiella pneumoniae and other Gram-negative species.[65, 66] 
 
1.3.4. Cell envelope structures 
Besides LPS, located in the outer membrane of Gram-negative bacteria, two other structures of the cell 
envelope play a significant role in the virulence of Bcc species. The flagellum enables bacterial strains to 
invade lung epithelial cells by making bacteria motile and serving as an adhesin, and cable pili contribute 
to binding and killing of human airway epithelial cells.[67, 68] 
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1.3.5. Synthesis of exopolysaccharides (EPS) 
Bcc species have the ability to produce EPS which play a role in stability, adherence and protection 
against environmental factors.[69] EPS are essential for biofilm formation and/or biofilm maintenance in 
many bacteria. Five different EPS have been identified in members of the Bcc including PS-I, PS-II (also 
called cepacian) and levan, with cepacian being the most frequently encountered EPS.[70] Cepacian is a 
heteropolysaccharide with a branched heptasaccharide as the basic unit with D-glucose, D-rhamnose, D-
mannose, D-galactose and D-glucuronic acid. Cepacian has been found in both mucoid and non-mucoid 
Bcc strains where it provides multiple functions.[71, 72] In addition to its importance in biofilm 
formation, cepacian plays a role in the inhibition of neutrophil chemotaxis, interference with 
neutrophilic phagocytosis and the scavenging of reactive oxygen species (ROS).[73] Some Bcc strains 
exclusively produce cepacian as EPS, other strains also produce other EPS, while some strains do not 
produce any cepacian at all.[36, 74] B. cenocepacia LMG 16656, for example, lacks cepacian production 
due to a frameshift mutation (11-bp deletion) in BCAM0856, a coding DNA sequence in the gene cluster 
associated with cepacian production.[45, 73] 
 
1.3.6. Resistance to oxidative stress 
In mammalian hosts, phagocytic cells produce ROS to help eliminate bacterial species.[75] High 
concentrations of ROS (including peroxides, superoxide, hydroxyl radicals and singlet oxygen) can cause 
significant damage to cells, ultimately leading to cell death.[76] However, Bcc bacteria are able to resist 
oxidative stress by producing catalases, peroxidases and superoxide dismutases (SOD). In B. cenocepacia 
two different catalase/peroxidase systems were identified; KatB as the major catalase/peroxidase 
system and KatA required for resistance to hydrogen peroxide.[77] SODs convert superoxide to hydrogen 
peroxide which is further degraded to water and oxygen by catalases.[78, 79] The production of 
catalases, peroxidases and SODs by Bcc species play an important role in their protection against ROS 
and therefore also for intracellular survival and virulence.[78] 
The gene hppD, encoding an enzyme required for pigment production, is suggested to protect B. 
cenocepacia from both ROS and reactive nitrogen species. Disruption of this gene leads to a 
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nonpigmented B. cenocepacia strain which has increased sensitivity to hydrogen peroxide and 
superoxide.[80] 
 
1.3.7. Iron acquisition 
Iron is an essential component for important bacterial processes including DNA synthesis and 
respiration, and siderophores are essential for Bcc bacteria to scavenge iron ions (Fe3+).[81] The solubility 
of the resulting Fe3+-complexes is higher than the Fe3+ ion alone and they can therefore be taken up by 
active transport.[82] Bcc bacteria produce four different siderophores (pyochelin, ornibactin, 
cepaciachelin, and cepabactin), with ornibactin and pyochelin being the most predominant siderophores 
in B. cenocepacia.[83, 84] B. cenocepacia can also use heme as an iron source and can obtain iron from 
the iron-binding protein ferritin, which is found at up to 100-fold higher concentrations in the lungs of CF 
patients compared to healthy individuals.[82, 85]  
To prevent iron toxicity, the host sequesters free iron ions in iron binding proteins (e.g. transferrin, 
lactoferrin or ferritin), in heme and hemoproteins. Therefore, the amount of freely available iron in host 
cells and/or animal tissues is extremely limited and the ability of bacterial pathogens to grow under 
limited iron conditions is an important virulence factor.[82, 86] 
 
1.4. Treatment of Bcc infections 
Anti-infective therapy can be subdivided into prevention and infection control, early antibiotic 
treatment, maintenance therapy as suppression of chronic infections, and acute exacerbation therapy.  
Most commonly used antibiotics to treat Bcc infections act by inhibition of cell wall synthesis (β-lactams), 
inhibition of cell membrane function (polymyxins, taurolidine), inhibition of nucleic acid synthesis 
(fluoroquinolones) or inhibition of protein synthesis (macrolides, aminoglycosides). Trimethoprim 
interferes with the folic acid pathway by binding to dihydrofolate reductase and sulfamethoxazole 
inhibits an enzyme further upstream in the same pathway. Most compounds are bactericidal, except for 
macrolides, trimethoprim and sulfamethoxazole which have bacteriostatic activity.[87] 
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1.4.1. Infection control 
Guidelines for preventing transmission and controlling spread of an infection among CF patients have 
been established to reduce the impact of bacterial infections (especially Bcc) on morbidity and mortality. 
These guidelines recommend segregation of CF patients infected with Bcc species from other patients 
with CF and taking precautions when caring for a CF patient with Bcc infections in hospital, ambulant and 
social settings.[88] 
 
1.4.2. Early antibiotic treatment 
Bcc isolates are recovered in respiratory secretions of 3% of all US CF patients, whom are almost all 
previously colonized with mucoid P. aeruginosa.[88] Data from clinical studies concerning the treatment 
of Bcc infections in CF patients suggest that therapy of serious infections should include at least two 
parenteral antibiotics at a standard dose.[89, 90] For susceptible strains, parenteral trimethoprim-
sulfamethoxazole (co-trimoxazole) should be administered in combination with a β-lactam (e.g. 
ceftazidime, meropenem, piperacillin), a fluoroquinolone (e.g. ciprofloxacin) or chloramphenicol. For Bcc 
strains resistant to co-trimoxazole, combination therapy guided by antibiotic sensitivity patterns should 
be used.[90-92] 
 
1.4.3. Maintenance therapy 
Chronic infections should be treated with maintenance therapy in order to reduce progressive lung 
damage and to lower the frequency of pulmonary exacerbations. Because systemically administered 
antibiotics may lead to sub-therapeutic concentrations in the lungs and because their long-term systemic 
use may lead to side-effects, much research has been focused on inhalation therapy.[93] Guidelines from 
the UK CF Trust recommend the use of inhaled ceftazidime, colistin or taurolidine for the treatment of 
chronic Bcc infections.[94, 95] Antibiotic agents that are currently being investigated as inhalation 
therapy are aztreonam lysine, macrolides (erythromycin and azithromycin) or tobramycin in high 
concentrations.[96-99] Moreover, combination therapy with nebulized tobramycin and amiloride has 
been used in two case reports as eradication therapy for Bcc strains.[100, 101] 
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The role of oral maintenance therapy for chronic Bcc infections in CF has not yet been defined. When 
oral therapy is used, co-trimoxazole is recommended for susceptible strains and oral minocycline or 
doxycycline for resistant strains.[90, 102] However, the development of resistance and toxicity, including 
skin and dental discoloration, are of great concern.[102]   
 
1.4.4. Treatment of pulmonary exacerbations 
Therapy for acute pulmonary exacerbations is commonly based on intravenous administration of 
minimum two antibiotics for 14 – 21 days, chest physiotherapy to improve airway clearance and 
bronchodilator administration.[103] 
Recommended treatment for exacerbations associated with Bcc strains is a combination of meropenem 
plus one of the following: tobramycin, amikacin, ceftazidime or co-trimoxazole.[104] When P. aeruginosa 
and Bcc are both identified in sputum cultures, combination therapy with an aminoglycoside and a β-
lactam antibiotic is often suggested.[105] 
A systematic review in 2011 concludes that there is a lack of randomized trials and therapies for the 
treatment of pulmonary exacerbations associated with Bcc strains. Therefore, clinicians must assess 
treatment for every CF patient individually guided by in vitro susceptibility results, previous clinical 
response and clinical experience.[106] 
 
1.4.5. Treatment of Bcc infections in CGD patients 
Bcc species are also an important cause of infections in patients suffering from CGD, mostly due to the 
ability of these microorganisms to resist neutrophil-mediated bacterial killing. The antimicrobial regimen 
in CGD patients should include co-trimoxazole combined with ceftazidime or a similar broad-spectrum 
antimicrobial agent.[107, 108] 
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2. NONMEVALONATE PATHWAY 
2.1. Introduction 
Animals (including humans), fungi, Archaea, insects and some bacteria use the mevalonate pathway for 
isoprenoid biosynthesis.[109-112] Isoprenoids play important roles in all living organisms. Most bacteria 
use an alternative pathway to synthesize isoprenoids;  the 1-deoxy-D-xylulose-5-phosphate (DOXP) 
pathway or nonmevalonate pathway and some plant species (e.g. Glycine max, Zea mays) are able to use 
both pathways.[113, 114] The DOXP pathway is present in several important pathogenic microorganisms 
including Acinetobacter, Klebsiella, Mycobacterium, Pseudomonas and Bcc species.[115] Since this 
pathway is not present in human cells, it is possibly an interesting target for the development of 
antibacterial chemotherapy. In 1998, fosmidomycin was discovered as an inhibitor of DXR, the second 
enzyme in the DOXP pathway, of E. coli K-12 and was also shown to completely inhibit bacterial 
growth.[116, 117] Consequently, several studies described inhibitory activity of fosmidomycin and its 
acetyl analogue against P. falciparum, P. aeruginosa and K. pneumonia.[118, 119] Jomaa and colleagues 
also confirmed that inhibitors of this pathway can be used for the treatment of the malaria parasite 
Plasmodium falciparum.[120] Nevertheless, few studies have explored the nonmevalonate pathway in 
bacteria and investigation of the potential of this pathway as antibacterial target was mainly restricted to 
E. coli and Mycobacterium tuberculosis.[118, 121] Fosmidomycin is currently clinically used in 
combination with clindamycin for the treatment of malaria caused by P. falciparum. However, difficulties 
with toxicity, short half-life and low bioavailability limit its potential as an antimalarial drug.[122-124]  
In the further chapters, several bacteria were studied (including P. aeruginosa, P. acnes, M. smegmatis 
as a model for M. tuberculosis and Bcc species) for which analysis of the genome sequence 
demonstrated that the nonmevalonate pathway is the sole pathway for isoprenoid biosynthesis.[115, 
125-127]  
 
2.2. Isoprenoids 
Isoprenoids (also called terpenoids) form one of the largest classes of natural compounds, with over 
30,000 compounds identified. They play a significant role in essential physiological processes in all living 
organisms including regulation of growth (steroid hormones), electron transport (menaquinone), cell 
wall and membrane biosynthesis, and conversion of light in chemical energy (carotenoids).[119, 128] All 
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isoprenoids consist of a sequence of the common isoprene units, i.e. five-carbon units, isopentenyl 
diphosphate (IPP) and its isomer dimethylallyl diphosphate (DMAPP) (Figure 4; adapted from [129]).[128]  
  
 
 
2.3. Mevalonate versus nonmevalonate pathway 
In the 1990s, the nonmevalonate pathway was identified as an alternative pathway for isoprenoid 
biosynthesis (Figure 5; adapted from [130]).[131] The final products of both biochemical pathways are 
IPP and its isomer DMAPP, the building blocks for further synthesis of isoprenoid compounds.[128, 132] 
The mevalonate pathway starts with the condensation of three acetyl-coenzyme A (acetyl-CoA) 
molecules to 3-hydroxy-3-methylglutaryl CoA (HMG-CoA). Consequently, HMG-CoA is reduced by HMG-
CoA reductase (HMGCR) to mevalonate, which is in turn converted to IPP and its isomer DMAPP.[133] 
Figure 4. Biosynthesis of different isoprenoid classes, all derived from isopentenyl diphosphate (IPP) and its isomer 
dimethylallyl diphosphate (DMAPP). Figure adapted from [129]. 
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Figure 5. Schematic overview of mevalonate and nonmevalonate (MEP) pathways. ACAT; Acetyl-CoA acetyltransferase, HMGCS; 
HMG-CoA synthase, HMGCR; HMG-CoA reductase, MVL; mevalonate kinase, PMVK; Phosphomevalonate kinase, PMD; 
Phosphomevalonate decarboxylase, MVD; diphosphomevalonate decarboxylase, IPK; Isopentenyl phosphate kinase, DXS; DOXP-
synthase, DXR/IspC; DOXP-reductase, IspD; CDP-ME synthase, IspE; CDP-ME kinase, IspF; MER-cPP synthase and IDI; isopentenyl 
disphosphate isomerase. Adapted from [130] 
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The nonmevalonate pathway (DOXP or MEP-pathway) starts with the condensation of D-glyceraldehyde-
3-phosphate and pyruvate to DOXP, catalysed by the enzyme DOXP synthase (DXS). Next, DOXP is 
converted to 2-C-methyl-D-erythritol-4-phosphate (MEP) by DOXP reductoisomerase (DXR). 
Consequently, 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) is formed in a reaction mediated by 
CDP-ME synthase (IspD). CDP-ME is then phosphorylated by CDP-ME kinase (IspE), with the formation of 
CDP-ME-2-phosphate. This diphosphate is converted by MER-cPP synthase (IspF) to 2-C-methyl-D-
erythritol-2,4-cyclodiphosphate (MER-cPP) and  this cyclic diphosphate molecule gives rise to the 
synthesis of IPP and DMAPP.[113] 
 
The rate-limiting step in the nonmevalonate 
pathway is the conversion of DOXP to MEP, 
catalysed by DXR, the second enzyme in the 
pathway. Fosmidomycin and FR900098 (Figure 
6), the N-acetyl derivative of fosmidomycin, are 
effective inhibitors of purified DXR from several 
bacteria but have limited effect on whole 
bacterial cells.[116, 117] A possible explanation 
for this limited antibacterial effect is the low bioavailability and poor cellular uptake by passive diffusion 
into bacterial cells due to the high polarity and negative charge of these molecules at physiological 
pH.[134, 135] 
 
2.4. Nonmevalonate pathway as a target for antibacterial chemotherapy 
Fosmidomycin and FR900098 are natural products isolated from Streptomyces lavendulae and 
Streptomyces rubellomurinus and mimic DOXP, the substrate of DXR.[118, 119, 136, 137] The activity of 
FR900098 is twice as high as that of fosmidomycin against P. falciparum in vitro and against Plasmodium 
vinckei in a mouse infection model.[120] Both fosmidomycin and FR900098 require hexose-phosphate or 
glycerol-3-phosphate transporters (GlpT) for accurate uptake into bacterial cells, just as their structural 
analogue fosfomycin.[119, 138] 
Figure 6. Structures of fosmidomycin (top) and FR900098 
(bottom) 
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P. falciparum and M. tuberculosis are the causative agents of malaria and human tuberculosis (TB), 
respectively, two infectious diseases which require urgent attention according to the World Health 
Organization (WHO).[139-141] For both organisms, most of the available antibiotic treatments lost their 
efficacy because of the development of multi-drug-resistant (MDR) strains and also extensively-drug-
resistant (XDR) strains of M. tuberculosis have been described.[140, 141] Fosmidomycin and FR900098 
show potent inhibition of isolated DXR from E.coli, P. falciparum and M. tuberculosis and demonstrate 
growth inhibition of P. falciparum cultures. Both compounds are inactive against M. tuberculosis, due to 
the lack of a GlpT transporter required for fosmidomycin uptake. Additionally, the highly lipophilic nature 
of the M. tuberculosis membrane structure prevents fosmidomycin and FR900098 (strongly polar 
compounds) to penetrate the mycobacterial cell. E. coli does possess GlpT transporters, making it 
possible for fosmidomycin to traverse into the cell and inhibit bacterial growth.[118, 119, 139]  
Fosmidomycin and FR900098 lack activity against species of the Bcc, although GlpT transporters are 
encoded in their genome. Unfortunately, during treatment with fosmidomycin and FR900098, the 
upregulation of a fosmidomycin resistance gene (fsr), encoding an efflux pump, is observed. This finding 
helps to explain the limited antibacterial activity against Bcc strains.[127] 
 
2.5. Molecular basis of DXR inhibition by fosmidomycin 
The DXR enzyme from P. falciparum (PfDXR) is a homo-dimer with each subunit consisting of a NAPDH-
binding domain and a divalent metal ion (Mn2+ or Mg2+). Both NADPH and a divalent cation are required 
for the DXR-mediated transformation of DOXP to MEP. A similar organization of DXR has been observed 
in other organisms.[142-144]  
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Each subunit of DXR comprises two large domains separated by a large gap where a deep pocket, a linker 
region and a small C-terminal domain are located (Figure 7 [142]). Both large domains have a specific 
function; one domain is responsible for NADPH binding and the second domain provides catalytic groups 
for metal and substrate binding. Fosmidomycin binds in the catalytic domain forming an inhibitor-bound 
quaternary complex.[142] 
2.6. Fosmidomycin derivatives 
Limited antibacterial activities of fosmidomycin and FR900098 can be attributed to poor cellular uptake 
by passive diffusion due to their high polarity. Attempts have been made to improve this cellular uptake 
by synthesizing more lipophilic inhibitors of the nonmevalonate pathway. First, fosmidomycin derivatives 
with modified physicochemical properties (e.g. introduction of an aromatic functional group) were 
synthesized.[133, 145, 146] Both the hydroxamate and phosphonate group of fosmidomycin are 
essential for their activity, but modifications to the three-carbon spacer linking these moieties have 
shown to lead to potent analogues. Substitutions at the α-position of fosmidomycin have been widely 
Figure 7. The three-dimensional structure of PfDXR. The structure of one subunit is depicted in A., with the NAPDH-binding 
domain coloured in blue, the catalytic domain in green, the linker region in yellow and the C-terminal domains in red. 
Fosmidomycin and NAPDH are represented in a ball-and-stick model, with the carbon atoms coloured in black and grey, 
respectively. Structure B. shows the overall DXR-structure, with one subunit shown in identical colours as A. and the other 
subunit coloured in cyan.[142] 
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explored in the past, but β-modifications have only recently received more attention (Figure 8 
[139]).[133, 139] 
 
Figure 8. Fosmidomycin analogues with A. α-modifications and B. β-modifications at the three-carbon spacer.[139] 
 
Secondly, attempts have been made to improve cellular uptake and bioavailability (currently <30%) by 
synthesizing prodrugs of fosmidomycin and its analogues (Figure 9 [137]), for example through the 
ProTide approach.[134, 135] The principle of synthesizing prodrugs is masking the charged phosphonate 
or hydroxamate functional groups with variable aryl or amino ester groups to increase cellular uptake. 
Once inside the bacterial cell, the prodrugs are hydrolysed by non-specific esterases, releasing the 
functional product.[119, 135, 137] 
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Figure 9. A. Lipophilic prodrugs of fosmidomycin and FR900098 [137] and B. ProTide prodrugs of fosfoxacin (Chofor R., Van 
Calenbergh S., unpublished data). 
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One sometimes finds what one is not looking for 
Sir Alexander Fleming 
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3. β-LACTAM RESISTANCE 
3.1. Introduction 
The first β-lactam antibiotic was discovered in 1921, when Alexander Fleming found a mould (Penicillium 
rubrum) producing a substance with antimicrobial activity against Staphylococcus, later identified as 
penicillin.[147] 
β-lactam antibiotics are one of the major classes of drugs available to treat bacterial infections. This class 
of antibiotics contains several families, including penicillins, cephalosporins, carbapenems and 
monobactams, all characterized by a four-membered lactam ring within their structure, as shown in 
Figure 10.[148, 149] β-lactams irreversibly inhibit the action of penicillin-binding proteins (PBPs) involved 
in cell wall synthesis by binding and inactivation of an essential serine residue in the enzyme’s active 
site.[147, 150] The bacterial cell wall consists of alternating N-acetyl muramic acid (NAM) and N-
acetylglucosamine (NAG) units, linked by transglycosidases, as shown in Figure 11 ([151]). Each NAM unit 
is attached to a pentapeptide by PBPs which catalyse the cross-linking of two D-alanine-D-alanine-NAM 
pentapeptides. This cross-linking is responsible for the structure and rigidity of the cell wall. As β-lactam 
rings are sterically similar to D-alanine-D-alanine of the NAM pentapeptide, the PBPs use the β-lactams 
as building blocks during synthesis of the cell wall. Consequently, the PBP is acylated, rendering it unable 
to catalyse further cross-linking reactions and ultimately leading to cell lysis, as shown in Figure 12.[65, 
152, 153] 
 
Figure 10. Structure of different β-lactam antibiotic families.[148,149] 
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The frequent use of β-lactam antibiotics has led to the development of broad resistance to most β-
lactams, for example in the well-known methicillin-resistant S. aureus (MRSA).  Resistance to β-lactams is 
most commonly mediated by expression of β-lactamases, efflux pumps or modifications of PBPs.[46, 47] 
 
Figure 11. Organization of the cell wall of Gram-positive and Gram-negative bacteria.[151] 
 
Figure 12. Mechanism of action of β-lactam antibiotics in Gram-negative and Gram-positive bacterial cells. Β-lactams inhibit 
transpeptidation by binding to penicillin-binding proteins (PBPs) on maturing peptidoglycan strands. This decrease in 
peptidoglycan leads to cell wall defects and eventually cell lysis and cell death.[153] 
 
3.2. Classification of β-lactam antibiotics 
Penicillins are the most widely prescribed antibiotics worldwide, both for community-acquired (CA) 
infections, and for hospital-acquired (HA) infections. Commercially available penicillins (including 
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amoxicillin, piperacillin and ticarcillin), are usually prescribed for treatment of Gram-positive 
infections.[154] 
Members of a second β-lactam family, the cephalosporins, are used both in outpatient settings (for 
treatment of Gram-positive and Gram-negative infections) and in hospital settings for prophylaxis of 
infection during surgery. The cephalosporin family includes cephalexin, ceftriaxone, ceftazidime, cefdinir 
and cefepime as most frequently prescribed antibiotics.[150] 
Carbapenems, e.g. meropenem, imipenem-cilastatin, ertapenem and doripenem, are “last resort 
antibiotics” for many serious infections and can only be used by parenteral administration.[155, 156] 
The fourth and last group of β-lactam antibiotics, monobactams, are only active against Gram-negative 
bacteria, with aztreonam as the commonly used antibiotic for Pseudomonas and other Gram-negative 
infections. Only intravenous (IV) or intramuscular (IM) administration is used in hospital 
environments.[150] 
β-lactamase inhibitors are regularly prescribed in combination with β-lactam antibiotics, to protect the 
latter against hydrolysis by β-lactamase enzymes, one of the most common mechanism of resistance 
against β-lactam antibiotics. Currently available inhibitors are clavulanic acid, tazobactam, sulbactam and 
the recently discovered avibactam (structures shown in Figure 13).[65, 157] 
 
Figure 13. Chemical structures of β-lactamase inhibitors; A. clavulanic acid, B. tazobactam, C. sulbactam and D. 
avibactam.[65,157] 
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3.3. Classification of β-lactamases 
The first β-lactamase enzyme was identified in 1940 (even before the clinical use of penicillin) as 
penicillinase in E. coli, and similar enzymes have since been identified in a variety of other bacteria, 
including species of the Bcc.[65, 158] β-lactamases are able to inactivate β-lactam antibiotics by 
hydrolysing the β-lactam ring. 
Two molecular classification schemes for β-lactamases are currently used: the Ambler molecular 
classification scheme (based on amino acid sequences and structural similarities) and the Bush-Jacoby-
Medeiros scheme (according to functionality or activity against β-lactam antibiotics).[157, 159, 160] 
In the Ambler scheme (Table 2), four classes of β-lactamases are recognized; class A through D.[65] 
Enzymes belonging to class A, C and D have a serine active site while class B enzymes are metallo-β-
lactamases (MBLs) that require Zn2+ as a cofactor.[65, 161] The most commonly encountered β-
lactamases are class A enzymes with TEM and SHV enzymes regularly found in Gram-negative bacteria 
(e.g. E. coli and Klebsiella spp.), as well as CTX-M extended-spectrum β-lactamases (ESBLs) and K. 
pneumoniae carbapenemases (KPCs) which are now also frequently encountered. Class B β-lactamases 
(MBLs) pose a particular challenge for medicinal chemists and clinicians because they can hydrolyse 
carbapenems and none of the available inhibitors can effectively inhibit members of this class.[162, 163] 
The recently discovered New-Delhi metallo β-lactamase (NDM) causes resistance to almost every 
antibiotic (except colistin and tigecycline), including imipenem and meropenem, and is one of the major 
reasons for antibacterial resistance in Enterobacteriaceae (e.g. E. coli and K. pneumoniae).[164] NDM-1-
carrying bacteria were first described in New Delhi, India in 2009 but have since mid-2010 also been 
introduced in other countries including the United States and UK.[165] Class C or AmpC β-lactamases are 
mostly chromosomally encoded, although the prevalence of plasmid-mediated AmpC-enzymes is also 
increasing. Oxacillinases or class D β-lactamases are active against a broad range of β-lactam antibiotics, 
besides carbapenems.[46, 65, 161] 
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Table 2. Classification of β-lactamases according to the Ambler molecular classification scheme.[65] 
Molecular class Main substrates Active β-lactamase inhibitors? Examples 
A penicillins Clavulanic acid TEM 
Serine penicillinases cephalosporins Tazobactam ESBL 
 monobactams Sulbactam SHV 
 carbapenems Avibactam CTX 
B Most β-lactams  / NDM 
Metallo-β-lactamases (incl. carbapenems)   
C penicillins Avibactam AmpC 
Cephalosporinases cephalosporins   
 monobactams   
D penicillins Avibactam  OXA 
Oxacillinases oxacillins (inhibits some class D enzymes)  
The β-lactamase classification scheme proposed by Bush, Jacoby and Medeiros mostly correlates with 
the Ambler molecular classification scheme. This functional classification takes substrate and inhibitor 
profiles into account and groups β-lactamase enzymes according to phenotypic characteristics in clinical 
isolates.[160] In 2010, Bush and Jacoby published an updated classification system (Table 3) including 
group 1 (Ambler class C) cephalosporinases, group 2 (Ambler classes A and D) broad-spectrum, inhibitor-
resistant and extended-spectrum β-lactamases and serine carbapenemases, and group 3 (Ambler class 3) 
metallo-β-lactamases.[159] 
Table 3. Updated functional β-lactamase classification scheme according to Bush and Jacoby and correlating Ambler 
classes.[159] 
Bush-Jacoby class Ambler class Main substrates Examples 
1 C cephalosporins E. coli AmpC 
1e C cephalosporins CMY-37 
2a A penicillins PC-1 
2b A penicillins TEM-1, TEM-2, SHV-1 
  early cephalosporins  
2be A extended-spectrum cephalosporins TEM-3, SHV-2 
  monobactams PER-1, VEB-1 
2br A penicillins TEM-30, SHV-10 
2ber A extended-spectrum cephalosporins TEM-50 
  monobactams  
2c A carbenicillin PSE-1 
2ce A carbenicillin, cefepime RTG-4 
2d D cloxacillin OXA-1, OXA-10 
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2de D extended-spectrum cephalosporins OXA-11, OXA-15 
2df D carbapenems OXA-23, OXA-48 
2e A extended-spectrum cephalosporins CepA 
2f A carbapenems KPC-2 
3a B carbapenems IMP-1, VIM-1 
3b B carbapenems CphA 
 
3.4. β-lactam resistance in Bcc species 
Resistance against β-lactam antibiotics in Bcc bacteria appears to be the result of two synergistic 
methods; decreased drug access caused by decreased porin content and the induction of chromosomal 
β-lactamases.[166-169] Porins play a fundamental role in antibiotic uptake into Bcc species and β-lactam 
resistant B. cenocepacia isolates of CF patients were shown to have a decreased porin content.[168, 169] 
Resistance to β-lactam antibiotics such as ceftazidime is in Bcc species mostly caused by class A β-
lactamases, first described in 1997 and now named PenB and PenR.[167, 170]However, a recent study in 
B. cenocepacia also identified ceftazidime-driven mutations caused by AmpC β-lactamases.[171] 
Elucidation of the whole genome sequence of B. cenocepacia LMG 16656 (J2315) led to the identification 
of at least 21 different β-lactamases encoded in this Bcc strain (shown in Table 4).[45, 65] These enzymes 
were shown to confer resistance against ceftazidime, clavulanic acid and a variety of other β-lactams.[45, 
172] Interestingly, all classes of β-lactamases are represented in this B. cenocepacia strain but most 
enzymes (15 out of 21) belong to the metallo β-lactamase (MBL) family. As mentioned before, MBL 
enzymes pose particular challenges since none of the available β-lactamase inhibitors is able to inhibit 
members of this β-lactamase class.[162] 
In conclusion, bacterial resistance occurs as a consequence of various different mechanisms and 
constitutes a continuous challenge for researchers, clinicians and pharmaceutical companies to provide 
counter-acting agents in the fight against infections. 
 
 
 
 
CHAPTER I. INTRODUCTION  3. β-LACTAM RESISTANCE 
35 
 
Table 4. β-lactamases encoded on the genome of B. cenocepacia LMG 16656 (J2315); the locus tag, replicon (Chr. Indicates 
‘chromosome’) and description of the gene product.[65] 
Locus Tag Replicon Product description 
BCAS0156 Chr. 3 AmpC; class C beta-lactamase/ family S12 serine peptidase 
BCAM0393 Chr. 2 class D putative acetyltransferase/putative beta-lactamase 
BCAM2596 Chr. 2 beta-lactamase family protein/ family S12 serine peptidase 
BCAM2643 Chr. 2 beta-lactamase family protein/ family S12 serine peptidase 
BCAM2165 Chr. 2 PenA; putative beta-lactamase/ family S11 serine peptidase 
BCAM1779 Chr. 2 class A putative beta-lactamase 
BCAS0557 Chr. 3 metallo βL superfamily protein 
BCAL0673 Chr. 1 metallo βL superfamily protein 
BCAM0300 Chr. 2 metallo βL superfamily protein 
BCAL0158 Chr. 1 metallo βL superfamily protein 
BCAL2183 Chr. 1 metallo βL superfamily membrane protein 
BCAM2668 Chr. 2 metallo βL superfamily protein 
BCAS0689 Chr. 3 metallo βL superfamily protein 
BCAL1818 Chr. 1 metallo βL superfamily protein 
BCAL2584 Chr. 1 metallo βL superfamily protein 
BCAM2120 Chr. 2 metallo βL superfamily protein 
BCAS0034 Chr. 3 metallo βL superfamily protein 
BCAL2165 Chr. 1 metallo βL superfamily protein 
BCAM1430 Chr. 2 metallo βL superfamily protein 
BCAS0179 Chr. 3 metallo βL superfamily protein 
BCAL0386 Chr. 1 putative exported metallo βL superfamily protein 
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Infectious diseases are still one of the main sources of mortality with respiratory infections, malaria, 
tuberculosis and HIV/AIDS belonging to the top 10 causes of death worldwide.[173, 174] The 
introduction of antibiotics since the 1930s provided us with a weapon to fight microbial infections, but 
after the golden era of antibiotic drug discovery there has been a ‘discovery void’.[175] Furthermore, the 
utility of currently available antibiotics has become increasingly compromised due to the development of 
antimicrobial resistance.[87, 176] Therefore, research should focus with high priority on the 
development of antibiotics with a novel mechanism of action.[176, 177] Bacteria belonging to the 
Burkholderia cepacia complex or Bcc are important human pathogens in patients with cystic fibrosis and 
especially require attention because of their innate intrinsic resistance against many antimicrobial 
drugs.[7, 73] The main objective of my work was to explore two novel strategies to tackle Bcc infections, 
including the nonmevalonate pathway for isoprenoid biosynthesis and combination therapy of β-lactam 
antibiotics with β-lactamase inhibitors. 
First, the in vitro antibacterial activity of potential inhibitors of the nonmevalonate pathway was 
determined against Bcc species, P. aeruginosa, Propionibacterium acnes and Mycobacterium smegmatis. 
Furthermore, different resistance mechanisms against these inhibitors were identified and methods to 
circumvent them were examined. 
Because of the low in vitro activity of the compounds tested in this first part, the essentiality of different 
genes of the nonmevalonate pathway in B. cenocepacia was determined. Therefore, we constructed 
conditional knock-down mutants of B. cenocepacia where a rhamnose-inducible promoter controlled the 
expression of the candidate essential genes. Consequently, the expression kinetics, phenotypic 
characteristics and virulence of these conditional mutants were explored in appropriate in vitro and in 
vivo models. 
Finally, we investigated the ability of β-lactamase inhibitors to restore the antibacterial activity of β-
lactam antibiotics against members of the Bcc. Moreover, the β-lactamase activity after different 
treatment conditions was determined to validate the role of β-lactamase production in resistance 
against β-lactams. Both older and newer inhibitors were included in this study, including clavulanic acid, 
sulbactam, tazobactam and avibactam. 
 
 39 
 
 40 
 
 41 
 
 
 
 
 
CHAPTER III. EXPERIMENTAL 
WORK 
CHAPTER III. EXPERIMENTAL WORK  PAPER 1 
42 
 
CHAPTER III. EXPERIMENTAL WORK  PAPER 1 
43 
 
1. THE NONMEVALONATE PATHWAY AS NOVEL TARGET FOR CHEMOTHERAPY AGAINST 
MULTIDRUG-RESISTANT BACTERIA 
1.1. Introduction 
In contrast to the more common mevalonate pathway, some bacteria use an alternative pathway for 
isoprenoid biosynthesis, the 1-deoxy-D-xylulose-5-phosphate (DOXP) or nonmevalonate pathway. Since 
this pathway is not present in human cells, it is a potential target for the development of antibacterial 
agents against multidrug-resistant bacteria. The rate-limiting step in this metabolic pathway is the 
conversion of 1-deoxy-D-xylulose-5-phosphate (DOXP) to 2-C-methyl-D-erythritol-4-phosphate (MEP), 
catalyzed by the enzyme DOXP-reductoisomerase (DXR). Previous studies confirmed that fosmidomycin 
and its acetylated analogue FR900098 are active inhibitors of DXR from E. coli, M. tuberculosis and P. 
falciparum.[118, 121, 139] Fosmidomycin and FR900098 can be used for the treatment of malaria caused 
by P. falciparum, but relatively few studies have explored the use of inhibitors of the nonmevalonate 
pathway in bacteria.[120] So far, investigation of the DOXP pathway as a potential antibacterial target 
was mainly restricted to E. coli and M. tuberculosis. Fosmidomycin and FR900098 are effective inhibitors 
of purified DXR from several bacteria but have limited effect on whole bacterial cells.[116, 117] A 
possible explanation for this limited antibacterial effect is the poor cellular uptake by passive diffusion 
into bacterial cells due to the high polarity of these molecules. Several attempts have been made to 
improve limited cellular uptake, by modification of physicochemical properties or the synthesis of 
prodrugs of fosmidomycin.[133-135, 145, 146] 
 
1.2. Objectives 
A first goal of the present study was to evaluate the activity of potential new inhibitors of the 
nonmevalonate pathway against various bacterial pathogens. The second goal was to identify different 
resistance mechanisms against fosmidomycin analogues and other DOXP inhibitors and to examine how 
to circumvent these mechanisms.  
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1.3. Materials and methods 
1.3.1. Bacterial strains and culture conditions 
The following bacterial strains were used for MIC determination: P. aeruginosa PAO1, several members 
of the Bcc (B. cenocepacia LMG 16656, B. cepacia LMG 1222 and B. multivorans LMG 13010), P. acnes 
LMG 16711, M. smegmatis ATCC 607 and ATCC 700084. E. coli ATCC 8739, ATCC 25922, and K-12 were 
included as control strains. In further experiments, additional Bcc strains were included: Burkholderia 
ambifaria LMG 19467 and LMG 19182, and B. multivorans LMG 18825 and LMG 18822. One additional P. 
acnes strain (P. acnes LMG 16712) and two additional mycobacterial strains (M. smegmatis LMG 8190 
and Mycobacterium phlei LMG 4056) were also included. All strains were obtained from the BCCM/LMG 
Bacteria collection (Ghent, Belgium) or from the ATCC collection (Manassas, VA, USA). Bacterial cultures 
were stored at -80°C in Microbank vials (Prolab Diagnostics, Richmond Hill, ON, Canada). P. aeruginosa, 
Bcc and E. coli strains were subcultured twice on Luria-Bertani agar (LBA; LabM Limited, Heywood, UK) 
before use and incubated aerobically at 37°C. P. acnes strains were subcultured on Brain Heart Infusion 
agar (BHIA; Sigma-Aldrich, Saint-Louis, USA) and anaerobically incubated at 37°C. Strains of M. 
smegmatis were subcultured on Middlebrook 7H10 agar (MBA) supplemented with 10% OADC 
enrichment (BD, Erembodegem, Belgium) and aerobically incubated at 37°C.  
 
1.3.2. Antibacterial compounds 
The DXR-inhibitors fosmidomycin (Invitrogen, Thermo Fisher Scientific, Merelbeke, Belgium) and 
FR900098 (Sigma-Aldrich) were tested together with a selection of β-substituted analogues and 
nucleoside phosphoramidate prodrugs (ProTides), synthesized as previously described and provided by 
Prof S. Van Calenbergh (Ghent University, Belgium).[119, 139, 178, 179] The DXS-inhibitors clomazone 
and 4(3H)-pyrimidinone were obtained from Sigma-Aldrich and 5-ketoclomazone was purchased from 
Tebu-Bio (Le Perray-en-Yvelines, France). The thiazolopyrimidines ritanserin and ketanserin (both 
purchased from Sigma-Aldrich) were included as IspF-inhibitors, together with the structurally related 
molecules altanserin, setoperone (both obtained from ABX Chemicals, Radeberg, Germany) and IspF-
inhibitor-1 (obtained from Echelon-Biosciences, Salt Lake City, UT, USA). All chemical structures are 
shown in Figure 14, Figure 15 and Figure 16.[180-182] Control antibiotics tobramycin, kanamycin, 
isoniazid and rifampicin were obtained from Sigma-Aldrich and fosfoxacin was kindly provided by Prof. S. 
Van Calenbergh.  
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Efflux pump inhibitors carbonyl-cyanide-3-chlorophenyl hydrazine (CCCP) and phenylalanine-arginine-β-
napthylamide (PaβN) were both purchased from Sigma-Aldrich. The cell-penetrating peptides colistin, 
polymyxin B and polymyxin B nonapeptide (PMBN) were also obtained from Sigma-Aldrich and 
octaarginine was purchased from Eurogentec (Seraing, Belgium). 
 
Figure 14. Fosmidomycin, FR900098 and β-substituted fosmidomycin analogues.[139] 
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Figure 15. ProTide prodrugs of fosmidomycin, synthesized by Prof. S. Van Calenbergh and Dr. R. Chofor (Ghent University, 
Belgium). [Chofor R. & Van Calenbergh S., data not published] 
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1.3.3. Determination of the minimal inhibitory concentration (MIC) 
Susceptibility screening of the test panel towards the nonmevalonate inhibitors was performed 
according to the EUCAST broth dilution guidelines.[183] MICs were determined in triplicate, using flat-
bottomed 96-well microtitre plates (TPP, Trasadingen, Switzerland), with concentrations ranging from 
0.49 µM to 250 µM. Mueller-Hinton broth (MHB) (BD) was used as growth medium for P. aeruginosa, B. 
cenocepacia and E. coli. Brain heart infusion broth (BHIB) (Sigma-Aldrich) was used for the growth of P. 
acnes, and M. smegmatis was grown in Middlebrook 7H9 broth (MBB) supplemented with 10% ADC 
enrichment (BD). For the susceptibility screening of ProTides, standard media were enriched with 5% 
horse blood (Biotrading, Keerbergen, Belgium) according to the EUCAST agar dilution guidelines.[184] 
Horse blood contains histidine triad nucleotide-binding protein 1 (HINT-1), which is essential for the 
intracellular enzymatic conversion of ProTides to their active form.[185]  
Figure 16. Chemical structures of A. DXS-inhibitors and B. IspF-inhibitors.[180-182] 
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Planktonic bacterial cultures were grown overnight in liquid medium at 37°C, adjusted with double-
concentrated medium to obtain a final inoculum of approximately 5 x 105 colony forming units/ml 
(CFU/ml) and added to the 96-well plates. Plates were incubated for 24h at 37°C and optical density was 
determined at 590 nm using an Envision multilable plate reader (Perkin Elmer, Waltham, MA, USA). The 
MIC value is the lowest concentration of the antibiotic that completely inhibits bacterial growth. The 
MIC50 is the lowest concentration that reduces bacterial growth to 50% of the untreated control.[183, 
186]  
In every experiment, fosmidomycin and FR900098 were included as controls. Kanamycin was added as 
additional control antibiotic for E. coli, P. aeruginosa and P. acnes strains, tobramycin for Bcc species, 
and isoniazid and rifampicin for M. smegmatis strains. 
 
1.3.4. Evaluation of the bactericidal effect on mature biofilms 
Biofilm cultures were grown in U-bottomed 96-well microtitre plates for 4h at 37°C, then washed twice 
with physiological saline (PS) and incubated for another 20h. Subsequently, mature biofilm cells were 
washed twice and treated with antibiotic solutions at 37°C for 24h. The bactericidal effect was 
determined by quantification of the percentage of bacterial survival after antibiotic treatment by 
resazurin staining or plating. Resazurin (CellTiter-Blue, Promega, Madison, WI, USA) is a non-fluorescent 
dye which can be converted to the fluorescent resorufin by metabolically active cells. The Envision 
multilable plate reader was used to determine the amount of formed resorufin, which is an indication for 
the amount of metabolically active cells present in the wells.[187] Quantification of the CFU was done 
using conventional plating on standard growth media, described above.[188, 189] 
 
1.3.5. Determining the role of efflux pumps in resistance 
To determine the role of efflux pumps in resistance, we determined MIC values of DOXP-inhibitors in the 
presence of efflux pump inhibitors CCCP and PaβN. First, we determined the intrinsic inhibitory effect of 
CCCP or PAβN on planktonic bacterial cultures. Therefore, MIC values were determined (with 
concentrations ranging from 0.195 µM to 100 µM) for E. coli ATCC 25922 and ATCC 8739 , P. aeruginosa 
PAO1, B. cenocepacia LMG 16656, B. cepacia LMG 1222 and B. multivorans LMG 13010. Consequently, 
different concentrations (5 µM, 50 µM and 100 µM) of CCCP or PAβN were added to treatment with 
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fosmidomycin or β-substituted fosmidomycin-analogues. Finally, the differences in MIC values of the 
antibacterial agents in the presence or absence of an efflux pump inhibitor were determined. 
 
1.3.6. Effect of increasing cellular permeability 
Two different strategies were tested to enhance the cell penetration of our set of analogues. First, MIC 
values of the nonmevalonate inhibitors in CDM-G were determined against B. cenocepacia LMG 16656, 
B. cepacia LMG 1222, B. multivorans LMG 13010, E. coli ATCC 8739 and K-12. CDM-G is a Chemically 
Defined Medium in which the carbon source glucose is replaced by equimolar concentrations of glucose-
6-phosphate, which increases cellular uptake, and glucose-1-phosphate, which has no effect on MIC 
values but is able to improve bacterial growth.  
Second, the effect of the addition of cell-penetrating peptides (CPPs) was explored by performing 
checkerboard synergy assays in combination with the nonmevalonate inhibitors. Planktonic cells of E. 
coli K-12 and M. smegmatis ATCC 700084 were treated with fosmidomycin (concentration range 3.9 µM 
– 250 µM) in combination with several peptides; colistin (0.625 µg/mL – 40 µg/mL), polymyxin B (8 µM – 
512 µM), octaarginin (1.25 µg/mL – 80 µg/mL) and polymyxin B nonapeptide (PMBN; 0.78 µg/mL – 
50µg/mL) (all purchased from Sigma-Aldrich). After addition of the bacterial suspension (50 µl in a total 
volume of 100 µl), the plate was incubated at 37°C for 24h and the absorbance was measured at 590 nm 
using an Envision multilable plate reader. Finally, the fractional inhibitory concentration (FIC) index was 
calculated.  
FIC index = (A/MICA) + (B/MICB) 
  A = MICfosmidomycin + CPP   B = MICCPP + fosmidomycin 
  MICA = MICfosmidomycin   MICB = MICCPP 
 A FIC index smaller than 0.5 indicates a synergistic effect of the combination and a FIC greater than 4 
indicates an antagonistic combination.[190-192] 
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1.3.7. Statistical analysis 
Statistical analysis was performed by comparison of mean values through an independent samples t-test 
using SPSS 23.0 software (SPSS, Chicago, IL, USA). 
 
1.4. Results and discussion 
1.4.1. Determination of the MIC 
1.4.1.1. β-substituted fosmidomycin analogues 
The results for the susceptibility screening of our test panel in standard bacterial growth media are 
shown in Table 5. All MIC values of the β-substituted fosmidomycin analogues are >250 µM, for each 
bacterial strain examined. These results indicate that the in vitro activity of the β-substituted 
fosmidomycin analogues is at best equal to the activity of fosmidomycin and FR900098. Chofor and 
colleagues investigated the inhibitory activity of these β-substituted fosmidomycin analogues on 
recombinant DXR-enzymes from E. coli, M. tuberculosis and P. falciparum.[139] In their research is stated 
that the 8-series compounds have better inhibitory activity on DXR than the 7-series compounds (see 
Figure 14), but fosmidomycin itself has a higher inhibitory activity on recombinant DXR, which could be a 
possible explanation for the lack of in vitro antibacterial activity up to 250 µM.  
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Table 5. MIC values (µM) of β-substituted fosmidomycin analogues and several control antibiotics (fosmidomycin, FR900098, kanamycin, tobramycin, isoniazid and rifampicin) in 
standard growth media.  
Compound  MIC (µM)          
 GRAM (-) GRAM (+) MYCOBACTERIA 
 E. coli  P. aeruginosa B. cenocepacia B. cepacia B. multivorans P. acnes M. smegmatis 
 ATCC 8739 ATCC 25922 K-12 PAO1 LMG 16656 LMG 1222 LMG 13010 LMG 16711 ATCC 607 ATCC 700084 
7a >250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
7b >250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
7c >250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
7d >250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
7e >250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
8b >250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
8c >250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
8d >250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
9 >250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
FOS 0.98 250 7.8 62.5 250 >250 >250 >250 >250 >250 
FR900098 7.8 62.5 15.6 >250 >250 125 >250 >250 >250 >250 
Kanamycin 3.9 3.9 3.9 62.5  -  -  - 31.25 62.5 62.5 
Tobramycin 3.9  3.9  - 1.95 0.98 1.95 3.9  -  -  - 
Isoniazid  -  -  -  -  -  -  -  - 62.5 62.5 
Rifampicin  -  -  -  -  -  -  -  - 31.25 31.25 
1. 7a – 9; β-substituted fosmidomycin analogues, FOS; fosmidomycin. “-“; not determined.  
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1.4.1.2. ProTide prodrugs of fosmidomycin 
ProTide prodrugs of fosmidomycin are expected to have higher in vitro antibacterial activity than 
fosmidomycin itself, due to their masked polarity. Unfortunately, MIC values of all ProTides tested are 
>250 µM for E. coli ATCC 8739, P. aeruginosa PAO1, B. cenocepacia LMG 16656, B. cepacia LMG 1222 
and B. multivorans LMG 13010 (see Table 6) and thus higher (for E. coli, P. aeruginosa and B. 
cenocepacia) or equal (for B. cepacia and B. multivorans) than the MIC values of fosmidomycin and 
FR900098. The activity of these ProTide prodrugs against recombinant DXR-enzymes has not yet been 
investigated, which is purposeless because prodrugs are inactive molecules and have to be intracellularly 
converted to their active compounds. Several potential explanations exist regarding the lack of 
antibacterial activity of the prodrugs, including limited inhibitory activity against the target enzyme DXR, 
export of the prodrugs by efflux pumps and/or low membrane permeability.  
Table 6. MIC values (µM) of ProTide fosmidomycin prodrugs (Cf3353 – Cf3361) and control antibiotics. 
Compound  MIC (µM)     
 GRAM (-) 
 E. coli  P. aeruginosa B. cenocepacia B. cepacia B. multivorans 
 ATCC 8739 PAO1 LMG 16656 LMG 1222 LMG 13010 
Cf3353 >250 >250 >250 >250 >250 
Cf3354 >250 >250 >250 >250 >250 
Cf3355 >250 >250 >250 >250 >250 
Cf3356 >250 >250 >250 >250 >250 
Cf3357 >250 >250 >250 >250 >250 
Cf3358 >250 >250 >250 >250 >250 
Cf3359 >250 >250 >250 >250 >250 
Cf3360 >250 >250 >250 >250 >250 
Cf3361 >250 >250 >250 >250 >250 
FOS 0.98 62.5 250 >250 >250 
Fosfoxacin >250 >250 >250 >250 >250 
Tobramycin 3.9 0.98 0.98 1.95 3.9 
Cf3353 – Cf 3361; ProTide fosmidomycin prodrugs, FOS; Fosmidomycin.  
The membrane permeability of fosmidomycin is expected to be low due to its high polarity, but cellular 
uptake of ProTide prodrugs would be facilitated by temporarily “masking” the polar functional groups of 
fosmidomycin.[134, 135] Unfortunately, the ProTide strategy does not increase in vitro antibacterial 
activity of fosmidomycin against the strains tested in this study.   
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1.4.1.3. DXS- and IspF-inhibitors 
The susceptibility of our test panel towards DXS- and IspF-inhibitors is displayed in Table 7. Because no 
complete growth reduction was observed after treatment, susceptibility is expressed as MIC50 which is 
the lowest concentration that reduces bacterial growth to 50% of the untreated control. Most inhibitors 
tested show MIC50 values >250 µM. To our knowledge, the inhibitory activity of the tested compounds 
on recombinant enzymes has not yet been described. Only the thiazolypyrimidines ritanserin and 
ketanserin and their structural analogue altanserin show some in vitro antibacterial activity. Ritanserin 
shows a MIC50 of 125 µM against P. acnes LMG 16711 and M. smegmatis ATCC 700084, MIC50 of 62.5 µM 
against P. aeruginosa PAO1 and a MIC50 of 31.25 µM against B. cenocepacia LMG 16656. Ketanserin is 
able to inhibit in vitro growth of M. smegmatis ATCC 700084 in concentrations starting from 250 µM. 
Table 7. MIC50 values (µM) of DXS-inhibitors (clomazone, 5-ketoclomazone and 4(3H)-pyrimidinone) and IspF-inhibitors 
(ritanserin, ketanserin, altanserin, setoperone and IspF-inhibitor-1). 
Compound  MIC50 (µM)     
 GRAM (-) GRAM (+) MYCOBACTERIA 
 E. coli  P. aeruginosa B. cenocepacia P. acnes M. smegmatis 
 K-12 PAO1 LMG 16656 LMG 16711 ATCC 700084 
Clomazone >250 >250 >250 >250 >250 
Ketoclomazone >250 >250 >250 >250 >250 
Pyrimidinone >250 >250 >250 >250 >250 
Ritanserin >250 62.5 31.25 125 125 
Ketanserin >250 >250 >250 >250 250 
Altanserin >250 >250 >250 >250 250 
Setoperone >250 >250 >250 >250 >250 
Isp-inhibitor-1 >250 >250 >250 >250 >250 
As ritanserin is able to inhibit in vitro planktonic growth of B. cenocepacia, P. acnes and M. smegmatis, 
and ketanserin can also inhibit M. smegmatis growth, we expanded our test panel of bacterial strains. A 
number of additional Bcc strains were included (B. multivorans LMG 18825, B. ambifaria LMG 19182 and 
B. ambifaria LMG 19467), together with one additional P. acnes strain (P. acnes LMG 16712) and three 
mycobacterial strains (M. smegmatis ATCC 607, M. smegmatis LMG 8190 and M. phlei LMG 4056).  
The results for this extended susceptibility screening are presented in Table 8. The antibacterial activity 
of ketanserin and altanserin is limited, as concentrations of ketanserin as high as 250 µM are required to 
inhibit growth of M. smegmatis ATCC 700084. Ritanserin, however, does show a greater capacity to 
inhibit planktonic growth of strains in our test panel, as shown in Table 8. 
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Table 8. MIC50 values (µM) of ritanserin, ketanserin, altanserin and control antibiotics (FOS; fosmidomycin and FR900098) for an 
expanded test panel of Gram-negative, Gram-positive and mycobacterial strains.  
Compound  MIC50 (µM)      
 GRAM (-) 
 B. cenocepacia B. cepacia B. multivorans B. multivorans B. ambifaria B. ambifaria 
 LMG 16656 LMG 1222 LMG 13010 LMG 18825 LMG 19182 LMG 19467 
Ritanserin 31.25 62.5 >250 250 62.5 62.5 
Ketanserin >250 >250 >250 >250 >250 >250 
Altanserin >250 >250 >250 >250 >250 >250 
FOS 250 >250 >250 >250 >250 >250 
FR900098 >250 125 >250 >250 >250 >250 
 GRAM (+) MYCOBACTERIA 
 P. acnes P. acnes M. smegmatis M. smegmatis M. smegmatis M. phlei 
 LMG 16711 LMG 16712 ATCC 700084 ATCC 607 LMG 8190 LMG 4056 
Ritanserin 125 125 125 >250 250 250 
Ketanserin >250 >250 250 >250 >250 >250 
Altanserin >250 >250 >250 >250 >250 >250 
FOS >250 >250 >250 >250 >250 >250 
FR900098 >250 >250 >250 >250 >250 >250 
 
1.4.1.4. Survival of planktonic organisms after ritanserin treatment 
Ritanserin inhibits planktonic growth of some strains of our test panel, as described above. However, 
except for P. acnes LMG 16711, it seemed that treatment with ritanserin does not lead to complete 
inhibition of planktonic growth. We determined the growth reduction of B. cenocepacia LMG 16656, B. 
ambifaria LMG 19467, P. acnes LMG 16711, M. smegmatis ATCC 700084 and M. smegmatis LMG 8190 by 
cultivating these in the presence of ritanserin (125 µM, 250 µM or 500 µM) and quantifying the 
percentage survival after treatment with conventional plating. The results for this experiment are shown 
in Figure 17. 
Ritanserin caused complete growth inhibition of P. acnes LMG 16711 in concentrations starting from 125 
µM. For B. cenocepacia LMG 16656, B. ambifaria LMG 19467, M. smegmatis ATCC 700084 and M. 
smegmatis LMG 8190 ritanserin caused significant growth inhibition of planktonic cells, but no complete 
growth reduction, up to 500 µM. These results were in line with the expectations from the susceptibility 
screening.  
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Figure 17. Percentage survival of planktonic bacterial cultures, relative to untreated controls, of B. cenocepacia LMG 16656, B. 
ambifaria LMG 19467, P. acnes LMG 16711, M. smegmatis ATCC 700084 and M. smegmatis LMG 8190 after ritanserin 
treatment. Error bars represent standard deviations. ‘ * ‘  represents statistically significant differences compared to untreated 
controls (p < 0.05, n = 3). 
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Figure 19. Intrinsic antibacterial activity of A. CCCP and B. PAβN. 
1.4.1.5. Survival of sessile organisms after ritanserin treatment 
 
To determine the growth inhibition of biofilms of B. cenocepacia LMG 16656, we cultivated sessile cells 
in the presence of ritanserin (125 µM, 250 µM and 500 µM) and quantified the percentage survival after 
ritanserin treatment by conventional plating. As shown in Figure 18, ritanserin induced a significant 
growth inhibition of biofilm cells of B. 
cenocepacia LMG 16656, but no complete growth 
reduction, up to 500 µM. 
 
1.4.2. Determining the role of efflux pumps in 
resistance 
One of the main resistance mechanisms in 
bacterial cells is efflux of antibacterial compounds 
by the action of efflux pumps.[193-195] Due to 
the low in vitro activity of the β-substituted 
derivatives and ProTide prodrugs of 
fosmidomycin, we wanted to determine the 
importance of efflux in this antimicrobial 
resistance. Therefore, we investigated the in vitro 
activity of the DXR-inhibitors in combination with 
broad-spectrum efflux pump inhibitors CCCP and 
Figure 18. Percentage bacterial 
survival, relative to untreated control, 
of sessile cells of B. cenocepacia LMG 
16656 after ritanserin treatment. GC; 
untreated control. Error bars 
represent STDEV. ‘ * ‘ indicates 
statistically significant differences 
compared to untreated control (p < 
0.05, n=3).  
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PAβN. CCCP acts as a PMF uncoupler, inhibiting the energy source of RND efflux pumps [193, 196] and 
PaβN is able to inhibit efflux pumps in Gram-negatives belonging to the RND family.[197] 
First, the intrinsic antibacterial activity of both efflux pump inhibitors alone was determined. CCCP 
caused no growth inhibition of B. multivorans LMG 13010. Minimum 10% growth inhibition of E. coli 
ATCC 25922 was caused by 6.25 µM CCCP, of E. coli ATCC 8739 by 12.5 µM CCCP, of B. cepacia LMG 1222 
by 25 µM CCCP, and of P. aeruginosa PAO1 or B. cenocepacia LMG 16656 by 100 µM CCCP (see Figure 
19A). PAβN did not cause growth inhibition of E. coli ATCC 25922 or P. aeruginosa PAO1. Minimum 10% 
growth inhibition of E. coli ATCC 8739 was caused by 12.5 µM PAβN, of B. cenocepacia LMG 16656 or B. 
cepacia LMG 1222 by 50 µM PAβN, and of B. multivorans LMG 13010 by 100 µM PAβN (see Figure 19B). 
To explore the role of efflux pumps in resistance against fosmidomycin analogues, we determined the 
susceptibility of our test panel towards the combination of these analogues with CCCP or PAβN. Fixed 
concentrations (5 µM, 50 µM and 100 µM) of CCCP and PAβN were tested, based on results obtained in 
previous studies and the intrinsic antibacterial activity determined above.[196] The results are shown in 
Table 9. The results in the presence of 5 µM or 50 µM efflux pump inhibitor were similar and therefore 
not presented. 
Table 9. MIC50 values (µM) for β-substituted fosmidomycin analogues (7a-9), fosmidomycin (FOS) and tobramycin in 
combination with 100 µM CCCP or PAβN.  
Compound  MIC50 (µM)      
 E. coli ATCC 8739 E. coli ATCC 25922 P. aeruginosa PAO1 
  + CCCP  + PAβN  + CCCP  + PAβN  + CCCP  + PAβN 
7a >250 >250 >250 >250 >250 >250 
7b >250 >250 >250 >250 >250 >250 
8b >250 >250 >250 >250 >250 >250 
8c >250 >250 >250 >250 >250 >250 
8d >250 >250 >250 >250 >250 >250 
9 >250 >250 >250 >250 >250 >250 
FOS 0.98 0.98 7.8 7.8 125 125 
Tobramycin 3.9 3.9 3.9 3.9 0.98 1.95 
 B. cenocepacia LMG 16656 B. cepacia LMG 1222 B. multivorans LMG 13010 
  + CCCP  + PAβN  + CCCP  + PAβN  + CCCP  + PAβN 
7a >250 >250 >250 >250 >250 >250 
7b >250 >250 >250 >250 >250 >250 
8b >250 >250 >250 >250 >250 >250 
8c >250 >250 >250 >250 >250 >250 
8d >250 >250 >250 >250 >250 >250 
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9 >250 >250 >250 >250 >250 >250 
FOS 250 250 >250 >250 >250 >250 
Tobramycin 0.98 0.98 1.95 3.9 3.9 3.9 
For none of the strains tested, changes in in vitro antibacterial activity of fosmidomycin and its analogues 
were observed upon addition of CCCP or PAβN. These results suggest that resistance of the strains tested 
against fosmidomycin and its analogues is not related to efflux. However, Messiaen and colleagues 
described a significant upregulation of a fosmidomycin resistance gene (fsr) encoding an efflux pump 
after fosmidomycin or FR900098 treatment in Bcc species.[127] In E. coli a similar fsr gene was identified 
which is involved in efflux of fosmidomycin from bacterial cells.[198]  
Table 10. MIC50 values (µM) of ritanserin against B. cenocepacia LMG 16656 and RND-efflux pump mutants.  
To expand our insight in the role of efflux pumps in resistance of B. 
cenocepacia LMG 16656, the susceptibility of RND-efflux pump 
mutants was tested. This collection of mutants was previously 
constructed by Silvia Buroni and Giovanna Riccardi from Pavia 
University.[199] MIC50 values of fosmidomycin, FR900098, 
ritanserin, ketanserin and the β-substituted fosmidomycin 
analogues 7a, 8b and 9 were determined. The results for ritanserin 
are shown in Table 10, MIC50 values for the other nonmevalonate 
inhibitors were all >250 µM (results not shown). These data 
indicate no clear differences between the wild-type strain of B. 
cenocepacia LMG 16656 and its RND-mutants, except for ∆RND5 
and ∆RND15 which, unexpectedly, showed a reduced susceptibility 
towards ritanserin.  
The results from this study suggest that resistance of E. coli ATCC 
8739 and ATCC 25922, P. aeruginosa PAO1, B. cenocepacia LMG 16656, B. cepacia LMG 1222 and B. 
multivorans LMG 13010 against nonmevalonate inhibitors is not related to efflux. Nevertheless, the 
comprehensiveness of this efflux-related study is rather limited and other methods may be used to 
further investigate the role of efflux pumps. Blair and Piddock describe a fluorometric determination of 
efflux by measuring the direct efflux of a fluorescent dye (e.g. ethidium bromide) in cells that are 
preloaded with high concentrations of antibiotics in the presence of an efflux inhibitor (e.g. CCCP).[200, 
Strain MIC50 (µM) 
LMG 16656 31.25 
ΔRND1 62.5 
ΔRND2 62.5 
ΔRND3 62.5 
ΔRND4 62.5 
ΔRND5 >250 
ΔRND6-7 62.5 
ΔRND8 62.5 
ΔRND9 125 
ΔRND4-9 31.25 
ΔRND10 125 
ΔRND11 125 
ΔRND12 125 
ΔRND13 62.5 
ΔRND14 125 
ΔRND15 >250 
ΔRND16 62.5 
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201] Quantitative PCR experiments (qPCR) could also offer an interesting approach to quantify the efflux 
pump RNA expression in bacterial cells after treatment with antibiotics.[202-204] 
 
1.4.3. Effect of increasing cellular permeability 
A possible explanation for the lack of antibacterial efficacy of fosmidomycin analogues and other 
nonmevalonate inhibitors could be the low cellular uptake by passive diffusion due to the polarity of 
these molecules, with a low bioavailability as a consequence.[126] Also, in several studies deficiencies in 
fosmidomycin uptake were characterized in various pathogens, due to the lack of a glpT-transport 
system or the acquisition of mutations (shown in Table 11).[205] 
Table 11. Fosmidomycin resistance mechanisms characterized in various pathogens, retrieved from [205]. 
Organism Resistance classification Resistance description 
Brucella abortus Lack of fosmidomycin-sensitive 
DXR 
Encodes a fosmidomycin insensitive DXR-like enzyme 
[206] 
Bcc Insufficient uptake and efflux 
stimulation 
Enhanced expression of fsr when treated with 
fosmidomycin [127] 
E. coli Expression of a fosmidomycin 
export protein 
Overexpression of a drug export protein [198] 
E. coli Lack of fosmidomycin uptake Adenylate cyclase deficient mutant: glpT function is 
cAMP-dependent [207] 
Francisella novicida Lack of fosmidomycin uptake Deletions in glpT encoding the L-α-glycerophosphate 
transport system [208] 
M. tuberculosis Lack of fosmidomycin uptake Lacks the L-α-glycerophosphate transport system 
[126] 
P. falciparum Gene amplification dxr gene duplication [209] 
P. aeruginosa Lack of fosmidomycin uptake Lacks the L-α-glycerophosphate transport system 
[210] 
Toxoplasma gondii Lack of fosmidomycin uptake Lacks the L-α-glycerophosphate transport system 
[211] 
Two different approaches to enhance the cell penetration of fosmidomycin and its analogues have been 
investigated. First, Messiaen and colleagues described that the MIC values of FR900098 for B. 
cenocepacia LMG 16656, B. cepacia LMG 1222 and B. multivorans LMG 13010 decreased at least 4-fold 
in CDM-G medium, compared to MICs in MHB. This phenomenon was clarified by qPCR; confirming a 
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significantly increased gene expression in B. cenocepacia of three genes involved in glycerol-3-phosphate 
transport (BCAL0282, BCAL0284 and BCAL0285) in the presence of glucose-6-phosphate (CDM-G) 
compared to controls without glucose-6-phosphate.[127] Therefore, the hypothesis was formulated that 
the susceptibility of our test panel towards fosmidomycin and its β-analogues would also increase in 
CDM-G. Unfortunately, the MIC-value of every β-substituted fosmidomycin analogue was > 250 µM (as 
illustrated in Table 12), for every bacterial strain examined in this experiment. 
Table 12. MIC values (µM) of β-substituted fosmidomycin analogues (7a – 9), FOS; fosmidomycin and FR900098 in CDM-G. 
Compound  MIC (µM)     
 GRAM (-)     
 E. coli  E. coli B. cenocepacia B. cepacia B. multivorans 
 ATCC 8739 K-12 LMG 16656 LMG 1222 LMG 13010 
7a >250 >250 >250 >250 >250 
7b >250 >250 >250 >250 >250 
7c >250 >250 >250 >250 >250 
7d >250 >250 >250 >250 >250 
7e >250 >250 >250 >250 >250 
8b >250 >250 >250 >250 >250 
8c >250 >250 >250 >250 >250 
8d >250 >250 >250 >250 >250 
9 >250 >250 >250 >250 >250 
FOS 0.98 7.8 250 >250 >250 
FR900098 7.8 15.6 >250 125 >250 
Second, combination therapy of antibiotics and the CPPs colistin, polymyxin, octaarginin and PMBN was 
tested. This experiment was performed with fosmidomycin in combination with a CPP, for treatment of 
E. coli K-12 and M. smegmatis ATCC 700084; FIC indexes are shown in Table 13. 
Table 13. FIC indexes for fosmidomycin treatment combined with a CPP. FIC < 0.5 indicates synergistic effect, FIC > 4 indicates 
antagonistic effect. FOS; fosmidomycin, COL; colistin, POLY; polymyxin, OCTA; octaarginin and PBMN, polymyxin B nonapeptide. 
Combination FIC index 
 E. coli K-12 M. smegmatis ATCC 700084 
FOS + COL 0.53 1 
FOS + POLY 0.74 0.75 
FOS + OCTA 2 2 
FOS + PMBN 1.5 2 
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All FIC indexes are between 0.5 and 4, indicating that neither a synergistic nor an antagonistic effect 
exists when combining fosmidomycin with colistin, polymyxin, octaarginin or PMBN to treat E. coli K-12 
or M. smegmatis ATCC 700084. 
The results of both experiments concerning enhancement of membrane permeability showed negative 
results. No differences in MIC values were observed in a chemically defined medium by which cellular 
uptake should be increased and the addition of CPPs also failed to increase the antibacterial activity of 
fosmidomycin. Nevertheless, it may be interesting to explore other approaches to enhance membrane 
permeability of fosmidomycin and its analogues (e.g. investigation of the effect of CPPs covalently bound  
to fosmidomycin). 
 
1.5. Conclusions 
The nonmevalonate or DOXP pathway is potentially an interesting target for the development of new 
antibacterial chemotherapeutics. In the present study, the antimicrobial activity of a set of new 
nonmevalonate inhibitors was evaluated by testing their in vitro activity on planktonic and sessile cells of 
Gram-negative, Gram-positive and mycobacterial species. Susceptibility screening of our test panel 
towards DXS-, IspF- and DXR-inhibitors (fosmidomycin and derivatives) showed that the in vitro activity 
of most compounds is low, with MIC values >250 µM. Only the thiazolopyrimidine ritanserin does 
partially inhibit planktonic and sessile growth of several Bcc species, two P. acnes strains and three 
mycobacterial strains. Subsequently, several experiments were performed to elaborate the mechanisms 
of resistance against fosmidomycin, fosmidomycin analogues, DXS- and IspF-inhibitors. Our data suggest 
that the role of efflux in resistance towards these compounds is limited and that the major issue is low 
membrane permeability leading to limited uptake into the bacterial cell. However, the results obtained 
in this study did not prove this hypothesis and further research upon resistance against DOXP-inhibitors 
therefore is essential.  
 
 
 62 
 
 
CHAPTER III. EXPERIMENTAL WORK  PAPER 2 
63 
 
2. IS THE NONMEVALONATE PATHWAY AN ESSENTIAL BIOCHEMICAL PATHWAY IN 
BURKHOLDERIA CENOCEPACIA? 
Annelien Everaert1, Andrea Sass1, Heleen Van Acker1, Freija Van den Driessche1, Tom Coenye1 
1 Laboratory of Pharmaceutical Microbiology, Faculty of Pharmaceutical Sciences, Ghent University, 
Ghent, Belgium 
Manuscript in preparation 
2016 
CHAPTER III. EXPERIMENTAL WORK  PAPER 2 
64 
 
2.1. Abstract  
The nonmevalonate pathway is the sole pathway for isoprenoid biosynthesis in B. cenocepacia and 
possibly a novel target for the development of antibacterial chemotherapy. The goal of the present study 
was to evaluate the essentiality of dxr and ispD, the second and third gene of the nonmevalonate 
pathway, in B. cenocepacia. We constructed rhamnose-inducible conditional knock-down mutants of B. 
cenocepacia K56-2 by using plasmid pSC200, which enables the delivery of a rhamnose-inducible 
promoter in the chromosome, to drive the expression of a candidate essential gene. A rhamnose-
inducible dxr mutant of B. cenocepacia K56-2 was successfully constructed, but we were unable to insert 
a correct ispD construct in K56-2. Growth experiments of planktonic and biofilm cultures of B. 
cenocepacia K56-2 showed that expression of dxr is important for growth, but not essential. MIC-values 
of ceftazidime and aztreonam decreased 16- and 8-fold, respectively, upon disruption of dxr in B. 
cenocepacia K56-2. Data obtained in a Caenorhabditis elegans infection model suggest that sufficiently 
high expression levels of dxr are required for full virulence of B. cenocepacia K56-2. Moreover, dxr seems 
to be involved in the ability of B. cenocepacia to metabolize several carbon sources, including D-
galactonate which is required for biosynthesis of D-glyceraldehyde-3-P, a start product of the 
nonmevalonate pathway. To conclude, although not essential, DXR appears to play an important role in 
different physiological processes of B. cenocepacia. Further research into inhibitors of DXR and other 
enzymes of the nonmevalonate pathway could lead to new treatment approaches for B. cenocepacia 
infections. 
 
2.2. Introduction 
Isoprenoids are a diverse class of naturally occurring compounds with widely varying roles in 
physiological processes of all living organisms. Animals (including humans), fungi, Archaea and some 
bacteria use the mevalonate pathway for isoprenoid biosynthesis.[133] An alternative metabolic 
pathway for the synthesis of isoprenoids, the 1-deoxy-D-xylulose-5-phosphate (DOXP)-pathway or 
nonmevalonate pathway, was discovered in the late 1980s.[212] This pathway starts with the 
condensation of D-glyceraldehyde-3-phosphate and pyruvate to DOXP, catalyzed by the enzyme DOXP-
synthase (DXS). Next, DOXP is converted to 2-C-methyl-D-erythritol-4-phosphate (MEP) by DOXP-
reductoisomerase (DXR). Subsequently, 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) is formed 
with CDP-ME-synthase (IspD) as catalyst. CDP-ME is then phosphorylated by CDP-ME kinase (IspE), with 
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the formation of CDP-ME-2-phosphate. This diphosphate is converted to 2-C-methyl-D-erythritol-2,4-
cyclodiphosphate (MER-cPP) by MER-cPP synthase (IspF) and finally, this cyclic diphosphate molecule 
gives rise to the synthesis of isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate 
(DMAPP).[113, 114] The rate-limiting step in the nonmevalonate pathway is the conversion of DOXP to 
MEP, catalyzed by DXR. Fosmidomycin, a natural phosphonic acid antibiotic, and FR900098, the acetyl 
derivative of fosmidomycin, are effective inhibitors of purified DXR from several bacteria but have 
limited effects on whole bacterial cells.[116, 117, 139] 
The Bcc is a group of 20 closely related opportunistic, Gram-negative species, which present particular 
challenges because of their innate resistance to a variety of antibiotics.[1] Since the early 1980s, 
members of the Bcc are well-known as rare but potentially life-threatening respiratory pathogens in 
patients with cystic fibrosis (CF), with B. multivorans and B. cenocepacia being the most frequently 
isolated Bcc species.[7] Therapeutic options to treat Bcc infections are very limited because of their 
intrinsic resistance to a wide range of antimicrobial agents[90, 171], and the ability of Bcc strains to form 
biofilms in vitro and in vivo contributes to reduced antimicrobial susceptibility, treatment failure and 
persistent infection.[36, 37] 
Bcc bacteria use the nonmevalonate pathway as sole pathway for isoprenoid biosynthesis and since this 
pathway is not present in human cells, it is possibly a novel target for the development of antibacterial 
chemotherapy against Bcc infections.[213, 214] A study from Messiaen et al. describes the in vitro 
susceptibility of 40 Bcc strains against fosmidomycin, FR900098 and several fosmidomycin derivatives. 
Resistance against all derivatives was observed for all Bcc strains, which could partly be explained by the 
lack of a glycerol-3-phosphate transporter (GlpT) system required for import of fosmidomycin and 
FR900098. However, Bcc species possess an alternative GlpT system which can be induced by addition of 
glucose-6-phosphate, leading to increased uptake of fosmidomycin. Unfortunately, a fosmidomycin 
resistance gene (fsr), involved in efflux of fosmidomycin and FR900098, is upregulated in treated cultures 
and is able to compensate for the increased fosmidomycin uptake in the presence of glucose-6-
phosphate.[127] Other research groups have also studied the potential of fosmidomycin and its 
analogues to combat Bcc species and observed Bcc species to be highly resistant to fosmidomycin.[136, 
215] Both studies state that this resistance is probably due to insufficient cellular uptake and the 
presence of a fosmidomycin efflux pump. Shtannikov et al. did not observe higher susceptibility of Bcc 
species to lipophilic fosmidomycin analogues and concluded that while these derivatives show higher cell 
penetration they also have lower affinity for DXR.[136] Isoprenoids are precursors for the biosynthesis of 
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hopanoids which are involved in regulation of membrane stability, permeability and fluidity, and 
contribute to the intrinsic resistance of Bcc bacteria against various antibiotics, including polymyxins, 
erythromycin and chlorhexidine.[215-217] Deletion of genes (BCAM2831 and BCAS0167) involved in 
hopanoid biosynthesis resulted in loss of swarming and swimming motility, suggesting that hopanoids 
play an important role in the physiology of B. cenocepacia.[216] Several studies provide evidence that 
reducing the amount of hopanoids in the Bcc membrane can increase susceptibility to antibiotics.[215-
219] Malott et al. described resistance of B. multivorans isolates to fosmidomycin and colistin when used 
alone, but they observed antimicrobial synergy when both antibiotics were used in combination.[215]  
The goal of the present study was to determine the essentiality of different genes of the nonmevalonate 
pathway in B. cenocepacia, because previous research upon promising nonmevalonate inhibitors did not 
show any in vitro activity against species of the Bcc (Chapter III.1). Identifying essential genes is 
important because the products of these essential genes are potential novel antibacterial targets for the 
treatment of multidrug-resistant bacteria. A number of techniques have been used in the past to identify 
and study candidate essential genes in B. cenocepacia, including antisense overexpression mutants 
[220], unmarked deletion mutants [221-223], transposon directed insertion-site sequencing (TraDIS) 
[224] and rhamnose-inducible conditional expression mutants.[225-228] In the present study, we used 
plasmid pSC200 to construct rhamnose-inducible conditional mutants of B. cenocepacia.[226-228] 
pSC200 enables the replacement of the native promoter of a gene by a rhamnose-inducible promoter to 
drive the expression of the targeted candidate essential gene. This procedure gives rise to conditional 
mutants in which the expression of the target gene is highly dependent on the rhamnose concentration 
in the growth medium.[226-228] The second and third enzyme (DXR and IspD, respectively) were chosen 
as targets of the nonmevalonate pathway. DXR catalyzes the rate-limiting step of this pathway namely 
the conversion of DOXP to MEP.[116, 117] IspD was also included because growth inhibition of B. 
cenocepacia strains was observed in previous experiments (Chapter III.1) by an inhibitor of IspF, which is 
located in one operon with IspD. Both genes were identified as essential in Escherichia coli, 
Mycobacterium tuberculosis and Plasmodium falciparum [119, 126] and recent TraDIS analysis by Wong 
et al. also showed that all five genes of the nonmevalonate pathway are essential in B. cenocepacia 
J2315.[224] 
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2.3. Materials and methods 
2.3.1. Bacterial strains, plasmids and growth conditions 
Bacterial strains and plasmids used in this study are listed in Table 14. Cultures E. coli and B. cenocepacia 
strains were grown in Luria-Bertani agar or broth (LBA or LBB; LabM, Lancashire, UK) or in a synthetic 
medium described by Ortega et al.[226], further referred to as ‘pSC200 broth’. pSC200 broth contains 
M9 minimal medium (42mM Na2HPO4, 22 mM KH2PO4, 8 mM NaCl and 10 mM NH4Cl) supplemented 
with yeast extract (5 g/L), casamino acids (2 g/L), vitamin B1 (2 mg/L), tryptophan (20 mg/L), CaCl2 (1µM) 
and 0.5% (wt/vol) glycerol. These media were supplemented with 0.5% (wt/vol) rhamnose or glucose, 50 
µg/mL gentamicin, 40 µg/mL kanamycin or trimethoprim (50 µg/mL or 800 µg/mL) when required (all 
purchased from Sigma-Aldrich, St-Louis, MO, USA). Liquid cultures were grown in a shaking hot water 
bath at 37°C.  
Pure cultures of mutant B. cenocepacia K56-2 strains were grown on LB agar supplemented with 800 
µg/mL trimethoprim and 0.5% rhamnose. Liquid cultures for phenotypic and genotypic experiments 
were grown in LBB or pSC200 broth, without addition of rhamnose or antibiotics.  
Table 14. Bacterial strains and plasmids used in this study 
Strain or plasmid Characteristics Reference 
B. cenocepacia   
K56-2 Wild type (wt), ET-12 lineage, CF isolate Lab. Collection 
K56-2dxr dxr knock-down mutant of K56-2 This study 
   
E. coli   
DH5α  λpir Lab. Collection 
HB101 pRK2013 Lab. Collection 
DH5αdxr λpir, pSC200dxr This study 
DH5αispD λpir, pSC200ispD This study 
   
Plasmids   
pRK2013 oricolE1, RK2 derivative [229] 
 Km
R
, mob
+
, tra
+ 
 
pSC200 pGpΩTp derivative [230] 
 oriR6K, rhaR, rhaS, PrhaB, e-gfp, dhfr [226] 
pSC200dxr pSC200 carrying fragment of dxr This study 
pSC200ispD pSC200 carrying fragment of ispD This study 
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2.3.2. Construction of conditional mutants of B. cenocepacia K56-2 
To confirm the essentiality of DOXP genes in B. cenocepacia K56-2, conditional knock-down mutants 
were constructed by replacing the native promoters of the target genes dxr (BCAL2085) and ispD 
(BCAL2016) with the rhamnose-inducible promoter PrhaB (Figure 20 [227, 228]). Primers used in this study 
are listed in Table 15. The genome sequence of B. cenocepacia K56-2 was obtained from the website of 
the Burkholderia Genome Database.[231] 
Primers were designed to amplify dxr and ispD fragments of 283 bp and 115 bp, respectively, spanning 
the 5’ region of each targeted gene, using the website of the National Center for Biotechnology 
Information (NCBI) and their specificity was evaluated using BLAST.[42, 43] The essential gene fragments 
were amplified by PCR with primers DXR F1/DXR R2 and IspD F1/IspD R5, digested with restriction 
enzymes XbaI and NdeI (Promega, Madison, WI, USA) and ligated into digested pSC200 downstream of 
the plasmid-borne PrhaB, resulting in plasmids pSC200dxr and pSC200ispD. Then, each of the recombinant 
plasmids was transformed into E. coli DH5α λpir by CaCl2 transformation resulting in E. coli DH5αdxr and 
DH5αispD which were subcultured on LB agar supplemented with 50 µg/mL trimethoprim and 0.5% 
glucose. Subsequently, recombinant plasmids were transferred into B. cenocepacia K56-2 by triparental 
mating, using the method described by Ortega et al. ([226]) with the following modifications. Overnight 
cultures of B. cenocepacia K56-2, E. coli HB101 (pRK2013) and E. coli DH5αdxr or DH5αispD were mixed 
in equal volumes, 300 µL was spotted on LB agar + 0.5 % rhamnose and incubated at 37°C for six hours. 
Afterwards, cells were washed with physiological saline (PS) and released from the agar surface, and 1 
Figure 20. Illustration of the strategy used to 
construct conditional mutants. NP; native 
promotor, EG; essential gene, RP; rhamnose-
inducible promotor, EGF; essential gene 
fragment, AM; antibiotic resistance marker, rhaR 
and rhaS; activators of rhamnose 
catabolism.[227] 
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mL of each cell solution was spotted on LB agar plus 50 µg/mL gentamicin (to select against E. coli), 800 
µg/mL trimethoprim, and 0.5% rhamnose. Plates were incubated at 37°C for about 48 hours and 
successful exconjugants (further referred to as K56-2dxr and K56-2ispD) were subcultured on LB agar 
plus 800 µg/mL trimethoprim and 0.5% rhamnose. 
Table 15. Primer sequences used in this study 
Name Sequence Purpose 
DXR F1 CAAAAACGTCTGACATTGCTC Amplification of dxr  fragment 
DXR R2 AGCCGTCGCTCTTCGACAC Amplification of dxr  fragment 
IspD F1 ACTCCCCGACTTTTCGCC Amplification of ispD fragment 
IspD R5 CGAGCGTGTAGTGCAGCAG Amplification of ispD fragment 
rhaF CACGTTCATCTTTCCCTGGT Confirmation of transformation and triparental mating 
200-MCS-R AACACTTAACGGCTGACATGG Confirmation of transformation 
DXR R4 AGGCCCTTGTTCATCATCG Confirmation triparental mating K56-2dxr 
ispD R4 GAGCTTCTCGTTGGTCTTCG Confirmation triparental mating K56-2ispD 
 
2.3.3. Chelex DNA-extraction and confirmation of transformation/triparental mating 
Chelex DNA-extractions were performed on colonies of E. coli DH5α λpir and B. cenocepacia K56-2 after 
transformation and triparental mating, respectively. A 5% Chelex suspension was prepared (200-400 
Mesh, Bio-rad Laboratories NV, Nazareth, Belgium) in DEPC-treated water (Invitrogen, ThermoFisher 
Scientific, Merelbeke, Belgium) and used for DNA-extraction. Subsequently, 2 µL of each supernatant 
was used as template DNA for PCR reactions using a C1000 Touch Thermal Cycler (Bio-rad). The cycling 
conditions included an initial denaturation at 95°C for 5 min, followed by 40 amplification cycles 
consisting of 1 min at 94°C, 1 min at 58°C and 1 min at 72°C and terminated with a final extension of 2 
min at 72°C. PCR primers rhaF/200-MCS-R were used to confirm transformation and primers rhaF/DXR 
R4 and rhaF/ispD R4 were used to confirm triparental mating. Purified PCR products were separated on a 
1% agarose gel and sent for Sanger sequencing (LightRun sequencing, GATC Biotech AG, Constance, 
Germany) to confirm the correct insertion of the desired construct into E. coli DH5α λpir or B. 
cenocepacia K56-2. Sequences obtained are presented in Supplementary file S1.  
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2.3.4. RNA-extraction and cDNA synthesis 
Cells of wild-type and mutant B. cenocepacia K56-2 were cultured in either pSC200 broth or in LBB. Both 
media were used without addition of a carbon source or were supplemented with 0.5% rhamnose or 
glucose. After 24 hours incubation at 37°C, cells were collected and RNA was extracted using the 
RiboPure Bacteria Kit (Ambion, Austin, TX) according to the manufacturer’s guidelines including a 1 h 
DNAse treatment. Subsequently, RNA concentrations were determined using BioDrop µLite (Isogen Life 
Science, Utrecht, The Netherlands) and 500 ng of each RNA sample was used to synthesize cDNA using 
qScript cDNA Synthesis kit (QuantaBio, Beverly, MA, USA). 
 
2.3.5. Quantitative real-time polymerase chain reaction (qPCR) 
qPCR experiments were performed on a Bio-Rad CFX96 Real-Time PCR Detection System using a Perfecta 
SYBR Green Fastmix (QuantaBio), according to the manufacturer’s instructions. The PCR cycling protocol 
included an initial denaturation at 95°C for 3 min, followed by 40 amplification cycles consisting of 15 s at 
95°Cand 1 min at 60°C; a melting curve analysis was performed at the end of each run. All PCR data were 
normalized to the mean expression value of three reference genes (BCAS0175, BCAM2784 and 
BCAL2694) which were stably expressed in all conditions. 
 
2.3.6. Evaluation of differences in planktonic growth 
To evaluate differences in planktonic growth between different B. cenocepacia strains, growth rates 
were measured. To this end bacterial cultures were grown overnight in pSC200 broth, and subsequently 
diluted in a variety of bacterial growth media, including LBB, pSC200 broth, M9 minimal medium (MM9), 
Tryptic Soy Broth (TSB, LabM), Mueller-Hinton broth (MHB, BD) and Synthetic Cystic Fibrosis Medium 
(SCFM, [232]) to obtain a final inoculum of approx. 5 x 105 colony forming units/mL (CFU/mL). 200 µl of 
each bacterial suspension was added in duplicate to a flat-bottomed 96-well microtiter plate (TPP, 
Trasadingen, Switzerland) and bacterial growth was monitored by measuring absorbance at 590 nm in an 
Envision multilable plate reader (Perkin Elmer, Waltham, MA, USA), every 30 min for 48-72 hours at 
37°C, until stationary phase was reached. 
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2.3.7. Evaluation of biofilm formation 
Wild-type and mutant strains of B. cenocepacia K56-2 were cultured in pSC200 broth. After overnight 
incubation, cell densities were again adjusted to obtain a final inoculum of approx. 5 x 105 CFU/mL, using 
six different growth media (LBB, LBB plus 0.5% rhamnose, LBB plus 0.5% glucose, pSC200, pSC200 plus 
0.5% rhamnose and pSC200 plus 0.5% glucose). Biofilms  were grown in U-bottomed 96-well microtiter 
plates for 4 h at 37°C, washed with PS and incubated at 37°C for another 20 h. Biofilm formation was 
quantified by resazurin staining and conventional plating. After 24 h of biofilm formation at 37°C, a 
resazurin solution (CellTiter-Blue, Promega) was added to the sessile cultures followed by 2h incubation 
at 37°C; fluorescence at 535 nm was measured in an Envision plate reader. [187] Quantification of the 
CFU per biofilm was performed through plating on LBA or LBA supplemented with 0.5% rhamnose. 
 
2.3.8. Evaluation of in vitro antimicrobial susceptibility 
Antimicrobial susceptibility was investigated by determination of the minimal inhibitory concentration 
(MIC) according to the EUCAST broth microdilution guidelines.[183] Antibiotics tested included 
ceftazidime, ciprofloxacine, meropenem, minocycline, tobramycin, aztreonam, erythromycin, 
chloramphenicol, rifampicin, tetracycline, fosmidomycin, FR900098 and ritanserin. Ceftazidime, 
ciprofloxacin, minocycline, erythromycin, chloramphenicol, rifampicin, tetracycline, FR900098 and 
ritanserin were all purchased from Sigma-Aldrich, meropenem was obtained from Hospira Benelux 
(Antwerp, Belgium), tobramycin and aztreonam were purchased from TCI Europe (Zwijndrecht, Belgium), 
and fosmidomycin was obtained from Invitrogen. MICs were determined in triplicate using flat-bottomed 
96-well microtiter plates, with concentrations ranging from 1 to 512 µg/mL except for fosmidomycin, 
FR900098 and ritanserin, where concentrations of 0.98 to 500 µM were tested. Planktonic bacterial 
cultures were grown overnight in pSC200 broth, adjusted to obtain a final inoculum of approx. 5 x 105 
CFU/mL and added to the 96-well plates. Plates were incubated for 24h at 37°C and absorbance was 
measured at 590 nm using an Envision plate reader.  
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2.3.9. Checkerboard assays 
The combinatorial effect of DXR-inhibitors and certain β-lactam antibiotics on wild-type and mutant B. 
cenocepacia K56-2 strains was investigated by performing checkerboard synergy assays. Planktonic cells 
of K56-2 and K56-2dxr were treated with fosmidomycin or FR900098 (concentration range 3.9 µM – 500 
µM) in combination with ceftazidime or aztreonam (0.06 – 64 µg/mL). After addition of the bacterial 
suspension (100 µl in a total volume of 200 µl), the plate is incubated at 37°C for 24h and the absorbance 
is measured at 590 nm using an Envision multilable plate reader. Experiments were performed in 
triplicate.  
 
2.3.10. Caenorhabditis elegans infection assay 
C. elegans was maintained under standard conditions, cleaned and synchronized by sodium hypochlorite 
bleaching, and subcultured on nematode growth medium (NGM) agar using E. coli OP50 as a nutrient 
source.[233] Synchronized worms (L4 stage worms) were suspended in OGM medium consisting of 95% 
M9 buffer (3g/L KH2PO4, 6 g/L Na2HPO4, 5g/L NaCl and 1mL of 1M MgSO4*7H2O), 5% Brain Heart Infusion 
broth (BHI, Oxoid, Aalst, Belgium) and 10 µg/mL cholesterol. Cultures of wild-type and mutant B. 
cenocepacia were grown overnight in pSC200 broth, centrifuged and resuspended to OD 2 in OGM 
medium. A flat-bottomed 96-well plate was used for the C. elegans infection assay. Uninfected controls 
contained 25 µL nematode suspension (approx. 15 worms) and 75 µL OGM, while other wells contained 
25 µL nematode suspension, 25 µL bacterial suspension (approx. 108 CFU/mL) and 50 µL OGM. 
Experiments were carried out in the presence or absence of 0.5% rhamnose or 0.5% glucose. Plates were 
incubated at 25°C for up to 72h and the ratio living/dead nematodes was determined every 24h using an 
EVOS microscope (Thermo Fisher Scientific, Waltham, MA, USA). After 72h incubation, the nematodes 
were collected (content of four wells was pooled) and rinsed three times with M9 buffer supplemented 
with 1 mM NaN3 (Sigma-Aldrich). Then, the nematodes were mechanically disrupted using sterile silicon 
carbide beads, vortexed for 10 min and a dilution series of every supernatant was prepared. The 
dilutions were plated on LB agar supplemented with 600 µg/mL polymyxin (Sigma-Aldrich) and 50 µg/mL 
gentamicin (to select against growth of E. coli OP50) and for plating of the mutant strains we also added 
0.5% rhamnose. After 24h incubation at 37°C the number of CFU/nematode was determined. Every 
CHAPTER III. EXPERIMENTAL WORK  PAPER 2 
73 
 
condition was tested at least four times in each assay and the assay was performed in triplicate (interday 
replicates, n=3 x 4). 
 
2.3.11. Evaluation of differences in carbon metabolism 
Biolog Phenotype Microarrays (Labconsult, Brussels, Belgium) were used to explore differences in carbon 
metabolism between wild-type and mutant B. cenocepacia strains. Bacterial cultures were grown at 37°C 
on LB agar. Inoculation fluids and cell suspensions were prepared according to the manufacturer’s 
guidelines. PM1 and PM2A Microplate Carbon Sources (Biolog) were inoculated with 100 µL cell 
suspension/well and incubated at 37°C for up to 72 hours. Every 24h, absorbance was measured at 590 
nm using an Envision plate reader. Experiments were performed in triplicate (n= 3). Carbon sources 
where defined as ‘not metabolized’ when the absorbance was equal to the negative control. For carbon 
sources that showed differences in metabolism between wild-type and mutant strains, the biochemical 
pathways in which they participate were identified using the KEGG Pathway Database and the 
Burkholderia Genome Database.[231, 234] 
 
2.3.12. Statistical analysis 
Statistical analysis was performed by comparison of mean values through an independent samples t-test 
or nonparametric test for independent samples, using SPSS 23.0 software (SPSS, Chicago, IL, USA). 
 
2.4. Results 
2.4.1. Construction of conditional mutants of B. cenocepacia K56-2  
Using the approach described above, we were able to construct B. cenocepacia K56-2dxr, a mutant strain 
in which the expression of dxr is controlled by a rhamnose-inducible promoter. However, we were 
unable to insert the correct ispD construct in B. cenocepacia K56-2. qPCR was used to determine 
differences in mRNA expression of dxr between K56-2 and K56-2dxr in the presence or absence of 
rhamnose or glucose, in both LB and pSC200 broth. In the absence of rhamnose, dxr mRNA expression in 
K56-2dxr is very low; while in the presence of rhamnose, the mRNA expression level was similar to that 
observed in the wild type strain (Fout! Verwijzingsbron niet gevonden.1). However, gene expression 
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of dxr is not completely switched off in the absence of rhamnose; the small amounts of mRNA can be 
enough to produce DXR.   
 
 
2.4.2. Differences in planktonic growth between B. cenocepacia K56-2 and K56-2dxr 
Growth curves of K56-2 and K56-2dxr in different culture media are shown in Figure 22. Planktonic 
growth in all six media tested shows two remarkable trends: (i) growth of K56-2dxr in the presence of 
0.5% rhamnose is similar to that of the wild type strain, and (ii) K56-2dxr requires more time to reach 
stationary phase when grown in the absence of rhamnose. Nevertheless, K56-2dxr is still able to grow 
without addition of rhamnose, suggesting that dxr is essential for planktonic growth of B. cenocepacia 
K56-2, but that low levels of dxr are still expressed (in accordance with qPCR results). 
Figure 21. Relative expression of dxr measured by qPCR. Expression levels are normalized to the 
expression observed in B. cenocepaciaz K56-2. Error bars represent min-max, n=2. 
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Figure 22. Growth curves of planktonic cultures of K56-2 and K56-2dxr in different growth media (LBB, pSC200 broth, MM9, TSB, 
MHB and SCFM. 
 
2.4.3. Biofilm formation 
Biofilm formation of B. cenocepacia K56-2 and K56-2dxr in LBB and pSC200 was evaluated and quantified 
by resazurin staining (Figure 23). When grown in LBB without rhamnose, biofilm formation of K56-2dxr is 
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significantly lower (p < 0.05, n=3) than that observed for the wild type, but no significant differences in 
biofilm formation are observed in pSC200 medium.  
 
 
 
To confirm these observations, we determined the number of CFU/biofilm by conventional plating 
(Figure 24). A small, but statistically significant decrease (p < 0.05, n=9) in biofilm formation of K56-2dxr 
was observed when grown in LBB or pSC200 without rhamnose, compared to K56-2 cultured under 
identical conditions. No significant differences in CFU/biofilm are observed in LBB or pSC200 with 0.5% 
rhamnose.  
 
 
 
 
 
 
 
 
Figure 23. Biofilm formation (24h) of B. 
cenocepacia K56-2 and K56-2dxr in LBB 
and pSC200 broth, quantified by 
resazurin staining. Concentration of 
rhamnose and glucose is 0.5% (wt/vol). 
Error bars represent standard deviation. 
‘ * ‘ indicates statistically significant 
differences with respect to K56-2 under 
identical growth conditions (p < 0.05, 
n=12). 
Figure 24. CFU/Biofilm of B. cenocepacia K56-2 and K56-2dxr in LB and pSC200, compared to K56-2. Error bars 
represent STDEV. Concentration of rhamnose and glucose is 0.5% (wt/vol). ‘ * ‘ indicates statistically significant 
differences with respect to K56-2 under identical growth conditions (p < 0.05, n=3x3). 
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2.4.4. Differences in in vitro antimicrobial susceptibility  
We evaluated whether there are differences in antimicrobial susceptibility between B. cenocepacia K56-
2 and K56-2dxr (Table 16). These experiments were carried out in the absence of rhamnose (i.e. very low 
levels of dxr expression). Relevant (i.e. more than two-fold) 
differences in MIC-values between K56-2 and K56-2dxr were 
only observed for ceftazidime and aztreonam. The MIC of 
ceftazidime decreased 16-fold (from 64 µg/mL for K56-2 to 4 
µg/mL for K56-2dxr) and the MIC of aztreonam decreased at 
least 8-fold (from > 512 µg/mL for K56-2 to 64 µg/mL for K56-
2dxr).  
 
 
Table 16. MIC-values (in µg/mL or µM) of 13 different antibiotics for B. 
cenocepacia K56-2 and K56-2dxr. 
 
The increased susceptibility of B. cenocepacia K56-2dxr for aztreonam and ceftazidime raised the 
possibility of specific DXR-inhibitors to potentiate the antibacterial activity of both antibiotics. Therefore, 
checkerboards synergy assays were performed with DXR-inhibitors fosmidomycin or FR900098 in 
combination with ceftazidime or aztreonam on planktonic cultures of K56-2 and K56-2dxr. Results for 
ceftazidime-FR900098, which was shown to be the most effective combination, are shown in Figure 25 
and results for the remaining combinations are depicted in Supplementary file S2. In vitro checkerboard 
assays with B. cenocepacia K56-2dxr in the presence of rhamnose showed that the susceptibility for 
ceftazidime is reversed to wild-type levels, with an MIC-value of 32 µg/mL without addition of FR900098 
(graphs presented in Supplementary file S3). 
MIC (µg/ml) K56-2 K56-2dxr 
Ceftazidime 64 4 
Ciprofloxacin 8 8 
Meropenem 16 8 
Minocycline 8 4 
Tobramycin 128 256 
Aztreonam >512 64 
Erythromycin 256 256 
Chloramphenicol 16 16 
Rifampicin 64 64 
Tetracyclin 32 32 
MIC (µM) K56-2 K56-2dxr 
Ritanserin >500 >500 
Fosmidomycin >500 >500 
FR900098 >500 250 
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Figure 25. In vitro activity of ceftazidime (CAZ) combined with FR900098 (FR) against B. cenocepacia K56-2 and K56-2dxr. 
‘500FR’, ‘250FR’, etc. indicates the concentration of FR900098 (in µM). 
 
2.4.5. Survival of C. elegans infected with B. cenocepacia K56-2 or K56-2dxr 
The virulence of B. cenocepacia K56-2 and K56-2dxr was evaluated using a C. elegans in vivo model 
system. Percentage survival of C. elegans after 24, 48 and 72 hours of infection is shown in Figure 26. 
Percentage survival of the conditional mutant K56-2dxr was compared to wild type K56-2 cultured under 
the same conditions. In the absence of rhamnose, significantly more (p < 0.05) worms survived infection 
with the conditional K56-2dxr mutant than with the wild type strain, at all time points. When C. elegans 
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Figure 27. LOG CFU/worm determined by conventional 
plating after 72 hours infection of C. elegans (n=3). 
Concentration of rhamnose and glucose is 0.5% 
(wt/vol). 
was infected with K56-2dxr in the presence of 0.5% rhamnose, significantly (p < 0.05) more worms 
survived infection at 24 and 48 hours, compared to wild type K56-2. But, no significant (p > 0.05) 
difference in survival percentage was observed between mutant and wild type K56-2 after 72 h infection.  
 
Figure 26. Percentage survival of C. elegans; uninfected (+) or infected with K56-2 or K56-2dxr. The results are expressed as 
percentage survival after 24, 48 and 72 hours of infection, relative to uninfected controls with identical culture conditions. 
Rhamnose and glucose are added at 0.5% (wt/vol). Error bars represent STDEV (n=12), ‘ * ‘ indicates statistically significant 
differences compared to K56-2 cultured under the same conditions (p < 0.05, n=12). 
Additionally, we quantified the number of CFU/worm by conventional plating after 72h of infection. No 
significant differences in the number of bacteria per nematode were observed, confirming that the 
difference shown in Figure 26 are not due to 
differences in bacterial growth (Figure 27).  
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2.4.6. Evaluation of differences in carbon metabolism 
Biolog Phenotype Microarrays were used to analyze the metabolism of 190 different carbon sources by 
B. cenocepacia K56-2 and the conditional mutant K56-2dxr. Carbon sources for which the absorbance 
was equal to the negative controls were identified as ‘not metabolized’. Eight compounds were 
identified that are metabolized by K56-2 but not by K56-2dxr: D-galactose, N-acetyl-D-galactosamine, D-
tagatose, β-methyl-D-glucoside, salicin, lactitol, capric acid (decanoic acid) and D-galactonic acid-γ-
lactone (D-galactonate).  
 
2.5. Discussion 
B. cenocepacia is one of the major pathogens causing bacterial infections in CF patients and is difficult to 
treat because of its high innate antimicrobial resistance. The goal of the present study was to evaluate 
the essentiality of the nonmevalonate pathway in B. cenocepacia and its potential as a novel 
antibacterial target. A conditional mutant of DXR was constructed in B. cenocepacia K56-2 and its 
phenotype was studied. Combined, our qPCR and sequencing data clearly indicate that we successfully 
constructed a rhamnose-inducible B. cenocepacia K56-2 dxr mutant. Unfortunately, we were unable to 
insert the correct ispD construct in B. cenocepacia, possibly because the size of the ispD fragment was 
too small or because ispD is expressed in one operon with ispF. However, disrupting dxr is sufficient to 
investigate essentiality of this pathway in B. cenocepacia since this enzyme catalyzes the rate-limiting 
step. 
Growth experiments showed that DXR is essential for planktonic growth of B. cenocepacia in several 
culture media. Our data also show that biofilm growth of B. cenocepacia K56-2 in LBB is dependent on 
expression of dxr. In pSC200 broth, no differences of sessile growth of K56-2 are observed with resazurin 
staining however, a significant decrease in CFU/biofilm is observed upon disruption of dxr. We currently 
do not have an explanation for this discrepancy between both quantification methods or between LB 
and pSC200, although it cannot be attributed to differences in CFU/biofilm between both media. The 
growth inhibition of B. cenocepacia upon disruption of DXR is contradictory to the negative MIC results 
of the DXR inhibitors in Chapter III.1. Two explanations can possibly clarify this discrepancy. First, the in 
vitro activity of the DXR inhibitors has not yet been tested on purified DXR of B. cenocepacia, previous 
research has mostly been focused on inhibitory activity on the enzymes of E. coli, P. falciparum or M. 
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tuberculosis. Second, the lack of in vitro activity of the tested compounds against whole cells of B. 
cenocepacia is most likely related to limited cellular uptake. Therefore, it is not straightforward to 
correlate the MIC results in Chapter III.1 to differences in growth observed in the current chapter.  
Susceptibility of B. cenocepacia K56-2 towards ceftazidime and aztreonam increased upon disruption of 
dxr, which can possibly be attributed to cell wall defects through a lack of isoprenoid biosynthesis. 
Therefore, the increased susceptibility of B. cenocepacia K56-2dxr for aztreonam and ceftazidime raised 
the possibility to use specific DXR-inhibitors to potentiate antibacterial activity of both antibiotics. In 
vitro checkerboard assays with fosmidomycin or FR900098 and ceftazidime or aztreonam confirmed this 
hypothesis. Addition of at least 250 µM FR900098 to ceftazidime treatment against B. cenocepacia K56-2 
reduced the MIC of ceftazidime from 64 µg/mL to 4 µg/mL which represents a shift from resistant to 
susceptible, according to EUCAST breakpoints.[235] However, FR900098 also increased the activity of 
ceftazidime against K56-2dxr in the absence of rhamnose, where the expression of dxr is shown to be 
very low. This MIC-decrease from 4 µg/mL to less than 0.06 µg/mL upon addition of at least 125 µM 
FR900098 could be explained by the fact that this DXR-inhibitor might also target other nonmevalonate 
enzymes when used at high concentrations. This in vitro activity screening showed that combination 
therapy of ceftazidime with FR900098 (or other potent DXR inhibitors) could offer an approach to treat 
B. cenocepacia infections. 
Results obtained in an in vivo C. elegans infection model suggest that full virulence of B. cenocepacia 
K56-2 in this model requires sufficiently high levels of expression of dxr. Significantly more worms 
survived infection with K56-2dxr in the absence of rhamnose (40-70% survival), compared to wild type 
K56-2 (15-50% survival). When glucose is added to the medium, a high survival percentage of 90-100% is 
observed. This can be explained by the fact that in this mutagenesis system, expression of PrhaB (and thus 
of dxr) upon glucose addition is even lower than without an extra carbon-source. The fact that DXR 
significantly affects in vivo virulence of B. cenocepacia can be of substantial value.  
Data obtained with Biolog Phenotype microarrays showed that disruption of dxr in B. cenocepacia leads 
to alterations in the metabolism of eight carbon sources. Investigation of all eight compounds through 
the KEGG Pathway Database and the Burkholderia Genome Database led to the following 
observations.[231, 234] β-D-glucoside plays a role in starch and sucrose metabolism of B. cenocepacia; it 
is converted by beta-glucosidases to D-glucose. Salicin is involved in gluconeogenese and the 
phosphotransferase system through synthesis of β-D-glucose-6-P and phospho-β-glucoside, respectively. 
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Capric acid (decanoic acid) is a fatty acid which is involved in catabolic and anabolic reactions to generate 
energy and biologically important molecules. Thus, three out of eight carbon sources play an important 
metabolic role in B. cenocepacia but no clear relation with DXR or the nonmevalonate pathway could be 
found. For the five other compounds, an interesting connection with DXR was observed. D-galactose, N-
acetyl-D-galactosamine, D-tagatose, lactitol and D-galactonic acid-γ-lactone (D-galactonate) can all be 
metabolized to D-glyceraldehyde-3-phosphate (G3P).[236] G3P is essential for isoprenoid biosynthesis in 
B. cenocepacia since it is, together with pyruvate, the precursor for the nonmevalonate pathway.[213] 
The results in this study suggest that disruption of dxr in B. cenocepacia does not only inactivate the 
nonmevalonate pathway for isoprenoid biosynthesis, but also has an influence on upstream metabolic 
pathways such as galactose metabolism and synthesis of G3P. 
To conclude, the present study proves that DXR is essential for in vitro growth of planktonic and sessile 
cultures of B. cenocepacia K56-2. DXR also has an influence on antimicrobial resistance against 
ceftazidime and aztreonam and plays a key role in in vivo virulence in a C. elegans infection model. Our 
data indicate that the nonmevalonate pathway is an interesting target for antibacterial chemotherapy 
against B. cenocepacia.  
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SUPPLEMENTARY DATA 
S1. Data Sanger sequencing 
DNA sequence B. cenocepacia K56-2dxr  
(primers rhaF/DXR R4) 
AGGTCGCGAATTCAGGCGCTTTTTAGACTGGTCGTAATGAAATTCAGCAGGATCACATATGCAAAAACGTCTGACA
TTGCTCGGTTCCACAGGCTCGATCGGAGACAGCACGCTCGACGTGGTCGCGCGCCATCCCGAGCGCTTCTCGGTCT
ATGCGCTGACCGCGCACCGCAACGGCGACAAGCTCGTCGAGCAGTGTCTGCGCTTCGCGCCTGAAGTGGCGGTGG
TCGGCGATGCCGCGACGGCCGCGCACGTCGACGCCAAACTGCGCGCGGCCGGCAGCAAGACGGTCGTGCTGCAC
GGGCCGCAGGCGCTCGTCGACGTGTCGAAGAGCGACGGCTGCGACACGGTGGTCGCGGCGATCGTCGGCGCGGC
CGGCCTCGCGCCGAGCCTGGCGGCCGCACGCGCCGGCAAGCGGATCCTGCTCGCGAACAAGGAAGCGCTCGTGA
TGTCGGGCGCGATCTTCATGGACGCCGTACGCGACCATGGCGCGATCCTGCTGCCGGTCGACAGCGAACACAACG
CGATCTTCCAGTGCATGCCGCGCGACGCGGCCGAGCACGGCGGGATCTCGAAGATCATCCTGACCGCGTCGGGCG
GCCCGTTCCGTACGCGCGAACCGGCCACGCTGGTCGACGTCACGCCGGACGAAGCGTGCAAGCACCCGAACTGGG
TGATGGGCCGCAAGATCTCGGTCGATTCCGCGACGATGATG 
dxr sequence (nucleotide 1-657 of 1197) 
PrhaB sequence (nucleotide 226-255) 
CATATG NdeI restriction site 
 
DNA sequence E. coli DH5α λpir containing pSC200 with ispD insert   
(primers rhaF/200-MCS-R) 
GGCGCTTTTTAGACTGGTCGTAATGAAATTCAGCAGGATCACATATGACTCCCCGACTTTTCGCCCTGATTCCCTGT
GCCGGCACGGGCAGCCGTTCCGGCTCGGCCGTGCCGAAGCAATACCGGACGCTGGCCGGCCGCGCGCTGCTGCA
CTACACGCTCGTCTAGAGGTACCGCATGCGATATCGAGCTCTCCCGGGAATTCCACAAATTGTTATCCGCTCACAAT
TCCACATGTGGAATTCCACATGTGGAATTCCCATGTCAGCCGTTAAGTGTT 
Sequence ispD insert (amplified with primers ispD F1/ispD R5) 
PrhaB sequence (nucleotide 226-255) 
Partial MCS and mob sequence of pSC200 
CATATG NdeI restriction site 
TCTAGA XbaI restriction site 
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S2. Checkerboard assay on B. cenocepacia K56-2 and K56-2dxr with ceftazidime (CAZ) or aztreonam 
(AZT) in combination with fosmidomycin (FOS) or FR900098 (FR). 
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S3. Checkerboard assay on B. cenocepacia K56-2dxr with ceftazidime (CAZ) in combination with 
FR900098 (FR), in the presence of 0.5% rhamnose.  
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3.1. Abstract 
BACKGROUND. Bacteria belonging to the Bcc are an important cause of chronic respiratory tract 
infections in cystic fibrosis patients. Intrinsic resistance to a wide range of antimicrobial agents, including 
a variety of β-lactam antibiotics, is frequently observed in Bcc strains. Resistance to β-lactams is most 
commonly mediated by efflux pumps, alterations in penicillin-binding proteins or the expression of β-
lactamases. β-lactamase inhibitors are able to restore the in vitro activity of β-lactam molecules against a 
variety of Gram-negative species , but the effect of these inhibitors on the activity of β-lactam treatment 
against Bcc species is still poorly investigated.   
METHODS. In the present study, the susceptibility of a panel of Bcc strains was determined towards the 
β-lactam antibiotics ceftazidime, meropenem, amoxicillin, cefoxitin, cefepime and aztreonam; alone or in 
combination with a β-lactamase inhibitor (clavulanic acid, sulbactam, tazobactam and avibactam). 
Consequently, β-lactamase activity was determined for active β-lactam/β-lactamase inhibitor 
combinations.  
RESULTS. Clavulanic acid had no effect on minimum inhibitory concentrations, but addition of sulbactam, 
tazobactam or avibactam to ceftazidime, amoxicillin, cefoxitin, cefepime or aztreonam leads to increased 
susceptibility (at least 4-fold MIC-decrease) in some Bcc strains. The effect of β-lactamase inhibitors on 
β-lactamase activity is both strain- and/or antibiotic-dependent, and other mechanisms of -lactam 
resistance (besides production of -lactamases) appear to be important.  
CONCLUSIONS. Considerable differences in susceptibility of Bcc strains to β-lactam antibiotics were 
observed. Results obtained in the present study suggest that resistance of Bcc strains against β-lactam 
antibiotics is mediated by both β-lactamases and non-β-lactamase-mediated resistance mechanisms.  
 
3.2. Background 
Infections caused by antibiotic-resistant bacteria pose an increasing threat to public health, both in 
terms of human suffering and in economic terms. In addition to the costs associated with an extended 
hospital stay, the costs for treating infections caused by multidrug-resistant organisms are much higher 
than the costs for treating similar infections caused by sensitive organisms.[237] Despite the impact of 
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these infections, the number of novel antibiotics in the pipeline is small. This is partly due to the high 
costs and extensive research-time associated with the development of a new antibiotic.[238]  
The Bcc is a group of 20 closely related opportunistic, Gram-negative pathogens.[1] Bcc species are an 
important cause of severe chronic respiratory infections in patients with cystic fibrosis (CF).[186] Bcc 
infection in CF patients often correlates with a rapid decrease in lung function leading to a poorer 
prognosis, longer hospital stays and an increased risk of death. The ability of Bcc strains to form biofilms 
in vitro and in vivo contributes to reduced antimicrobial susceptibility, treatment failure and persistent 
infection.[7, 36, 37] Intrinsic resistance to a wide range of antimicrobial agents, including 
aminoglycosides, polymyxin, first and second generation cephalosporins, carboxypenicillins and other β-
lactam antibiotics is frequently observed in Bcc strains. Resistance of Gram-negative microorganisms to 
β-lactam molecules is most commonly mediated by inducible or constitutively expressed β-lactamases, 
efflux pumps or alterations in PBPs.[46, 47] β-lactamase was first identified in 1940 as penicillinase in E. 
coli even before the clinical use of penicillin, and has since been identified in a variety of other bacteria, 
including species of the Bcc.  [65, 158, 171, 239] 
β-lactam antibiotics cause cell death by inhibition of bacterial cell wall synthesis. They do so by binding 
to PBPs, resulting in a decreased cross-linking of peptidoglycan in the cell wall, eventually leading to cell 
death.[46, 161] The utility of β-lactams has become compromised through the increasing presence of 
both chromosomally and plasmid-encoded β-lactamase enzymes. Two classification schemes are 
currently used, i.e. the Ambler molecular classification (based on amino acid sequences and structural 
similarities) and the Bush-Jacoby-Medeiros scheme (classification according to functionality or activity 
against β-lactam antibiotics).[157] In the Ambler scheme, four groups of β-lactamases are recognized; 
class A through D. Class A, C and D have a serine active site and class B enzymes are metallo-β-
lactamases (MBLs) that need Zn2+ as a cofactor for their activity.[65, 161] The most commonly 
encountered β-lactamases are class A enzymes with TEM and SHV enzymes regularly found in Gram-
negative bacteria (e.g. E. coli and Klebsiella spp.), as well as CTX-M extended-spectrum β-lactamases 
(ESBLs) and K. pneumoniae carbapenemases (KPCs) which are now also frequently encountered. Most 
class A enzymes can be inhibited with the commercially available β-lactamase inhibitors clavulanic acid, 
sulbactam or tazobactam. Class B β-lactamases (MBLs) pose a particular challenge for medicinal chemists 
and clinicians because thus far, none of the available inhibitors can effectively inhibit members of this 
class.[162, 163] Currently, treatment of MBL-producing organisms is limited to relatively toxic antibiotics 
(e.g. colistin) and/or antimicrobials likely to cause further development of resistance (e.g. tigecycline). 
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EDTA, that functions as a chelator of divalent cations (including Zn2+), was used earlier as an active MBL 
inhibitor but was withdrawn from the market in 2008 due to toxicity concerns.[152, 161] Class C or 
AmpC β-lactamases are encoded by genes on the bacterial chromosome, although the prevalence of 
plasmid-mediated AmpC-enzymes is increasing. Only the novel β-lactamase inhibitor avibactam is able to 
inhibit class C enzymes.[65, 161] Finally, class D β-lactamases (also known as oxacillinases), are active 
against a broad range of β-lactam antibiotics. Clavulanic acid, sulbactam nor tazobactam inhibit these 
enzymes, but  avibactam inhibits some class D enzymes. [46, 65, 161] 
The fact that some β-lactamase inhibitors restore the in vitro activity of ceftazidime against a variety of 
Gram-negative bacteria is known and well-established [46, 161, 240, 241], but the effect of adding these 
inhibitors to β-lactam antibiotics is still poorly investigated for Bcc species. Previous research on this 
matter led to contradictory results; Lagacé-Wiens et al. reported that avibactam does not have the 
ability to potentiate ceftazidime against clinical Bcc isolates, but Mushtaq et al. observed that avibactam 
does have variable ability to restore ceftazidime activity against Bcc isolates from patients with CF.[161, 
242] These data suggest that in these Bcc isolates resistance against ceftazidime is not only mediated by 
expression of β-lactamases but is also due to other resistance mechanisms (efflux pumps or altered 
PBPs). In the present study we wanted to validate this assumptions for a larger research panel; therefore 
we systematically investigated the effect of β-lactamase inhibitors (clavulanic acid, sulbactam, 
tazobactam and the novel inhibitor avibactam) on the susceptibility of Bcc species against several β-
lactam antibiotics.  
 
3.3. Methods 
3.3.1. Strains and culture conditions 
The following strains were used: B. cepacia LMG 1222 and LMG 18821; B. multivorans LMG 18822, LMG 
18825, LMG 13010 and LMG 17588; B. cenocepacia LMG 16656, LMG 18828, LMG 18829 and LMG 
18830; Burkholderia vietnamiensis LMG 10929 and LMG 18835; B. ambifaria LMG 19182 and LMG 
19467; Burkholderia lata LMG 6992 and R-9940; Burkholderia stabilis LMG 14294 and LMG 14086; 
Burkholderia dolosa LMG 18943 and LMG 18941; Burkholderia anthina LMG 20980 and LMG 20983; 
Burkholderia pyrrocinia LMG 21824; Burkholderia ubonensis LMG 20358 and LMG 24263; Burkholderia 
latens LMG 24064; Burkholderia arboris LMG 24066 and R-132; Burkholderia seminalis LMG 24067 and 
LMG 24272; Burkholderia metallica LMG 24068 and R-2712; and Burkholderia contaminans LMG 16227 
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and R-12710. The biological and geographic origin of every Bcc strain is presented in Supplementary data 
(Table S1). All strains were obtained from the BCCM/LMG Bacteria Collection (Ghent, Belgium) or were 
kindly provided by Prof. P. Vandamme (Ghent University, Belgium). Two control strains were included; P. 
aeruginosa ATCC 27853 and E. coli ATCC 25922, both obtained from the ATCC collection (Manassas, VA, 
USA). Bacterial cultures were stored at -80°C in Microbank vials (Prolab Diagnostics, Richmond Hill, ON, 
Canada) and were subcultured twice on Luria-Bertani agar (LBA; LabM Limited, Heywood, UK) before 
use. All cultures were incubated aerobically at 37°C. 
 
3.3.2. Antibiotics and β-lactamase inhibitors 
We used several β-lactam antibiotics of different classes including amoxicillin (AMOX; aminopenicillin), 
cefoxitin (CFX; 2nd generation cephalosporin), ceftazidime (CAZ; 3rd generation cephalosporin), cefepime 
(CFP; 4th generation cephalosporin), meropenem (MEM; carbapenem) and aztreonam (AZT; 
monobactam). The effect of combining these antibiotics with the β-lactamase inhibitors clavulanic acid 
(CLA), sulbactam (SUL), tazobactam (TAZ) and avibactam (AVI) was investigated. AMOX, CFX, CAZ, CFP, 
CLA, SUL and TAZ were purchased from Sigma-Aldrich (St. Louis, MO, USA). MEM was obtained from 
Hospira Benelux (Antwerp, Belgium), AZT from TCI Europe (Zwijndrecht, Belgium) and AVI was obtained 
from Adooq Bioscience (Irwin, CA, USA). The concentration range tested for CAZ and MEM was 0.25 to 
128 mg/L. Higher concentrations were tested for AMOX, CFX, CFP and AZT; between 1 and 512 mg/L 
(according to Peeters et al. [186] and CLSI guidelines). The β-lactamase inhibitors were added at fixed 
concentrations as mentioned in the European Committee on Antimicrobial Susceptibility testing 
(EUCAST) breakpoint tables; 2 mg/L for CLA and 4 mg/L for SUL, TAZ and AVI.[235]  
 
3.3.3. MIC determination 
Susceptibility of the selected Bcc strains was investigated by determining minimum inhibitory 
concentrations (MICs) (in triplicate) of β-lactam antibiotics in the presence or absence of β-lactamase 
inhibitors, according to the EUCAST broth dilution guidelines using flat-bottomed 96-well microtitre 
plates (TPP, Trasadingen, Switzerland).[183] Antibiotic solutions were added to the wells and two-fold 
dilutions were made. Planktonic cultures were grown overnight in Luria-Bertani broth (LBB; LabM, 
Lancashire, UK) at 37°C. The cultures were then adjusted with double-concentrated Mueller-Hinton 
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broth (MHB; Beckton, Dickinson & Company (BD), Erembodegem, Belgium) to obtain a final inoculum of 
5 x 105 cfu/ml. Plates were incubated for 24h at 37°C and optical density was determined at 590 nm 
using an Envision multilable plate reader (Perkin Elmer, Waltham, MA, USA). The MIC value is the lowest 
concentration of the antibiotic that completely inhibits bacterial growth.[183, 186]  
 
3.3.4. β-lactamase activity assay 
We explored differences in β-lactamase activity by using a β-lactamase activity assay kit (Sigma-Aldrich, 
St. Louis, MO, USA). This assay is based on the hydrolysis of the chromogenic molecule nitrocefin, a non-
antimicrobial cephalosporin, by β-lactamase which leads to the production of a colorimetric product. 
Formation of this product is monitored by measuring absorbance at 490 nm in an Envision multilable 
plate reader; every minute, for 60 to 90 minutes at 25°C. The amount of enzyme required to hydrolyze 
1.0 µmol of nitrocefin per minute at pH 7.0 at 25°C is equal to one unit of β-lactamase.[65, 158, 243] 
Bacterial cultures were grown in 96-well microtitre plates in the presence or absence of antibiotics. 
Antibiotics were added to the microtitre plates at concentrations of ¼ MIC and the β-lactamase 
inhibitors SUL, TAZ and AVI were added at 4mg/L. Planktonic cultures were grown overnight in LB broth 
at 37°C, then adjusted with double-concentrated MHB to obtain a final inoculum of 5 x 105 cfu/ml in the 
96-well plates. For every condition 10 wells in the same plate were filled and the plates were incubated 
at 37°C for 24h. After incubation, the content of the 10 wells was collected in a pre-weighed plastic tube 
and centrifuged at 10 000 RCF for 10 minutes. Then, supernatant was discarded and the pellet was 
weighed and resuspended with 5 µL of β-lactamase assay buffer per mg sample. Subsequently, samples 
were sonicated for 5 minutes, placed on ice for 5 min and centrifuged at 16 000 RCF at 4°C for 20 
minutes. 1 – 50 µL of the unknown samples was added to a clear flat 96-well plate and supplemented 
with nitrocefin and buffer to a final volume of 100 µL. Immediately after addition of nitrocefin, 
absorbance at 490 nm was measured in an Envision plate reader. 
 
3.4. Results and Discussion 
3.4.1. MIC determination 
For six Bcc strains (B. cepacia LMG 1222, B. multivorans LMG 18822, B. cenocepacia LMG 16656, B. 
vietnamiensis LMG 10929, B. ambifaria LMG 19182 and B. lata LMG 6992) and two control strains (P. 
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aeruginosa ATCC 27853 and E. coli ATCC 25922) MIC values of all compounds and combinations were 
determined (Table 17). When the MIC value for a given antibiotic decreased 4-fold or more upon 
addition of a β-lactamase inhibitor, the inhibitor was considered to have meaningful activity. CLA showed 
no effect in this initial screening and was not included in further experiments. SUL, TAZ and AVI did show 
some effect in the initial screening and these three inhibitors were tested against a larger Bcc strain 
panel (Table 18). 
In general, the MICs of each β-lactam antibiotic alone varied widely; with MIC values of CAZ ranging from 
0.25 to >128 mg/L, MEM from 0.25 to 64 mg/L, AMOX from 8 to >512 mg/L, CFX from 2 to >512 mg/L 
and of CFP and AZT ranging from 1 to >512 mg/L. Antibiotic susceptibility results for Bcc species can be 
expressed as susceptible (S) or resistant (R) according to the EUCAST PK/PD (non-species related) 
breakpoints.[235] In vitro activity of CAZ against some Bcc strains was increased when combined with 
SUL or AVI; e.g. for B. multivorans LMG 17588 the MIC for CAZ decreased from 16 mg/L in the absence of 
a β-lactamase inhibitor to 2 mg/L in the presence of SUL. Hence, addition of SUL to CAZ for treatment of 
B. multivorans LMG 17588 induces a shift from R to S. Also for AMOX and AZT an increased in vitro 
activity against some strains was observed, in combination with SUL or AVI. However, only the addition 
of SUL to AZT treatment leads to a change from R to S for a selection of strains (B. anthina LMG 20980, B. 
multivorans LMG 13010 and B. vietnamiensis LMG 18835). CFP showed at least 4-fold increased activity 
against some Bcc strains when combined with SUL, TAZ or AVI and especially addition of TAZ and SUL 
lead to a shift from R to S for certain Bcc strains.  Resistance towards MEM due to β-lactamases has not 
yet been observed in the Bcc and MEM is one of the β-lactam antibiotics with the best growth-inhibitory 
activity against Bcc species at clinically relevant concentrations.[186, 244] We did not observe altered 
susceptibility to MEM when it was combined with SUL, TAZ or AVI, confirming that Bcc strains do not 
produce β-lactamases that can degrade MEM. For CFX only one combination with meaningful activity 
was observed; MIC of CFX against B. lata LMG 6992 decreased from 32 mg/L in the absence of a β-
lactamase inhibitor to 8 mg/L in the presence of SUL. Due to the lack of PK/PD breakpoints for CFX, it is 
unclear whether this change is clinically relevant. These results suggest that for most Bcc strains non-β-
lactamase-mediated resistance to CFX, in the form of efflux pumps, altered PBPs, and/or reduced 
permeability, plays a more important role than β-lactamases in β-lactam resistance. To summarize, the 
β-lactam resistance of 21.6% of the Bcc strains (8 out of 37) was reduced by 1 β-lactamase inhibitor, 
24.3% (9/37) by 2 β-lactamase inhibitors and 8.1% (3/37) was effectively inhibited by 3 or more β-
lactamase inhibitors.  
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Table 17. MICs of six antibiotics (in mg/L); alone or in combination with a -lactamase inhibitor.  
 CAZ MEM AMOX CFX CFP AZT 
  -   + 
Cla 
 + 
Sul 
 + 
Taz 
 + 
Avi 
 -   + 
Cla 
 + 
Sul 
 + 
Taz 
 + 
Avi 
 -   + Cla  + Sul  + Taz  + Avi  -   + 
Cla 
 + 
Sul 
 + 
Taz 
 + 
Avi 
 -   + 
Cla 
 + 
Sul 
 + 
Taz 
 + 
Avi 
 -   + Cla  + Sul  + Taz  + Avi 
B. ambifaria LMG 19182 4 4 2 4 1 2 2 2 2 1 >512 >512 >512 >512 >512 64 64 64 64 64 4 8 4 4 1 32 32 8 32 2 
B. cenocepacia LMG 16656 32 32 32 32 32 32 16 16 16 32 >512 >512 >512 >512 >512 256 256 256 256 256 512 512 512 512 512 >512 >512 >512 >512 >512 
B. cepacia LMG 1222 32 32 32 32 32 8 8 8 8 8 >512 >512 >512 >512 >512 256 256 256 256 256 256 128 64 256 64 >512 256 256 512 512 
B. lata LMG 6992 1 0.50 0.25 1 0.50 0.50 0.50 0.25 0.25 0.25 >512 >512 >512 >512 >512 32 16 8 16 32 16 16 8 4 1 32 16 8 16 2 
B. multivorans LMG 18822 2 2 0.50 2 1 4 4 2 2 4 >512 >512 >512 >512 >512 256 128 256 128 256 2 2 1 1 1 8 4 2 8 2 
B. multivorans LMG 18825 8 8 2 8 8 32 32 32 32 32 >512 >512 >512 >512 >512 512 512 256 512 512 32 16 2 2 8 32 16 16 16 16 
B. vietnamiensis LMG 10929 16 16 16 32 16 0.50 0.50 0.25 0.25 0.50 16 32 2 16 1 16 16 16 16 16 2 2 2 1 1 >512 >512 >512 >512 >512 
E. coli ATCC 25922 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 8 8 2 4 2 2 2 2 2 2 1 1 1 1 1 1 1 1 1 1 
P. aeruginosa ATCC 27853 2 2 2 2 2 0.50 0.25 0.50 0.50 0.25 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 2 2 2 2 2 4 4 4 4 4 
Bold values indicate combinations leading to at least 4-fold MIC-reduction upon addition of the β-lactamase inhibitor. Underlined values indicate a shift from resistant to 
susceptible upon addition of the β-lactamase inhibitor, according to PK/PD (non-species related) EUCAST breakpoints.[235] “-“ represents treatment with β-lactam antibiotic 
alone. CAZ, ceftazidime; MEM, meropenem; AMOX, amoxicillin; CFX, cefoxitin; CFP, cefepime; AZT, aztreonam. Cla, clavulanic acid; Sul, sulbactam; Taz, tazobactam; Avi, 
avibactam.  
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Table 18. MICs of six antibiotics (in mg/L), alone or in combination with a -lactamase inhibitor.  
 CAZ MEM AMOX CFX CFP AZT 
  -   + Sul  + Avi  -   + Sul  + Avi  -   + Sul  + Avi  -   + Sul  -   + Sul  + Taz  + Avi  -   + Sul  + Avi 
B. ambifaria LMG 19467 2 1 2 4 4 4 >512 >512 >512 4 4 8 4  1 8 8 4 8 
B. anthina LMG 20980 4  0.25 4 4 4 4 >512 >512 >512 128 128 4 1 1 2 16  1 16 
B. anthina LMG 20983 2  0.25 2 4 4 4 >512 >512 >512 64 64 2 1 1 1 16 8 8 
B. arboris LMG 24066 32 16 32 16 16 16 >512 >512 >512 128 128 256 64 128 128 >512 >512 >512 
B. arboris R-132 >128 16 16 32 32 32 >512 >512 >512 256 256 128 64 64 128 512 512 512 
B. cenocepacia LMG 18828 128 128 128 32 32 32 >512 >512 >512 512 512 >512 >512 >512 >512 >512 >512 >512 
B. cenocepacia LMG 18829 16 8 8 4 4 4 >512 >512 >512 64 64 64 64 64 64 512 512 512 
B. cenocepacia LMG 18830 16 16 16 16 16 16 >512 >512 >512 128 128 128 128 64 64 >512 512 512 
B. cepacia LMG 18821 64 64 64 32 32 32 >512 >512 >512 512 512 256 256 256 256 >512 >512 >512 
B. contaminans LMG 16227 64 64 64 16 16 16 >512 >512 >512 128 128 256 256 256 256 >512 >512 >512 
B. contaminans R-12710 16 16 16 8 8 8 >512 >512 >512 128 128 64 32 16 64 >512 512 >512 
B. diffusa LMG 24065 16 32 16 8 8 8 >512 >512 >512 256 256 128 128 128 128 >512 >512 >512 
B. diffusa LMG 24266 32 32 32 4 8 8 >512 >512 >512 128 128 128 128 128 128 512 512 512 
B. dolosa LMG 18941 64 32 64 64 32 32 >512 >512 >512 128 128 >512 512 512 >512 >512 >512 >512 
B. dolosa LMG 18943 >128 >128 >128 64 64 64 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 
B. lata R-9940 1 0.25 1 1 1 1 >512 >512 >512 32 32 4 2 1 2 2 2 2 
B. latens LMG 24064 4 4 4 4 4 4 >512 >512 >512 64 64 1 1 1 2 256 256 128 
B. latens R-11768 8 8 8 32 32 32 >512 >512 >512 256 256 32 32 32 32 32 32 32 
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B. metallica LMG 24068 32 32 32 32 32 32 >512 >512 >512 256 256 128 128 128 128 512 512 512 
B. metallica R-2712 8 8 8 16 16 16 >512 >512 >512 256 256 64 16 16 16 128 64 128 
B. multivorans LMG 13010 8 2 4 8 8 8 >512 >512 >512 256 256 2 1 2 2 32 4 16 
B. multivorans LMG 17588 16 2 8 16 16 16 >512 >512 >512 256 256 16 16 4 8 16 4 16 
B. pyrrocinia LMG 21824 32 16 32 8 8 8 >512 >512 >512 32 32 512 128 128 512 >512 >512 512 
B. seminalis LMG 24067 32 16 16 8 8 8 >512 >512 >512 256 256 128 128 128 128 512 512 512 
B. seminalis LMG 24272 8 2 4 4 4 4 >512 >512 >512 128 128 8 2 4 8 32 32 32 
B. stabilis LMG 14086 8 8 8 8 8 8 >512 >512 >512 128 128 32 32 32 8 64 64 64 
B. stabilis LMG 14294 >128 >128 >128 16 16 16 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 
B. ubonensis LMG 20358 2 2 2 16 16 16 >512 >512 >512 256 128 16 16 8 16 128 128 128 
B. ubonensis LMG 24263 8 4 4 32 32 32 >512 >512 >512 128 128 128 128 128 128 256 256 128 
B. vietnamiensis LMG 18835 4 0.25 4 2 2 2 512 512 512 128 128 16 1 16 16 8 1 8 
Bold values indicate combinations leading to at least 4-fold MIC-reduction upon addition of the β-lactamase inhibitor. Underlined values indicate a shift from resistant to 
susceptible upon addition of the β-lactamase inhibitor, according to PK/PD (non-species related) EUCAST breakpoints.[235] “-“ represents treatment with β-lactam antibiotic 
alone. CAZ, ceftazidime; MEM, meropenem; AMOX, amoxicillin; CFX, cefoxitin; CFP, cefepime; AZT, aztreonam. Cla, clavulanic acid; Sul, sulbactam; Taz, tazobactam; Avi, 
avibactam 
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3.4.2. β-lactamase activity assay 
For the Bcc strains for which active β-lactam antibiotic/β-lactamase inhibitor combinations were 
identified, we investigated whether there is a relation between differences in β-lactamase activity and 
the altered susceptibility observed upon addition of a β-lactamase inhibitor. Therefore, a β-lactamase 
activity assay was used to measure β-lactamase activity. Only the combinations which showed at least a 
4-fold MIC decrease upon addition of a β-lactamase inhibitor were included (i.e. CAZ + SUL, CAZ + AVI, 
AMOX + SUL, AMOX + AVI, CFX + SUL, CFP + SUL, CFP + TAZ, CFP + AVI, AZT + SUL and AZT + AVI). 
Differences in β-lactamase activity were explored between untreated samples, samples treated with a β-
lactam antibiotic alone and samples treated with β-lactam/β-lactamase inhibitor combination 
treatments mentioned above (Figure 28). Results of the β-lactamase screening are expressed as relative 
β-lactamase activities compared to untreated bacterial samples. For B. multivorans LMG 18825 (Fig. 27a) 
the MIC for CFP decreased from 32 mg/L in the absence of an inhibitor to 8 mg/L in the presence of AVI, 
or to 2 mg/L in the presence of SUL or TAZ. As expected, treatment with 0.5 mg/L CFP significantly 
(p<0.05, n=5) increased relative β-lactamase activity to 5.44 and addition of 4 mg/L SUL significantly 
(p<0.05, n=5) decreased β-lactamase activity to 1.43. However, addition of 4 mg/L AVI had no significant 
(p>0.05, n=5) influence on β-lactamase activity (5.99) and addition of TAZ to CFP-treatment caused a 
significant (p<0.05, n=5) increase in relative β-lactamase activity to 13.64. These data demonstrate that 
there is no correlation between measured -lactamase activity and MIC, suggesting that non-β-
lactamase-mediated resistance mechanisms play an important role in CFP resistance in B. multivorans 
LMG 18825. For B. arboris R-132 (Fig. 27b), the situation is different. We observed high -lactamase 
activity (7.29) when cells were exposed to CAZ, and a high MIC for CAZ (128 mg/L). Combination 
treatment with SUL or AVI led to a statistically significant (p<0.05, n=4) decrease in -lactamase activity 
(1.10 and 3.30, respectively), associated with an 8-fold MIC decrease for CAZ. These data suggest that for 
this Bcc strain β-lactamase is the major cause of resistance to CAZ. For B. cenocepacia LMG 16656 (Fig. 
27c), no differences in MIC-values for CAZ (MIC = 512 mg/L) or CFP (MIC = 32 mg/L) were observed upon 
addition of a β-lactamase inhibitor (SUL, AVI or TAZ). β-lactamase activity assay results showed that 
treatment with CAZ or CFP induces β-lactamase activity in this strain, and that addition of a β-lactamase 
inhibitor to CAZ- or CFP-treatment has no significant (p>0.05, n=3) influence on β-lactamase activity. A 
likely explanation for this is that 15 of the 21 β-lactamases currently identified in the genome of B. 
cenocepacia LMG 16656 belong to the metallo-β-lactamase protein family.[245] As mentioned , this class 
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of β-lactamases is not inhibited by any of the currently available β-lactamase inhibitors. The MIC- and β-
lactamase activity results for B. cenocepacia LMG 16656 confirm that SUL, AVI or TAZ are not able to 
effectively inhibit metallo-β-lactamases and thus have no effect on the resistance of this strain against β-
lactam antibiotics. Susceptibility of B. vietnamiensis LMG 18835 (Fig. 27d) for CAZ, CFP and AZT is altered 
upon addition of SUL; addition of SUL decreased the MIC for CAZ from 4 mg/L to 0.25 mg/L, for CFP from 
16 mg/L to 1 mg/L and for AZT from 8 mg/L to 1 mg/L. However, relative β-lactamase activity for all 
three β-lactams is significantly increased upon addition of SUL. We currently have no explanation for 
these at first sight contradictory results, but it seems likely that both -lactamase dependent and 
independent mechanisms are involved in -lactam resistance in this strain. Results for the other Bcc 
strains investigated (see Fig. S1-S5) confirm that for most Bcc strains investigated the influence of a β-
lactamase inhibitor on β-lactamase activity is both strain- and/or antibiotic-dependent.  
Figure 28. β-lactamase activity and corresponding MIC values for a selection of Bcc strains tested. Dark grey bars: β-lactamase 
activity relative to untreated controls, light grey bars: MIC values (mg/L) for a) B. multivorans LMG 18825, b) B. arboris R-132, c) 
B. cenocepacia LMG 16656 and d) B. vietnamiensis LMG 18835. * represents statistically significant differences compared to 
treatment with the β-lactam antibiotic alone (p < 0.05, n ≥ 3) 
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3.5. Conclusions 
There are considerable differences in susceptibility of Bcc strains to different β-lactam antibiotics. In the 
present study we investigated the effect of β-lactamase inhibitors on the susceptibility of Bcc species 
against β-lactam antibiotics. CLA had no effect on this susceptibility for any of the strains tested, but 
addition of SUL, TAZ or AVI to CAZ, AMOX, CFX, CFP or AZT leads to increased susceptibility (at least 4-
fold decrease in MIC) in several Bcc strains. An important fact to take into account is that up to date, 
there is no clear evidence that in vitro susceptibility of Bcc species against a specific antimicrobial 
compound is related to clinical outcome.[246] 
Investigation of the relation between altered susceptibility upon addition of SUL, TAZ or AVI and 
differences in β-lactamase activity was performed with a β-lactamase activity assay kit. Pronounced 
differences in β-lactamase activity after exposure to different β-lactam antibiotics and β-lactamase 
inhibitors, as well as between the Bcc strains tested were observed. Some of the results observed are in 
line with our expectations, confirming that resistance against β-lactam antibiotics is mediated by 
expression of β-lactamase enzymes which can be successfully inhibited in vitro by β-lactamase inhibitors. 
However, results obtained with other strains suggest that non-β-lactamase-mediated resistance 
mechanisms to β-lactam antibiotics (likely including reduced membrane permeability, altered PBPs and 
presence of efflux pumps) are also important.  
Production of β-lactamases is clearly not the only mechanism Bcc strains use to survive treatment with 
β-lactam antibiotics, and it is therefore questionable that adding β-lactamase inhibitors to β-lactam 
therapy will be a valuable approach to combat Bcc infections.  
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SUPPLEMENTARY DATA 
Table S1. Biological and geographic origin of all Burkholderia cepacia complex strains used in this study.[247, 248] 
Species Strain Biological origin Geographic origin 
B. cepacia LMG 1222
T
 Allium cepa USA 
  LMG 18821 CF patient Australia 
B. multivorans LMG 18822 CF patient Canada 
  LMG 18825 CF patient UK 
  LMG 13010
T
 CF patient Belgium 
  LMG 17588 Soil Berkeley, USA 
B. cenocepacia LMG 16656
T
 CF patient Edinburgh, UK 
  LMG 18828 CF patient Canada 
  LMG 18829 CF patient USA 
  LMG 18830 CF patient Australia 
B. vietnamiensis LMG 10929
T
 Oryza sativa, rhizosphere soil Vietnam 
  LMG 18835 CF patient USA 
B. ambifaria LMG 19182
T
 Pea rhizosphere Wisconsin, USA 
  LMG 19467 CF patient Australia 
B. lata LMG 6992 Soil Trinidad & Tobago 
  R-9940 CF patient Canada 
B. stabilis LMG 14294
T
 CF patient Belgium 
  LMG 14086 Respirator UK 
B. dolosa LMG 18943
T
 CF patient USA 
  LMG 18941 CF patient USA 
B. anthina LMG 20980
T
 Soil rhizosphere Nashville, USA 
  LMG 20983 CF patient, sputum Blackpool, UK 
B. pyrrocinia LMG 21824 CF patient USA 
B. ubonensis LMG 20358
T
 Surface soil Thailand 
  LMG 24263 Nosocomial infection Thailand 
B. latens LMG 24064
T
 CF patient Italy 
B. arboris LMG 24066 Soil USA 
  R-132 CF patient USA 
B. seminalis LMG 24067
T
 CF patient USA 
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  LMG 24272 Nosocomial infection Thailand 
B. metallica LMG 24068
T
 CF patient USA 
  R-2712 CF patient Canada 
B. contaminans LMG 16227 CF patient, respiratory tract Sweden 
  R-12710 Sheep with mastitis, milk Spain 
 ' T '
= Type strain 
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Figure S1. β-lactamase activity (dark grey bars, relative to untreated controls) and corresponding MIC values (light grey bars, mg/L) for a) B. ambifaria LMG 19182, b) B. cepacia 
LMG 1222, c) B. lata LMG 6992 and d) B. multivorans LMG 18822.  Error bars represent min-max (n=2). 
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Figure S2. β-lactamase activity (dark grey bars, relative to untreated controls) and corresponding MIC values (light grey bars, mg/L) for a) B. vietnamiensis LMG 10929, b) B. 
ambifaria LMG 19467, c) B. anthina LMG 20980 and d) B. anthina LMG 20983.  Error bars represent min-max (n=2). 
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Figure S3. β-lactamase activity (dark grey bars, relative to untreated controls) and corresponding MIC values (light grey bars, mg/L) for a) B. arboris LMG 24066, b) B. cepacia LMG 
18821, c) B. contaminans R-12710 and d) B. lata R-9940.  Error bars represent min-max (n=2). 
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Figure S4. β-lactamase activity (dark grey bars, relative to untreated controls) and corresponding MIC values (light grey bars, mg/L) for a) B. metallica R-2712, b) B. multivorans 
LMG 13010, c) B. multivorans LMG 17588 and d) B. pyrrocinia LMG 21824.  Error bars represent min-max (n=2). 
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Figure S5. β-lactamase activity (dark grey bars, relative to untreated controls) and corresponding MIC values (light grey bars, mg/L) for a) B. seminalis LMG 24272, b) B. stabilis 
LMG 14086 and two control strains: c) E. coli ATCC 25922 and d) P. aeruginosa ATCC 27853.  Error bars represent min-max (n=2)
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1. Drugs versus bugs: an everlasting battle? 
The discovery of penicillin by Alexander Fleming in 1928 was the beginning of a golden era for 
antibacterial drug discovery.[249] From the 1930s to the 1960s almost every currently available 
antibiotic was discovered and introduced to the market (Figure 29).[250] Newer antibiotic 
compounds and classes have been introduced to the market since the golden era, but the rate has 
slowed down radically. Lipopeptides were discovered in 1987, representing the latest novel antibiotic 
class that was successfully commercialized for the market.[87] Antibiotics with novel mechanisms of 
action have not been discovered since; the period from 1987 until today is therefore referred to as 
the ‘discovery void’.[175] 
 
Figure 29. Timeline where the discovery of the first antibiotic of each class is pinpointed.[250] 
Infections remain one of the major sources of disease and death worldwide with respiratory 
infections, malaria, tuberculosis and HIV/AIDS being the most important diseases causing mortality in 
third-world countries.[173] Respiratory infections also belong to the top 10 causes of death in 
middle- and high-income countries.[174] The introduction of antimicrobials caused a transformation 
of human and animal health systems by providing a weapon against infectious diseases. 
Unfortunately, the euphoria was overshadowed almost as soon as antibiotics were deployed, since 
bacteria began to respond by developing resistance against them.[87, 176] During the golden age 
alternative therapies could be offered by the introduction of new antibiotic classes, but the lack of 
innovation in the last two decades is causing major problems.[177] As the usage of antibiotics 
increased over the years, so did the complexity of resistance mechanisms exhibited by bacterial 
pathogens.[251] Furthermore, because of cumulative acquisition of resistance traits against multiple 
antibiotics, more bacterial pathogens with multiple-drug resistance are being reported worldwide. 
Major human and animal pathogens such as Mycobacterium, Staphylococcus, Pseudomonas and 
Salmonella species have consequently become resistant to antibiotics that were previously quite 
efficacious.[87] For every major group of bacterial pathogens, multidrug-resistant (MDR), extensively 
drug-resistant (XDR) and pandrug-resistant (PDR) species have been described. MDR pathogens are 
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resistant to at least one compound in three or more antibiotic classes, XDR species to at least one 
antibiotic in all but one or two classes and PDR pathogens are resistant to every currently available 
antibiotic.[176, 252] The increasing prevalence of drug-resistant bacterial pathogens and the lack of 
novel antibiotics has led to a de facto post-antibiotic era where antimicrobial chemotherapy often is 
no longer effective.[87, 177, 253, 254] 
Infections with drug-resistant pathogens pose a global threat for public health due to higher 
morbidity and mortality rates, increased treatment costs and extended hospital stays, and the 
emergence of bacterial pathogens that cannot be adequately treated anymore.[237, 238, 255] 
Frequently encountered MDR organisms include vancomycin-resistant enterococci (VRE), methicillin-
resistant and MDR S. aureus (MRSA), penicillin-resistant pneumococci, MDR Streptococcus 
pneumoniae, XDR M. tuberculosis and MDR Gram-negative species such as P. aeruginosa, 
Acinetobacter baumannii, Enterobacter spp., ESBL-producing E. coli and K. pneumoniae, 
carbapenemase-producing Enterobacteriaceae (CPE) and the recently emerging colistin-resistant 
CPE.[62, 237, 256-259] 
To be able to win the battle against antimicrobial resistance we first need to reduce the selective 
pressure for the development of resistance, by limiting the use of antibacterial drugs, by using the 
appropriate dosage and by respecting the treatment duration.[176] A vital aspect to avoid 
inappropriate and ineffective therapies is knowledge of the intrinsic antibacterial resistance of a 
pathogen. Examples of intrinsic resistance traits and their resistance mechanisms are shown in Table 
19. Some bacterial pathogens, including M. tuberculosis and P. aeruginosa, which are intrinsically 
resistant to a large variety of antibiotics pose a particular concern due to limited treatment options. 
Consequently, frequent use of the remaining possible treatments further increase the risk of 
acquiring new resistance mechanisms.[87, 260, 261] Secondly, strict attention to infection control 
guidelines (especially in healthcare facilities) should reduce the spread of resistant microbial 
organisms. The third and probably most important aspect is the development of antibacterial agents 
with new mechanisms of action.[176, 177] With sufficient efforts from researchers, healthcare 
facilities and patients we should be able to remain at least one step ahead of the next resistant 
outbreak and prevent the post-antibiotic era. 
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Table 19. Examples of intrinsic resistance and their respective mechanisms.[260, 261] 
ORGANISMS 
NATURAL 
RESISTANCE 
AGAINST: 
MECHANISM 
Anaerobic bacteria Aminoglycosides 
Lack of oxidative metabolism to drive uptake of 
aminoglycosides 
Aerobic bacteria Metronidazole 
Inability to anaerobically reduce drug to its active 
form 
Gram-positive bacteria 
Aztreonam (β-
lactam) 
Lack of penicillin binding proteins (PBPs) that 
bind and are inhibited by this beta lactam 
antibiotic 
Gram-negative 
bacteria 
Vancomycin 
Lack of uptake resulting from inability of 
vancomycin to penetrate outer membrane 
Klebsiella spp. 
Ampicillin (β-
lactam) 
Production of enzymes (beta-lactamases) that 
destroy ampicillin before the drug can reach the 
PBP targets 
S. maltophila 
Imipenem (β-
lactam) 
Production of enzymes (beta lactamases) that 
destroy imipenem before the drug can reach the 
PBP targets. 
Lactobacilli 
and Leuconostoc 
Vancomycin 
Lack of appropriate cell wall precursor target to 
allow vancomycin to bind and inhibit cell wall 
synthesis 
P. aeruginosa 
Sulfonamides, 
trimethoprim, 
tetracycline, or 
chloramphenicol 
Lack of uptake resulting from inability of 
antibiotics to achieve effective intracellular 
concentrations 
Enterococci 
Aminoglycosides 
Lack of sufficient oxidative metabolism to drive 
uptake of aminoglycosides 
All 
cephalosporins 
Lack of PBPs that effectively bind and are 
inhibited by these beta lactam antibiotics 
 
2. The Burkholderia cepacia complex in cystic fibrosis patients: a silent killer 
Cystic fibrosis is the most common hereditary disease among the European population, with an 
incidence of approximately 1 in 2500 newborns in Belgium.[262] The median life expectancy of 
patients suffering from CF in the EU currently stands at 41 years old, according to the clinical CF 
registry of the CF Trust.[263] The major contributor to morbidity and mortality in CF patients is the 
occurrence of chronic lung infections. In children, these infections are mainly caused by H. 
influenzae, S. aureus or P. aeruginosa with the latter being the major pathogen in adults.[264, 265] 
The prevalence of major respiratory CF pathogens in 2015 is shown in Figure 30 ([265]). Members of 
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the Bcc are less frequently recovered from CF lungs, but the clinical outcome of Bcc infections is 
highly unpredictable and these microorganisms often cause a rapid decline in lung function.[7] Bcc 
species produce many different virulence factors, are capable of person-to-person transmission and 
Bcc infections are difficult to eradicate since these pathogens are intrinsically resistant to a wide 
range of available antibiotics.[7, 73] Therefore, research on the multifarious Bcc should focus on 
understanding their intrinsic resistance, virulence factors and treatment and eradication possibilities 
to enable CF patients to survive Bcc infections.  
The research for this dissertation mainly focused on two aspects to combat Bcc infections; the ability 
of β-lactam-β-lactamase inhibitor combinations to eradicate different members of the Bcc on the 
one hand and the potential of the nonmevalonate pathway as a novel antibacterial target on the 
other hand. 
 
3. Revival of the β-lactams? 
β-lactam antibiotics are among the most frequently prescribed group of antibiotics for both Gram-
positive and Gram-negative bacterial infections.[66, 147] This group includes penicillins, 
cephalosporins, carbapenems and monobactams and they work by inhibiting the bacterial cell wall 
biosynthesis.[148] The use of this life-saving antibiotic class has become compromised due to the 
production of β-lactamases which are able to inhibit the antibacterial activity of β-lactams through 
hydrolysis of their functional group, the β-lactam ring.[66] Two different strategies can be applied to 
Figure 30. Prevalence of major respiratory microorganisms isolated from CF lungs in 2015, by age cohort.[265] 
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circumvent the clinical threat of β-lactamase-mediated resistance: (i) the design of β-lactams that 
can evade enzymatic inactivation by β-lactamases (e.g. derivatives of carbapenems) and (ii) inhibition 
of β-lactamases by β-lactamase inhibitors.[65, 266]  
Since the 1980s the development of β-lactamase inhibitors provided a new approach to combat this 
clinical challenge. All clinically available inhibitors share the β-lactam backbone, but do not possess 
antimicrobial activities.[65] Clavulanic acid (CLA) is a natural compound that was isolated from 
strains of Streptomyces clavuligerus in 1977 and was first introduced to the market in 1985.[267, 
268] Sulbactam (SUL) and tazobactam (TAZ) are synthetic compounds developed by the 
pharmaceutical industry in 1978 and 1980, respectively, and share structural resemblance with 
penicillin.[269, 270] These three β-lactamase inhibitors are effective against most class A β-
lactamases (including TEM, ESBL, CTX-M and SHV) but have limited activity against class B, C and D 
enzymes.[271-274] Hence, there is still a considerable need for inhibitors with activity against class B 
metallo-β-lactamase, class C cephalosporinases and class D oxacillinases.[152] Avibactam (AVI), 
formerly known as NXL104 or AVE1330A, is a newer β-lactamase inhibitor based on a bridged 
diazabicyclooctane (DBO) structure. AVI was recently approved for the market in combination with 
ceftazidime for the treatment of Gram-negative complicated intra-abdominal infections (cIAIs), 
complicated urinary tract infections (cUTIs) and aerobic Gram-negative infections with limited 
treatment options.[152, 161, 275, 276] AVI has increased potency and an expanded spectrum 
compared to older inhibitors, including inhibitory activity against class A β-lactamases, class C 
enzymes (e.g. AmpC cephalosporinases) and against some class D enzymes. This compound is the 
first novel β-lactamase inhibitor introduced into clinical use in the past 20 years and offers new hope 
in the battle against multidrug-resistant Gram-negative bacterial infections.[152, 277-279] 
Extensive research has been conducted on the antibacterial potential of β-lactam-β-lactamase 
inhibitor combinations, and eight different combinations are currently approved for clinical use 
including amoxicillin-CLA (co-amoxiclav), ticarcillin-CLA (co-ticarclav), ampicillin-SUL, cefoperazone-
SUL, piperacillin-TAZ, ceftolozane-TAZ, ceftazidime-AVI and ceftolozane-AVI.[65, 275, 276, 280, 281] 
Some studies also suggest the combination of CLA with cefepime or cefpirome to be more effective 
against ESBL-producing organisms, but clinical trials have not yet been conducted.[282, 283] New 
combinations of AVI with ceftaroline or aztreonam are also currently under development.[284, 285] 
Several studies claim that ceftazidime-avibactam is a promising addition to our current therapeutic 
armamentarium in the biological chess match between antibiotics and multidrug-resistant Gram-
negative organisms (including Enterobacteraciae (e.g. K. pneumoniae) and P. aeruginosa).[46, 161, 
240, 241, 286] However, the effect of β-lactam-β-lactamase inhibitor combinations on members of 
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the Bcc is still poorly investigated. Mushtaq et al. evaluated the activity of ceftazidime-AVI and 
piperacillin-TAZ against various Bcc isolates by MIC determination of ceftazidime or piperacillin plus 4 
mg/L AVI or TAZ, respectively. They included 54 clinical CF isolates, comprising 37 B. multivorans, 8 B. 
cepacia, 6 B. cenocepacia and 3 B. vietnamiensis strains. The majority of the Bcc isolates exhibited 
resistance against ceftazidime, piperacillin and piperacillin-TAZ. However, their results showed a MIC-
reduction of ceftazidime by at least four- to tenfold in the presence of AVI, for most Bcc isolates 
screened.[242] Several research groups have studied the susceptibility of a variety of clinical Bcc 
isolates to ticarcillin-CLA. In these studies, all isolates demonstrated high resistance rates.[287-290] 
One Czech Republican and one Swiss study evaluated the antibacterial activity of piperacillin and 
piperacillin-TAZ against B. multivorans and B. cenocepacia strains isolated from both non-CF and CF-
patients. The authors demonstrated a 4-fold MIC-decrease of piperacillin in the presence of TAZ, for 
92.9% of the B. multivorans isolates and 60.7% of the B. cenocepacia isolates tested.[289, 291] The 
data from previous studies ([242, 287-291]) suggest that β-lactam resistance of Bcc isolates is not 
only related to β-lactamase production but also to the action of efflux pumps and/or altered PBPs. 
However, this has not been investigated in detail, nor for a larger collection of Bcc strains. 
In chapter 3.III we wanted to fill this gap by testing the susceptibility of a larger Bcc panel against 
combination therapy of β-lactam antibiotics of several classes with the β-lactam inhibitors CLA, SUL, 
TAZ and AVI. We included the β-lactams amoxicillin, cefoxitin, ceftazidime, cefepime, meropenem 
and aztreonam to cover every available class of β-lactam antibiotics. Not only did we investigate the 
susceptibility of our test panel (containing representatives of 16 Bcc species) towards different 
combinations, we also investigated the differences in β-lactamase activity upon addition of a β-
lactamase inhibitor. Our results indicated that some combinations, including ceftazidime-SUL, 
ceftazidime-AVI, amoxicillin-SUL, amoxicillin-AVI, cefoxitin-SUL, cefepime-SUL, cefepime-TAZ, 
cefepime-AVI, aztreonam-SUL and aztreonam-AVI caused at least a 4-fold MIC decrease upon 
addition of the β-lactamase inhibitor. However, investigation of β-lactamase activity induced by 
these antibiotic combinations did not lead to unambiguous conclusions. We observed pronounced 
differences in β-lactamase activity after treatment with different β-lactams and β-lactamase 
inhibitors, as well as between the Bcc strains tested, confirming the results from previous studies. 
Expression of β-lactamases is clearly not the only mechanism that Bcc species use to circumvent the 
action of β-lactam antibiotics. The approach of β-lactam-β-lactamase inhibitor combinations can 
offer an addition for Bcc-therapy, but it is important to evaluate every clinical situation individually. 
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4. The future of β-lactam-β-lactamase inhibitor combinations 
The future prospects of β-lactam antibiotics are highly dependent on the therapeutic design of 
effective β-lactamase inhibitors. The success of avibactam illustrates several important features for 
the development of new inhibitors. First, avibactam does not contain a β-lactam ring, and is 
therefore referred to as “non-β-lactam-inhibitor”, but it shows structural similarity to β-lactams at 
the carbonyl group.[65, 152] This structural distinction leads to rapid recognition and formation of a 
stable complex with β-lactamases.[292, 293] Secondly, analyses revealed that a covalent bond with 
class A, C and D β-lactamases is formed by a strong carbamoyl link between avibactam and the 
serine-residue of the β-lactamase.[293, 294] Thirdly, the enzymatic inhibition by avibactam is 
thought to be reversible and the active inhibitor can be regenerated through deacylation and 
recyclization of the 5-membered ring.[293] Avibactam’s characteristics serve as a lesson for the 
design of new β-lactamase inhibitors and two novel “non-β-lactam inhibitors” with DBO structure are 
currently being evaluated in clinical trials. Relebactam (MK-7655) has a similar activity spectrum as 
AVI and is currently in Phase III clinical trials for treatment of cUTIs and cIAIs in combination with 
imipenem or cilastatin.[152, 295] RG6080 (or OP0565), currently in Phase I clinical trials, has a similar 
spectrum of activity compared to other DBOs but additionally exhibits antibacterial activity against 
MBL-producing Enterobacteriaceae when combined with aztreonam, cefepime or piperacillin.[296] 
Two additional groups of inhibitors have recently received attention: boronic acid β-lactamase 
inhibitors that recently completed Phase I clinical trials, whereas cyclobutanone and penam sulfone 
inhibitors have the potential to inhibit class A and class C β-lactamases.[152, 281] The boronate 
RPX7009 represents a novel class of synthetic non-β-lactam inhibitors and is currently in Phase III 
clinical trials in the USA in combination with meropenem.[281, 297, 298] Although boronates have 
been described as effective serine β-lactamase inhibitors since the late 1970s, new modifications at 
the carboxamide group have rendered them clinically more relevant.[152, 299] RPX7009 serves as a 
reversible, competitive inhibitor showing very potent growth inhibition of microorganisms expressing 
class A and C β-lactamases, when combined with biapenem (a carbapenem antibiotic). In 2013, this 
combination showed strong potentiation of biapenem activity against class A carbapenemase-
producing Enterobacteriaceae.[300] Despite this promising result, RPX7009 is currently only 
developed in combination with meropenem to treat pathogens expressing serine 
carbapenemases.[281, 297] The second group of inhibitors comprises cyclobutanone-based 
compounds which demonstrate reversible activity against all four groups of β-lactamases.[301]  
To conclude, we can state that there are several interesting β-lactam-β-lactamase inhibitor 
combinations in the pipeline, but a close eye has to be kept on the evolution of two particular β-
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lactamase classes. Class B (MBL) β-lactamases pose a particular challenge since none of the available 
inhibitors have significant activity against members of this enzyme class. The increasing emergence 
of NDM-1 β-lactamase illustrates the rapid spread of MBL enzymes from one country to the whole 
world. Only two combinations show inhibitory activity against class B enzymes; meropenem-
cyclobutanone and aztreonam-AVI.[163, 301] Also class D (OXA) enzymes pose an increasing risk for 
multidrug-resistant traits by deactivation of both narrow- and broad-spectrum antibiotics, recently 
including carbapenems.[302, 303] Available β-lactamase inhibitors cannot effectively inhibit OXA-
enzymes and there is a scarcity of research addressing this challenge.[304-306]  
 
5. Evaluation of the nonmevalonate pathway as novel drug target 
Since the discovery of the mevalonate (MVA) pathway it has been generally accepted that this was 
the unique pathway for the formation of IPP and DMAPP, the fundamental building blocks in 
isoprenoid biosynthesis.[109, 307, 308] In the 1990s however, Rohmer and colleagues discovered 
that several bacteria, green algae and chloroplasts of higher plants utilize an alternative pathway; the 
nonmevalonate, DOXP or MEP pathway.[114, 131, 309-311] The distribution of the MVA and DOXP 
pathway is listed in Table 20, including some examples of each group of organisms. 
Isoprenoids or terpenoids are the largest class of naturally occurring organic compounds, comprising 
over 30 000 compounds, and play an essential role in several cellular processes in all living 
organisms.[119] They are vital for growth and survival by influencing cell wall and membrane 
biosynthesis (sterols in eukaryotes, bactoprenols and hopanoids in bacteria), regulation of 
transcription, electron transport (quinones), photosynthesis in plants (carotenoids) and many other 
processes.[128, 132, 311-313] 
Extensive research has focused on inhibitors of the MVA pathway and downstream isoprenoid 
pathways for prevention and therapy of cardiovascular diseases through reduction of the blood 
cholesterol.[114, 314] This research led to the development of statins which interrupt cholesterol 
synthesis in the liver by blocking the conversion of HMG-CoA to mevalonic acid,[315-317] and 
bisphosphonates which are effective drugs to treat metabolic bone disease through inhibition of 
osteoclast-mediated bone resorption by isoprenoid lipids.[307, 318] 
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Table 20. Distribution of the mevalonate (MVA) and the nonmevalonate (DOXP) pathway in different groups of 
organisms.[115] 
GENUS/SPECIES MVA DOXP 
 
GENUS/SPECIES MVA DOXP 
Animals  +  - 
 
Bacteria     
Gorilla gorilla (gorilla)  +  - 
 
Enterococcus  + (+) 
Homo sapiens (human)  +  - 
 
Staphylococcus   +  - 
Canis familiaris (dog)  +  - 
 
Streptococcus  +  - 
Mus musculus (mouse)  +  - 
 
Borrelia  +  - 
Rattus norvegicus (rat)  +  - 
 
Acinetobacter  -  + 
Sus scrofa (pig)  +  - 
 
Bacillus   -  + 
Other animals  +  - 
 
Bacteroides  -  + 
Plants  +  + 
 
Burkholderia   -  + 
Glycine max (Soy bean)  +  + 
 
Campylobacter   -  + 
Vitis vinifera (Wine grape)   +   + 
 
Chlamydia   -  + 
Zea mays (Maize)  +  + 
 
Clostridium   -  + 
Fungi  +  - 
 
Enterobacter  -  + 
Aspergillus  +  - 
 
Streptomyces  -  + 
Candida  +  - 
 
Escherichia   -  + 
Penicillium  +  - 
 
Haemophilus  -  + 
Saccharomyces cerevisiae   +  - 
 
Helicobacter   -  + 
Parasites     
 
Klebsiella   -  + 
Plasmodium  -  + 
 
Mycobacterium   -  + 
Toxoplasma  -  + 
 
Propionibacterium   -  + 
Trichomonas  +  - 
 
Pseudomonas   -  + 
Nematodes     
 
Salmonella   -  + 
C. elegans  +  - 
 
Vibrio   -  + 
MVA; mevalonate pathway, DOXP; nonmevalonate pathway. ‘ + ‘ indicates the presence and ‘ - ‘ indicates the absence of 
the pathway listed on top of the column. (+) indicates the presence of an incomplete pathway. 
We focused on the nonmevalonate pathway as a target for antibacterial chemotherapy, since this 
pathway is present in a variety of bacterial species and absent in human cells. In 1998, Kuzuyama and 
colleagues discovered fosmidomycin (previously disclosed as FR-31564) to be an inhibitor of purified 
DXR, the second enzyme in the nonmevalonate pathway, of E. coli K-12. Besides this activity towards 
the purified enzyme, it was shown that bacterial growth was also completely inhibited by 3.13 µg/mL 
fosmidomycin.[116, 117] Subsequently, several research groups described inhibitory activity of 
fosmidomycin and FR900098, fosmidomycin’s acetyl derivative, against important pathogens 
including P. falciparum, P. aeruginosa and K. pneumoniae.[118, 119, 137, 210] Fosmidomycin also 
demonstrates potent inhibition of purified DXR from M. tuberculosis, but is inactive against whole 
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cells of M. tuberculosis due to the absence of a GlpT-transporter for fosmidomycin uptake.[118, 119] 
Fosmidomycin is currently clinically used for treatment of malaria caused by P. falciparum and 
combination treatment with clindamycin showed favorable results.[319-321] However, problems 
with toxicity, short half-life and low bioavailability limit its potential as antimalarial drug.[122-124] 
Efforts to overcome low bioavailability and cellular uptake have been described extensively, by 
designing derivatives with altered physicochemical properties or prodrugs of fosmidomycin and 
FR900098.[133-135, 137, 145, 146, 322] The antimicrobial activity of fosmidomycin analogues was 
mainly evaluated in P. falciparum, M. tuberculosis and E. coli but the nonmevalonate pathway can 
also be an interesting target for antibacterial therapy against a variety of other bacterial pathogens. 
Therefore, we focused in this work on four groups of bacteria which use the nonmevalonate pathway 
as sole route for isoprenoid biosynthesis; Propionibacterium acnes, M.  smegmatis as a model for M. 
tuberculosis, P. aeruginosa and especially members of the Bcc.[115, 125-127]  
In chapter 3.I., we evaluated the in vitro susceptibility of our test panel towards different β-aryl-, β-
hydroxamate substituted derivatives and lipophilic phosphoramidate prodrugs of fosmidomycin, but 
also a variety of DXS-inhibitors and IspF-inhibitors were included. Our results showed limited in vitro 
activity of most compounds tested, with MIC values > 250 µM. Additional experiments to identify the 
resistance mechanisms against inhibitors of the DOXP pathway suggest that resistance is not 
mediated by the activity of efflux pumps. Literature upon resistance mechanisms describe that the 
major problem is low membrane permeability leading to limited cellular uptake. However, the results 
obtained in this study did not prove this hypothesis.  
The negative results in chapter 3.I. upon in vitro activity of promising inhibitors led to the question of 
the essentiality of the DOXP pathway in the studied bacteria. Also, insufficient research in the past 
has focused on the nonmevalonate pathway in Bcc species and therefore the goal in chapter 3.II. was 
to obtain a better insight in this pathway in B. cenocepacia. We constructed a rhamnose-inducible 
conditional mutant of dxr in B. cenocepacia K56-2 to determine the essentiality of this pathway. The 
conditional DXR mutant shows significant differences in planktonic growth compared to the wild-
type strain, suggesting that DXR is important for growth of B. cenocepacia K56-2, but not essential. 
The mutant strain also shows a significant reduction in biofilm formation when grown in LB without 
rhamnose. In pSC200 synthetic medium, disruption of dxr causes a significant decrease in 
CFU/biofilm, but no significant differences in biofilm formation are observed when quantification 
happened with resazurin staining. Currently, we do not have an explanation for this discrepancy 
between quantification methods or between media, although we know that it cannot be attributed 
to differences in CFU/biofilm between LB and pSC200. Experiments to evaluate differences in 
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virulence in C. elegans between the mutant and wild-type showed that virulence of B. cenocepacia 
K56-2 is considerably affected when dxr is not expressed. The fact that DXR affects in vivo virulence 
of B. cenocepacia in a C. elegans infection model can be of substantial value. However, it is important 
to evaluate differences in virulence in more complex in vivo models appropriate to study Bcc 
infections. Brackman et al. evaluated survival of Galleria mellonella larvae and of BALB/c mice in a 
lung infection model after infection with different Bcc strains.[323] Other in vivo models used earlier 
to study virulence profiles of bacteria belonging to the Bcc include zebrafish embryos [324-326], rat 
lung infection model [327], murine infection model [328-331] and a 3D human lung epithelial cell 
culture model.[332] Finally, we also evaluated differences in metabolism of 190 different carbon 
sources between wild-type and mutant K56-2. Eight compounds can be used as carbon source by 
K56-2 but not by the conditional DXR mutant, with D-galactonate being of most interest. D-
galactonate is required for the formation of G3P which is, together with pyruvate, the start product 
for isoprenoid biosynthesis through the nonmevalonate pathway.[213, 236] These results suggest 
that disruption of DXR in B. cenocepacia does inactivate the nonmevalonate pathway but also 
influences upstream metabolic pathways like the De Ley-Doudoroff (DD) pathway for biosynthesis of 
G3P. To our knowledge, no previous studies have described a relation between DXR and metabolic 
pathways upstream of the nonmevalonate pathway, although Ramos et al. described that the DD 
pathway greatly enhances isoprenoid production from D-galactose through the nonmevalonate 
pathway.[333]  
 
6. The future of the nonmevalonate pathway as an antibacterial target 
The enzymes of the nonmevalonate pathway are attractive targets for the development of novel 
antimicrobials targeting serious infectious diseases including malaria, tuberculosis and MDR bacterial 
infections.[113, 334-337] Hasan et al. described the enzymes of the nonmevalonate pathway as 
‘chokepoints’, meaning that the functionality of these enzymes and the specific products cannot be 
compensated by other enzymes.[338] Fosmidomycin and FR900098 effectively inhibit DXR, the first 
dedicated step in the DOXP pathway, in multiple organisms.[120, 126, 211] However, due to their 
highly charged structures, both compounds show suboptimal pharmacokinetic properties and low 
cellular uptake by microorganisms.[120, 126] Despite these challenges, fosmidomycin is currently in 
Phase II clinical trials for combination treatment against malaria.[339-342]  
Substantial research has already been performed on developing analogues of fosmidomycin and 
FR900098 with improved physicochemical properties. Most of the previous work focused on 
targeting DXR from P. falciparum ([120, 133, 135, 139, 145, 322, 343-348]) and from M. 
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tuberculosis.[118, 119, 137, 139, 349-353] Recently, more research has focused on the 
nonmevalonate pathway as a target for new antimicrobial agents to combat Gram-negative bacterial 
infections (including P. aeruginosa, Salmonella enterica and species of the Bcc).[127, 218, 354, 355] 
Improvement of cellular uptake of fosmidomycin and its derivatives remains one of the most 
important hurdles to overcome. However, if future research could lead to the development of DOXP 
inhibitors that are active against their target enzymes and efficiently get into bacterial cells, these 
compounds could become new weapons to fight infections by MDR organisms. Moreover, this 
pathway is probably important for viability and virulence in many more microorganisms and 
therefore, future research should also focus on investigating the importance of this pathway in other 
important pathogenic bacteria.  
This work demonstrates that the nonmevalonate pathway certainly poses an interesting target for 
development of novel antibiotics against B. cenocepacia infections,  if the issue of permeability can 
be addressed. Future research on this pathway should focus on determining essentiality of other 
DOXP genes and especially on the synthesis of active compounds able to inhibit this pathway and 
efficiently get into bacterial cells of B. cenocepacia.  
Notably, two other factors about the nonmevalonate pathway as antibacterial target have to be 
taken into account. First, inhibitors of the DOXP pathway are broad-spectrum antibiotics since they 
can affect many Gram-negative bacteria, some Gram-positives and some parasites.[117] The 
advantages of broad-spectrum compounds include a broader spectrum of activity in comparison with 
narrow-spectrum antibiotics and less need to identify the pathogen with certainty before treatment. 
On the other hand, treatment with broad-spectrum antibiotics pose a higher risk to develop 
resistance and children who receive broad-spectrum therapy have a higher risk to develop asthma. 
Also, broad-spectrum antibiotics can affect commensal microorganisms in the human body 
influencing the function of our immune system, our capacity to process food and our capability to 
resist secondary infections.[234, 356] Narrow-spectrum antibiotics such as azithromycin or 
erythromycin are less likely to cause resistance because only specific bacteria will be killed and they 
have less ability to cause superinfection on normal microorganisms present in the human body. 
However, narrow-spectrum compounds can only be applied if the specific pathogenic organism is 
identified and a very careful selection of the antibiotic is required.[87, 357] Secondly, new resistance 
mechanisms against fosmidomycin or related agents might develop upon clinical use. Up to date, the 
most commonly described mechanism is mutation or duplication of the target enzyme, DXR.[206, 
209, 231] A single punt mutation in DXR of E. coli has been described to confer resistance against 
fosmidomycin due to alterations in the fosmidomycin-binding site of DXR. Because this resistance 
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does not include apparent fitness disadvantages, the genetic barrier to resistance may be quite low 
and careful monitoring during treatment will be necessary.[231] Fosmidomycin resistance in P. 
falciparum was described due to a dxr gene duplication, leading to a bypass for isoprenoid 
biosynthesis during fosmidomycin treatment.[209] Other resistance mechanisms include expression 
of a fosmidomycin resistance gene (e.g. in B. cenocepacia [127]) and mutations or the absence of a 
specific GlpT transporter ([126, 207, 208]).  
 
7. Methods to identify essential bacterial genes   
Essential genes encode proteins that are absolutely required to maintain survival of any living 
organism. Essential genes are usually involved in key cellular functions including metabolism, 
replication of DNA, translation of genes into proteins, maintenance of cellular structure and 
transport processes in and outside the cell.[227, 358] Recently, newly-identified genes encoding 
essential cellular functions are increasingly being investigated as potential  targets for the 
development of new antimicrobial compounds.  
Genome-wide essential gene studies have been carried out using two major strategies: directed gene 
deletion and random transposon mutagenesis. The first approach systematically deletes complete 
individual genes or open-reading frames (ORFs) from the genome. Baba et al. used this approach to 
construct a collection of 3985 single-gene knockout mutants of E. coli. The Keio collection provides a 
useful resource for systematic genotypic analyses and also for genome-wide screening of similar 
bacterial strains.[359] With the second method, transposons are randomly inserted in as many 
genome positions as possible, with inactivation of the target essential gene as objective.[358, 360] 
Several studies prove the usefulness of transposon mutagenesis in the reliable identification of 
essential genes as drug targets.[361] Mobegi and colleagues report a proof of concept for the 
combination of genome-scale high-density transposon mutagenesis, high-throughput sequencing 
and integrative genomics to investigate potential essential targets in human respiratory 
pathogens.[362] A recent study of Wong describes a similar genome-wide screening tool for drug 
targets in B. cenocepacia; TraDIS or Transposon Directed Insertion-site Sequencing.[224] TraDIS uses 
shearing of genomic DNA followed by specific PCR amplification of DNA fragments containing 
transposons and Illumina sequencing to map unique transposon insertion sites.[363-365] Using this 
approach, Wong et al. predicted 383 genes to be essential for B. cenocepacia growth and viability in 
rich, undefined medium. Furthermore, an additional repertoire of 439 genes was revealed to be 
important for growth in nutrient-depleted minimal medium, providing an indication on how B. 
cenocepacia can adapt to nutritional limitation in the host environment.[224] Most genome-wide 
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studies also use computational analysis approaches such as comparative genomics between 
experimental data and data predicted using bioinformatics [366-370], online essential gene 
prediction servers [371] and  determination of a universal minimal set of essential genes (minimal 
genomes) [227, 372]. The minimal genome concept currently plays a key role in the identification of 
essential genes that are conserved across species because these genes are candidate targets for 
broad-spectrum drug development.[358, 373] 
However, for this PhD work we were interested in genes of a particular pathway in a specific 
bacterial organism and only to a lesser extent in genome-wide essential gene studies. The 
approaches to experimentally study essential genes are rather limited since, by definition, 
inactivation of an essential gene is lethal to the organism. By simply deleting or mutating essential 
genes it is impossible to characterize genotypic and phenotypic features and therefore it is more 
appropriate to construct inducible conditional mutants to study essential genes. Kofoed et al. 
constructed temperature-sensitive mutants of essential genes for which the products lose function at 
high temperatures and phenotypic differences are thus only observed at increased 
temperatures.[374] Several studies describe the construction of conditional unmarked deletion 
mutants. Flannagan et al. developed plasmids pDAI-SceI and pGPI-SceI to construct targeted, non-
polar unmarked deletion mutants of B. cenocepacia and Bloodworth et al. applied this approach, 
with some modifications, to construct rhamnose-inducible mutants of an electron transfer 
flavoprotein in B. cenocepacia. [221, 223] Conditional antisense mutagenesis is another approach 
that was applied earlier to investigate candidate essential genes.[220, 375] Wang et al. repressed the 
expression of certain candidate essential genes in P. aeruginosa by using antisense phosphorothioate 
oligomers and Greenberg et al. were able to inhibit growth of Bcc strains by the administration of 
antisense phosphorodiamidate-morpholino oligomers (PMOs) directed against the gene coding for 
the essential acyl-carrier protein AcpP.[220, 375] Because Greenberg et al. reported the proof of 
concept in B. multivorans we wanted to apply this approach in our study for B. cenocepacia. 
Rhamnose-inducible antisense overexpression mutants of dxr and ispD were constructed in B. 
cenocepacia LMG 16656 but unfortunately, every attempt failed to construct the desired antisense 
mutants. We currently do not have an explanation for this. However, there are alternative (and 
potentially more suitable) methods to investigate essential genes in the Bcc. Cardona et al. describe a 
transposon mutagenesis system in B. cenocepacia consisting of two vectors that deliver a rhamnose-
inducible promoter (PrhaB) at the transposon insertion site and in an enhanced green fluorescent 
protein gene (e-gfp) downstream from PrhaB. This system enabled the research group to 
systematically identify essential genes and operons in B. cenocepacia.[225] Later on, plasmid pSC200 
was constructed by Ortega and colleagues which enables the delivery of PrhaB into the chromosome 
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of B. cenocepacia K56-2 to drive the expression of a targeted gene.[226] Juhas et al. also used 
plasmid pSC200 for mutagenesis of B. cenocepacia H111 and both studies succeeded to construct 
conditional mutants in which expression of the target gene is dependent on the rhamnose 
concentration in the medium.[226, 228] In Table 21, an overview is shown of previous studies that 
describe the identification of novel essential genes in B. cenocepacia and other Bcc species. In the 
present study, we applied plasmid pSC200 to study the essentiality of nonmevalonate genes in B. 
cenocepacia and succeeded to construct a rhamnose-inducible conditional mutant of DXR in B. 
cenocepacia K56-2.  
Table 21. Overview of previous studies on the identification of essential genes in Bcc species.  
Study Outcomes Reference 
Juhas et al., 2012 84 essential genes   [228] 
  (species-specific for  Burkholderiales)   
Bloodworth et al., 2013 117 essential genes  [222] 
  * 66 with essential orthologs in E. coli or P. aeruginosa   
  * 51 species-specific for Burkholderiales   
     (whereof 38 present in B. cenocepacia)   
Wong et al., 2016 383 genes essential in B. cenocepacia  [224] 
  
(90% located on chromosome 1) 
* including five genes of nonmevalonate pathway   
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Bacterial infections remain one of the main causes of disease and death, with respiratory infections 
belonging to the top 10 causes of death worldwide. The Burkholderia cepacia complex (Bcc) is a complex 
of 20 closely related opportunistic Gram-negative bacterial species. Bcc species are important human 
pathogens in patients with cystic fibrosis (CF) with Burkholderia cenocepacia and B. multivorans currently 
being the most frequently isolated Bcc species from CF lungs. Chronic Bcc infections can cause a rapid 
decrease in lung function, ultimately leading to mortality and treatment options are limited due to their 
intrinsic resistance to a variety of available antibiotics. The main objective of my work was to explore two 
novel strategies to tackle Bcc infections, including the nonmevalonate pathway for isoprenoid 
biosynthesis and combination therapy of β-lactam antibiotics with β-lactamase inhibitors.  
The nonmevalonate pathway is a potential target for the development of new antibiotics against 
multidrug-resistant bacteria. Fosmidomycin and FR900098 are active inhibitors of DXR, the second 
nonmevalonate enzyme, from several bacteria but have limited effect on whole bacterial cells. 
Therefore, several attempts have previously been made to improve cellular uptake, by synthesizing 
analogues with modified physicochemical properties.  
The first goal of this work was to determine the in vitro antibacterial activity of fosmidomycin, FR900098 
and new analogues against various bacterial pathogens, and to identify different resistance mechanism 
against these nonmevalonate inhibitors. Susceptibility screening showed that in vitro antibacterial 
activity of most inhibitors tested was low, with MIC values > 250 µM. Only ritanserin, an inhibitor of the 
fifth enzyme IspF, does partially inhibit planktonic and biofilm growth of two P. acnes strains, three 
Mycobacterium strains and some Bcc strains. Moreover, our data suggest that the role of efflux pumps in 
resistance towards these compounds is limited. Previous publications describe that the main issue is low 
permeability leading to limited cellular uptake, however, the results obtained in this study did not prove 
this hypothesis.  
The second goal was to determine the essentiality of dxr and ispD, the second and third gene of the 
nonmevalonate pathway, in B. cenocepacia by constructing conditional knock-down mutants. Therefore, 
we used plasmid pSC200 which enables the delivery of a rhamnose-inducible promotor into the 
chromosome to drive the expression of a target gene.  We succeeded to construct a rhamnose-inducible 
dxr mutant of B. cenocepacia K56-2, but all attempts failed to insert a correct ispD construct in K56-2. 
Growth experiments showed that sufficiently high expression of dxr is essential for planktonic and 
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biofilm growth of B. cenocepacia K56-2. In vitro susceptibility for ceftazidime and aztreonam increased 
16- and 8-fold, respectively, upon disruption of dxr in B. cenocepacia K56-2. Moreover, data obtained in 
a C. elegans in vivo infection model showed that expression of dxr is required for full virulence of B. 
cenocepacia K56-2. Also, dxr appears to be important in B. cenocepacia to efficiently metabolize several 
carbon sources including D-galactonate which is required for biosynthesis of D-glyceraldehyde-3-P, a 
start product of the nonmevalonate pathway. In summary, DXR seems to play an important role in 
different physiological processes of B. cenocepacia and is therefore an interesting target for antibacterial 
chemotherapy against B. cenocepacia.  
Intrinsic resistance of Bcc species to β-lactam antibiotics is frequently observed and most commonly 
mediated by efflux pumps, alterations in penicillin-binding proteins or the expression of β-lactamases. 
The third goal of this work was to investigate the ability of β-lactamase inhibitors (clavulanic acid, 
sulbactam, tazobactam and avibactam) to restore the in vitro antibacterial activity of β-lactam antibiotics 
against members of the Bcc. Clavulanic acid did not cause an increased susceptibility, but addition of 
sulbactam, tazobactam or avibactam to ceftazidime, amoxicillin, cefoxitin, cefepime or aztreonam leaded 
to at least 4-fold MIC decrease in some Bcc strains. Moreover, we observed that the effect of β-
lactamase inhibitors on β-lactamase activity is both strain and/or antibiotic dependent, suggesting that 
β-lactam resistance in Bcc species is mediated by both β-lactamase production and non-β-lactamase 
related resistance mechanisms.  
To conclude, our work demonstrates that the nonmevalonate certainly is a potential target for the 
development of antibiotic chemotherapy against multidrug-resistant B. cenocepacia infections, if the 
issue of permeability can be addressed. Moreover, β-lactam-β-lactamase inhibitor combinations can 
offer an additional approach for Bcc-therapy, but it is important to evaluate every clinical situation 
individually. 
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Bacteriële infecties zijn één van de grootste oorzaken van ziekte en sterfte, en respiratoire infecties 
behoren momenteel tot de top 10 van belangrijkste doodsoorzaken wereldwijd. Het Burkholderia 
cepacia complex of Bcc is een complex van 20 nauw gerelateerde opportunistische Gram-negatieve 
bacteriën. Bcc species zijn belangrijke humane pathogenen in patiënten met mucoviscidose (CF), 
waarvan Burkholderia cenocepacia en Burkholderia multivorans de Bcc species zijn die meest frequent 
geïsoleerd worden uit CF longen. Chronische Bcc infecties kunnen een snelle achteruitgang in longfunctie 
veroorzaken, eventueel met sterfte als gevolg, en behandelingsopties zijn beperkt omwille van hun 
intrinsieke resistentie tegen verschillende beschikbare antibiotica. Het voornaamste doel van mijn werk 
was het evalueren van twee nieuwe strategieën om Bcc infecties aan te pakken, waaronder de 
‘nonmevalonaat pathway’ voor biosynthese van isoprenoïden en combinatiebehandeling met β-lactam 
antibiotica en β-lactamase inhibitoren. 
De ‘nonmevalonaat pathway’ is een potentieel target voor de ontwikkeling van nieuwe antibiotica tegen 
multidrug-resistente bacteriën. Fosmidomycine en FR900098 zijn actieve inhibitoren van DXR, het 
tweede enzym in de ‘nonmevalonaat pathway’, van verschillende bacteriën maar hebben slechts 
beperkte activiteit op volledige bacteriële cellen. Bijgevolg hebben reeds verschillende onderzoekers  
pogingen ondernomen om opname in de cel te verhogen via de aanmaak van fosmidomycine analogen 
met gemodificeerde fysicochemische eigenschappen. 
Het eerste doel was de bepaling van in vitro antibacteriële activiteit van fosmidomycine, FR900098 en 
nieuwe analogen tegen bepaalde bacteriële pathogenen, en de identificatie van resistentie 
mechanismen tegen deze inhibitoren. MIC experimenten toonden aan dat de in vitro antibacteriële 
activiteit van de meeste inhibitoren laag is, met MIC-waarden > 250 µM. Enkel ritanserine, een inhibitor 
van het vijfde enzym IspF, was in staat om planktonische en sessiele groei te inhiberen van twee P. acnes 
stammen, drie Mycobacterium stammen en verschillende Bcc stammen. Bovendien suggereren onze 
data dat resistentie slechts in beperkte mate wordt veroorzaakt door de activiteit van efflux pompen. 
Literatuur beschrijft dat de voornaamste oorzaak beperkte cellulaire opname is door een lage 
membraanpermeabiliteit, doch konden wij deze hypothese niet aantonen in deze studie.  
Ten tweede trachtten we om de essentialiteit te bepalen van dxr en ispD, het tweede en derde enzym 
van de ‘nonmevalonaat pathway’, in B. cenocepacia via het aanmaken van conditionele ‘knock-down’ 
mutanten. Derhalve gebruikten we plasmide pSC200 dat een rhamnose-induceerbare promotor 
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integreert in het chromosomaal DNA en zo de expressie van een bepaald gen beheerst. We slaagden erin 
om een rhamnose-induceerbare conditionele dxr mutant van B. cenocepacia K56-2 aan te maken, maar 
bovenstaande techniek bleek niet geschikt voor de aanmaak van een ispD mutant. Onze experimenten 
toonden aan dat expressie van dxr essentieel is voor planktonische en biofilm groei van B. cenocepacia 
K56-2. Bovendien nam in vitro antibacteriële activiteit van ceftazidime en aztreonam toe met een factor 
16 en 8, respectievelijk, wanneer dxr was uitgeschakeld. Overigens toonden onze data van een C. 
elegans in vivo infectiemodel aan dat voldoende hoge expressieniveaus van dxr nodig zijn voor optimale 
virulentie van B. cenocepacia K56-2. Tenslotte lijkt dxr ook belangrijk te zijn voor de metabolisatie van 
bepaalde koolstofbronnen in B. cenocepacia K56-2, waaronder D-galactonaat dat noodzakelijk is voor de 
biosynthese van D-glyceraldehyde-3-fosfaat (startproduct van de ‘nonmevalonaat pathway’). 
Samenvattend kunnen we stellen dat DXR een belangrijke rol speelt in verschillende fysiologische 
processen in B. cenocepacia waardoor dit een interessant target is voor de ontwikkeling van 
antibacteriële therapie tegen B. cenocepacia.  
Bcc species zijn intrinsiek resistant aan allerhande β-lactam antibiotica en deze resistentie wordt vooral 
veroorzaakt door efflux pompen, wijzigingen in pencilline-bindende eiwitten of de productie van β-
lactamase enzymen. In het derde hoofdstuk wouden we daarom onderzoeken of β-lactamase inhibitoren 
(clavulaanzuur, sulbactam, tazobactam en avibactam) in staat zijn om de in vitro antibacteriële activiteit 
van β-lactam antibiotica tegen Bcc species te herstellen. Clavulaanzuur bleek geen effect te hebben op 
de in vitro activiteit, maar toevoeging van sulbactam, tazobactam of avibactam aan ceftazidime, 
amoxicilline, cefoxitine, cefepime of aztreonam gaf aanleiding tot een minstens viervoudige daling in 
MIC-waarden tegen sommige Bcc stammen. Vervolgens observeerden we ook dat het effect van β-
lactamase inhibitoren op β-lactamase activiteit zowel stam- als antibioticum afhankelijk is, wat 
suggereert dat resistentie tegen β-lactam antibiotica veroorzaakt wordt door zowel β-lactamases als 
door niet-β-lactamase-gerelateerde resistentiemechanismen.  
Dit werk toont dus aan dat de ‘nonmevalonaat pathway’ een mogelijk target is voor ontwikkeling van 
nieuwe antibiotica tegen infecties met B. cenocepacia, als de permeabiliteitsproblemen van mogelijke 
inhibitoren kunnen worden aangepakt. Daarenboven kan ook de combinatie van β-lactam antibiotica 
met β-lactamase inhibitoren een nieuwe methode bieden voor therapie tegen Bcc bacteriën, waarbij het 
belangrijk is om elke klinische situatie individueel te beoordelen. 
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